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1 General introduction 
1.1 A dripping pipeline in drug discovery 
The number of well-validated therapeutic targets has increased substantially over the last 
decade. However, despite considerably increased investments in drug research and 
development in the same period,  the number of new targets that are exploited by drugs that 
make it to the market is still only three to four per year [1]. In addition, total numbers of 
drug approvals on a yearly basis have not improved. This last fact can be easily distilled 
from the number of FDA approved biologics license applications (i.e. biological medicines) 
and new molecular entities (i.e. small molecule drugs) from 1993 till 2011 (Figure 1.1). 
Regrettably, the combination of the increased investment and the relatively stable number 
of new drug approvals implies that the average cost per approved medicine has increased 
considerably [2, 3]. 
 
 
Figure 1.1. New FDA approvals from the period from 1993 to 2011. Adapted from Mullard [4]. 
Part of the reason for this reduced return on investment can be found in the strategies 
that are currently being applied in drug discovery. These strategies have changed several 
times over the course of modern history. Whereas initial discoveries were often the result 
of fortuitous accidents, such as Alexander Fleming‟s serendipitous discovery of penicillin, 
in more recent times drug discovery has been pursued through a wide array of strategies 
encompassing: high-throughput screening; structure-based design; fragment screening, i.e. 
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the testing of parts of molecules; and virtual screening, i.e. the computerized generation and 
testing of virtual libraries against drug target structures [5]. During the last couple of years, 
efforts to improve the quality of chemical compound libraries in order to make them more 
structurally diverse have also been growing. Moreover, there is also more interest in 
including compounds from the very beginning of the drug discovery process that have 
drug-like physicochemical properties [6]. In addition, the development of protein 
therapeutics has come to the fore and is playing an increasingly important role in medicine.  
Although protein therapeutics are on the market for a wide variety of indications and are 
used for their enzymatic or regulatory activity, their protein-binding activity or as protein 
vaccines, their use is largely restricted to extracellular applications [7]. Exceptions are few 
and include therapeutic enzymes that are trafficked to endocytic compartments via the 
mannose-6-phosphate receptors [8] and denileukin difitox (trade name: Ontak), a bacterial 
toxin of which the target resides in the cytosol [9]. 
Whereas these strategies have already proven their merits through the development of 
numerous clinically important drugs and will continue to play an important role in drug 
discovery in the foreseeable future, the number of targets that are amenable to being 
targeted by small molecules and/or extracellularly acting protein therapeutics remains low. 
For protein therapeutics, the reason is that the large pool of intracellular therapeutic targets 
has so far remained untapped. The bottleneck for developing small molecule drugs against 
many targets can be explained by the concept of so-called undruggable proteins, which are 
proteins that are extremely difficult to target with small molecules in a highly specific 
manner. Given the rise of protein therapeutics, the term undruggable proteins has become 
somewhat inadequate and/or fluid, but is still widely used because of its conceptual value. 
Frequently, undruggable proteins are involved in protein-protein interactions and do not 
contain any clefts or other structural characteristics that can be potently and specifically 
targeted by small molecules. Hence, most pharmaceutical companies aim to develop small 
molecule drugs against the same established and highly druggable targets, which represent 
only a small fraction of known therapeutically relevant proteins. Although precise numbers 
regarding druggable and undruggable proteins are continuously being disputed, an analysis 
by Hopkins and Groom showed that druggable proteins make up only a minor fraction of 
the disease-modifying genes (Figure 1.2) [10]. Of the estimated 600-1500 available human 
target proteins, an estimated 435 are being targeted by experimental, approved and 
withdrawn small molecule drugs [2]. Noteworthy is that attempts are being made to expand 
the number of targets that can be addressed with small molecules, mainly via targeting 
protein-protein interaction that exhibit hotspots, which are small regions of the protein 
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interaction surface that contribute most significantly towards the binding energy. Despite 
some notable successes in targeting protein-protein interactions with small molecules, these 
instances remain the exception rather than the rule [11].  
 
 
 
 
Figure 1.2. Schematic relationship between the human genome, the druggable genome for small molecule 
drugs, potential drug targets and the disease-modifying genes. Adapted from Hopkins and Groom with 
permission [10]. 
1.2 A growing need for drug delivery 
Because of the downward trend in drug discovery, the classical drug discovery strategies 
and the development of protein therapeutics against extracellular targets are being 
complemented in several ways by novel drug development strategies. A prime category of 
strategies is the one that aims to develop biological molecules as medicines (biologics) 
against intracellular targets. An evident advantage of biologics against intracellular targets 
is that they can be directed towards a much larger pool of therapeutically relevant targets. 
Also important to note is that, in contrast to targeting undruggable proteins with small 
molecules, it is relatively simple to target these undruggable proteins in a highly specific 
manner with biologics. 
Biological molecules can target proteins either through direct binding, as in the case of 
peptides, antibodies and alternative protein scaffolds, or through modifying their splicing or 
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expression levels, as is the goal of most nucleotide-based strategies, of which siRNA is the 
most well-known example. Employing large biological molecules against intracellular 
therapeutic targets, however, means that attention has to be paid to their delivery, as these 
molecules are generally not able to reach their intracellular target in vivo in sufficient 
amounts in their naked and/or unmodified forms.  
In this new way of designing therapeutic agents, the major bottleneck for the successful 
development of therapeutic strategies based on such biologicals is thus the adequate 
accumulation at the intracellular target site in vivo, where these molecules can accomplish 
their therapeutic task [12]. To achieve sufficient intracellular accumulation, several 
biological and/or synthetic hurdles must generally be overcome. Some of the issues, in 
particular those related to the biodistribution, are similar to those for extracellular protein 
therapeutics and have already been successfully addressed in various cases [7]. 
Biological hurdles include the first-pass effect, immune cell-mediated removal, 
aspecific cell- or tissue entry and the unduly recognition of specific blood vessel 
components [13]. Synthetic hurdles include the need to address poor solubility, poor 
stability and the tendency of proteins and/or nanosized drug delivery systems to aggregate 
in vivo. Naturally, the specific hurdles that are encountered depend on the choice of 
delivery route and the biomacromolecule in question. Even when sufficiently high 
concentrations can be reached at the target site, the minimization of side effects is also 
paramount to a successful development of a therapy. This usually depends not only 
strongly on the specificity of the delivery system, but also on the activity profile of the 
therapeutically active moiety.  
So far, technologies for the intracellular delivery of biomacromolecules have been 
mainly applied as research tools to elucidate molecular mechanisms of disease in cellulo, 
but interest in these technologies as platforms for drugs that act inside the cell is on the rise 
[2, 13-16]. At present, numerous strategies for the development of intracellular next-
generation medicines are being pursued, many of which are already in clinical trials [15, 
17]. Some of these depend on carriers designed from scratch in the lab, such as polyplexes 
and liposomes for gene or siRNA delivery, whereas others are adapted designs of nature, 
such as viral vectors or bioengineered bacteria [16]. Other notable strategies for the 
development of next-generation intracellular therapeutics include the use of polymer-drug 
conjugates for improved small-molecule delivery [18], monoclonal antibodies for targeting 
of overexpressed receptors on cancer cells that lead to endocytic internalization [19] and 
gold nanoparticles for delivery of small molecules, genetic materials and/or proteins [20]. 
A special class of molecules, which has been used in combination with many of the 
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aforementioned constructs is the class of cell-penetrating peptides. These molecules, which 
have the capacity to efficiently induce the cellular uptake of cargo into the cell, are the 
central theme of this thesis and will now be introduced.  
1.3 Cell-penetrating peptides  
Approximately twenty years ago, remarkable observations were made for the 
homeodomain of Antennapedia from Drosophila melanogaster [21] and the Tat protein 
from the human immunodeficiency virus 1 [22]. Contrary to their expectations, the 
researchers found that, when added to cells externally, both proteins reached the cytosol by 
themselves. Later studies identified short peptide domains in these proteins that were 
responsible for this notable activity [23, 24]. These crucial observations turned out to be the 
birth of the research field of cell-penetrating peptides. As indicated, cell-penetrating 
peptides (CPPs) are now loosely defined as a class of peptides that have in common that 
they can induce the cellular uptake of membrane impermeable macromolecules, such as 
peptides, proteins, nucleic acids and nanoparticles. In general, CPPs are either cationic, 
amphipathic, or both [25]. Unlike receptor-targeting moieties such as transferrin, folate or 
antibodies, they do not require specific receptors for internalization that are typically only 
expressed in a subset of cell-types, making them capable of entering a wide variety of cell 
lines and primary cell types in a highly efficient manner. Given their capacity to facilitate 
cargo delivery, CPPs or CPP-like peptidomimetics have the potential to play an important 
role in the development of next-generation medicines with an intracellular activity. Their 
ability to do so is also reflected by the increasing number of CPP-based strategies that is in 
or heading towards clinical trials (for details see chapter 2). 
1.1.1 Structural requirements of CPP for activity 
Several classes of CPPs can be distinguished, which have been extensively described 
elsewhere [25, 26]. Two of the most well-known classes of CPPs are the predominantly 
hydrophilic arginine-containing cell-penetrating peptides, of which Tat and penetratin are 
early members [23, 24], and the more membrane-active hydrophobic peptides, of which 
TP10 is the best investigated representative [27].   
For the arginine-containing peptides, the CPP activity depends strongly on the presence 
of arginine residues, as replacing arginines by lysines, histidines or ornithines leads to far 
less efficient CPPs [28, 29]. These initial structure-activity relationship studies have also 
led to the identification of the highly efficient CPP nona-arginine. Currently, the 
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guanidinium moiety is considered to be of paramount importance for effective 
internalization, as attaching this group to various peptidomimetic, polymeric or 
carbohydrate-like structures results in efficient transporters [30]. For example, oligomers of 
-amino acids exposing guanidinium groups via their side chains could be actively 
internalized [31, 32]. In addition, guanidinium groups have the ability to facilitate transport 
of dendritic polymers through liposomes and cellular membranes [33, 34]. Especially the 
combination of the delocalized positive charge and a bidentate hydrogen bond donor on the 
guanidinium group (Figure 1.3A-B) makes this chemical group ideally suited to interact 
with the negatively charged carboxylates, phosphates and sulfates that are present on many 
plasma membrane constituents including phospholipids, proteins and heparan sulfate 
proteoglycans [30]. Guanidinium groups are thought to promote uptake through direct 
interactions with these components, followed by an efficient partitioning into the lipophilic 
part of the bilayer. 
Various research groups have also looked more closely at the conformational 
requirements of the backbone and to the attachment of guanidinium groups to the backbone 
for the CPP activity of these groups. It was found that linearity of the backbone is not a 
requirement for CPPs, as branched arginine-rich peptides are internalized even more 
efficiently [35], as are circularized peptides [36-39]. The improved internalization 
properties of several circularized arginine-rich CPPs has been ascribed to the spatial 
arrangement of their guanidinium groups [38]. According to this line of reasoning, 
restricting the conformational freedom increases the uptake efficiency. For the CPP hLF, 
derived from human lactoferrin, the effect of circularization is even more pronounced. 
Contrary to other CPPs that are active both in their linear and circular form, this CPP 
completely loses its activity when its ability to cyclize through formation of a disulfide 
bond is abolished [40]. Next to the effect of circularization, the conformational freedom of 
the guanidinium groups has also been investigated in different ways. For instance, 
Rothbard et al. increased backbone spacing via carbon spacers, thereby enhancing 
conformational freedom (Figure 1.3C) [41]. Remarkably, this enhancement also resulted in 
a considerably increased cellular uptake efficiency. These results are in contrast with the 
enhancing effects of circularized peptides, which are clearly restricted with respect to their 
conformational flexibility. A similar improvement of the efficiency was obtained when the 
conformational freedom of the guanidinium groups was increased by adding methylene in 
the side chains (Figure 1.3D) [42]. Given the contrary findings that so far have been 
obtained on the role of spatial positioning and/or conformational flexibility, this area of 
study will benefit from further investigations. Moreover, an increasing number of studies 
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now also show that the structure-activity relationship may be cell-type dependent to some 
degree, thereby even further increasing the complexity of the role of the guanidinium group 
in determining CPP-like properties (see also chapter 4). 
 
 
Figure 1.3. Relevant chemical structures and interactions. A) Illustration of delocalization of the charge of the 
arginine side-chain, which is important for efficient formation of bidentate hydrogen bonds. B) Example of a 
bidentate hydrogen bond between an arginine residue and a phosphate residue. C) Illustration of the increased 
backbone spacing in arginines used by Rothbard et al. [41]. D) Enhanced side chain spacing used by Wender et al. 
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in N-substituted peptides [38]. X indicates the position where carbon spacers of increasing chain length were 
introduced. 
1.1.2 Interactions between cationic CPPs and glycosaminoglycans 
The first interaction of a CPP when in contact with a mammalian cell is by necessity a 
physical interaction with a membrane-proximal structure. Candidate structures include 
carbohydrates, lipids and proteins, with which guanidinium groups can form bidentate 
hydrogen bonds (see previous section). The ability of cationic CPPs to interact with lipid 
headgroups and glycosaminoglycans (GAGs) has been detailed in many studies looking at 
the biophysics of such interactions (for a review, see ref [43]). Supporting evidence that 
cationic CPP have the ability to interact with GAGs also in biological systems has come 
from studies using HS or GAG-deficient CHO cells [44-46], from studies using heparinase 
treatments [40, 46, 47], from studies in which HS-carrying syndecans were overexpressed 
[45, 48] or from competition of CPP uptake through soluble GAGs [44, 49]. Interestingly, 
when comparing the affinities of cationic CPPs for lipid bilayers and glycosaminoglycans 
(GAGs), cationic CPPs had a much higher affinity for GAGs, making these molecules a 
much more likely candidate for the initial interaction with a biological membrane [50-52].  
This idea is further supported by measurements of the apparent affinity of the CPP 
penetratin for membrane fragments of cells of WT and GAG-deficient CHO cells, which 
showed a greatly reduced affinity for the latter [53]. The interaction with GAGs on the 
plasma membrane is thought to be directly involved in the internalization. This means that 
it does not mediate a mere accumulation of peptide on the surface, which would passively 
increase the odds of an interaction with the real trigger for internalization. Instead, GAGs 
seem to actively respond to the presence of various well-known cationic CPPs, possibly 
through clustering [40, 51], which could facilitate the induction of uptake. For cationic 
CPPs, syndecans were recently shown to be directly involved in uptake [45, 48]. 
Interestingly, three cationic CPP, R8, Tat and penetratin, preferentially internalized via 
syndecan-4, which carries both heparan sulfate and chondroitin sulfate chains. It is at 
present unclear whether the preference is related to the glycosylation pattern or whether a 
direct interaction with a protein component on syndecan-4 is involved in this preference. A 
role for other GAGs besides HS is supported by a strong decrease in the internalization 
efficiency of several cationic CPP in GAG-deficient CHO cells as compared to HS-
deficient CHO cells [45]. Although reports indicate that removal of HS chains reduces 
delivery of bioactive peptide nucleic acid [47], other reports dispute the existence of a 
productive GAG-dependent delivery route to the cytosol [54], indicating that cell or cargo-
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type dependent differences may affect the productivity of GAG-dependent internalization. 
Peptide concentration may also affect their ability to exploit GAGs for improved cell entry, 
as GAG-dependency is reduced both at low [55] and at high peptide concentrations [39]. 
1.1.3 A three-step model for the cytosolic uptake of cationic CPPs 
Under most conditions, cationic CPPs reach the cytosol via three sequential steps (Figure 
1.4). First, they bind to heparan sulfates at the cell surface with low- or submicromolar 
affinity. Secondly, they trigger their own internalization into endosomes. It is not clear if 
the CPPs remain associated with HS chains, whether they must dissociate before entry, or 
whether both situations occur in parallel. Only in the third and final step do the peptides 
actually cross the membrane. In this translocation step, peptides leave the endosome and 
reach the cytosol in a process commonly referred to as endosomal escape. Endosomal 
escape is generally considered to be the rate-limiting step for cytosolic delivery. At present, 
it is unclear how arginine-rich peptides, which have a much higher affinity for HS chains 
compared to lipid membranes [43], manage to dissociate from HS chains before they can 
initiate the actual membrane translocation. The dissociation of CPPs from HS has indeed 
been implicated as a factor limiting their endosomal escape, as CPPs with an increased 
affinity for HS chains had a lower capacity to deliver splice-correcting steric-block 
oligonucleotides to the cytosol, which was independent of their ability to internalize via 
endocytosis [56]. An alternative hypothesis states that HS may be degraded in endosomal 
compartments, which would release CPPs in a manner that does not depend on the HS 
affinity [44]. Aside from endosomal escape, direct plasma membrane permeation has also 
been described both at high and at low concentrations for cationic CPPs [55, 57].  
1.1.4 Endosomal escape of CPPs 
Currently, the mechanisms of endosomal escape that distinct CPPs utilize are far from 
understood. Since CPPs with hydrophobic residues or hydrophobic cargo differ from 
exclusively arginine-rich peptides in their capacity to induce leakage and/or rupture of giant 
unilamellar vesicles [58], the existence of distinct escape mechanisms for different classes 
of CPPs is typically assumed. As indicated, the low affinity of arginine-rich peptides for 
lipid bilayers seems to be at odds with their ability to translocate these membranes [43]. 
Nevertheless, for both Tat and penetratin it has been shown that these peptides affect the 
membrane curvature and other properties of lipid bilayers in ways that support their 
capacity to directly translocate across such membranes [58-61]. The lipid 
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bis(monoacylglycero)phosphate, which is enriched in late endosomes, has been shown to 
enhance CPP-mediated membrane leakage, supporting the idea that specific lipids are 
required for efficient endosomal escape [62].  
Interestingly, for Tat, its ability to translocate through membranes has been implicated 
in its ability to induce endocytosis. When conjugated to a macromolecular cargo, it has 
been proposed that Tat reaches through the plasma membrane to affect the properties of the 
cytoskeleton, mainly through inducing actin polymerization and bundle formation. This 
may then lead to a reduction of the number of actin-membrane contact points, which may 
in turn cause membrane rearrangements and endocytic processes that are reminiscent of 
macropinocytosis [57].  
 While there is thus supportive evidence for the ability of various CPPs to translocate 
through lipid bilayers, it is often unclear how large cargo is translocated across membranes. 
Most translocation mechanisms that have so far been hypothesized do not allow for large 
cargo to be transported across intact membranes. The well-described mechanisms that do 
allow for large cargo delivery, such as Pep-1 mediated protein delivery over the plasma 
membrane, typically involve CPPs with a high affinity for lipids and depend on local lipid 
bilayer pertubation for cargo delivery [63]. As such, the concentration range where these 
vectors are active but not damaging is expected to be small. The existence of temporary 
membrane-disturbances caused by CPPs is further underscored by the activation of the 
membrane repair response as described by Palm-Apergi et al. [64]. Nevertheless, numerous 
studies underscore the ability of CPPs to deliver large functional cargo into the cytosol with 
low toxicity, albeit with modest efficacy [14]. Therefore, one of the main open questions is 
how macromolecular cargo is translocated across membranes by these vectors and whether 
the translocation process leaves the endosomes intact or whether the membrane integrity 
has to be compromised for effective cytosolic delivery. 
 
 
 
 
Chapter 1 – General introduction 
12 
 
 
Figure 1.4. Three general steps in the internalization of cationic CPPs. 1) Cationic CPPs bind to HS chains. 2) 
Peptides trigger their internalization, either dissociating from the HS chains (a) or while remaining attached to 
them (b). It is not clear what the driving forces for dissociation are, though a very high affinity has been shown to 
negatively affect translocation [56]. 3) In the rate-limiting final step, peptides reach the cytosol after translocating 
through the endosomal membrane in a step called endosomal escape. 
1.4 Outline of this thesis 
The major aim of this thesis was to contribute to an in-depth understanding of the biology 
of CPPs. To this end, in Chapter two, the thesis starts by reviewing biological responses 
that are being elicited by biological drug delivery vehicles, with the emphasis on CPPs. The 
review summarizes the accumulating evidence that drug delivery vehicles are not simply 
Trojan horses until they reach a toxicity threshold. Instead, it is argued that many potential 
drug carriers affect cellular physiology in ways more subtle than large-scale membrane 
toxicity or massive oxidative stress resulting in necrosis and/or apoptosis. A prime example 
is the induction of ceramide formation by acid sphingomyelinase through CPPs (see also 
chapter 3). 
Chapter three elucidates the molecular details of a previously described peptide 
translocation mechanism that occurs when peptide is present at concentrations of 10 M or 
higher. As part of this uptake mechanism, local nucleation zones at the plasma membrane 
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arise at which peptide accumulates before it directly enters into the cytosol. A particular 
pharmacological profile of the import route led to the formulation of the hypothesis that 
this internalization depends on ceramide formation via acid sphingomyelinase. In this 
chapter, a set of experiments is presented that together strongly support this hypothesis.  
In chapter four, differences in the internalization efficiency of CPPs composed of L- 
and/or D-amino acids are presented. Previously, no differences had been reported in the 
uptake of L- and D-CPPs, which had led to the paradigm that CPP internalization was 
independent of chirality. Here, it is shown that certain cell-types have a clear preference for 
L- over D-amino acid-containing peptides. In these cells, L-CPPs are internalized, whereas 
D-CPPs remain strongly membrane-bound, with D/L chimeric CPPs having a phenotype 
that depends on the number and position of the enantiomers in the peptide chain.  
In Chapter five, the effect of epimerization of NMR labels at individual positions in 
the amphipathic CPP TP10 is investigated. The chapter shows that for this CPP, properties 
such as internalization efficiency, cytotoxicity and membrane binding depend strongly on 
whether there is an L- or a D-epimer introduced at a specific position. Remarkably, there is 
little correlation between the effect of these epimerizations on CPP properties and the 
effects on physicochemical characteristics of these peptides. Furthermore, despite the lack 
of a measurable affinity, heparan sulfate chains affect the binding of these peptides to the 
membrane and internalization. 
Chapter six presents a protocol for the use of fluorescence correlation spectroscopy 
(FCS) to determine the intracellular stability of CPPs. The chapter not only presents a 
method for analyzing the intracellular stability using lysates of cells, but also provides a 
protocol for performing intracellular FCS to analyze the integrity of CPPs. 
Chapter seven is the first chapter of this thesis that gives a concrete application of 
CPPs. The study deals with the delivery of artificial organelles, or polymersomes, by means 
of their conjugation with the CPP Tat. Specifically, this chapter illustrates how Tat-
functionalized polymersomes loaded with enzymes are transported into various cell types 
through endocytosis. With horseradish peroxidase (HRP) as a model enzyme, enzymes 
remain active for much longer compared to what was previously observed for free 
enzymes. This indicates that polymersome-mediated enzyme delivery protects enzymes 
against intracellular degradation. 
Chapter eight describes a modular leucine zipper-based strategy for cellular delivery of 
proteins. In this application, Tat and the reporter protein GFP are coupled to two 
complementary leucine zipper strands. Only in the presence of both modules, delivery of 
GFP into the cells is accomplished. The modular nature of this strategy indicates that this 
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system can easily be modified for the delivery of a wide range of other proteins or be used 
in conjunction with other CPPs and/or targeting agents. 
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Abstract 
In drug development, major resources are invested into the development of cellular 
delivery systems to increase the effectiveness of a large array of potential therapeutics, such 
as proteins and oligonucleotides. These carriers comprise cell-penetrating peptides, cationic 
lipids and cationic polymers. In recent years, evidence has been accumulating that these 
carriers do not only act as mere pharmacokinetic modifiers, but interfere with cellular 
processes in various ways. In this review we present an overview of the biological side 
effects associated with carrier systems. The focus will be on cell-penetrating peptides 
(CPPs), which have been explored for a diverse set of cargos. Reported activities range 
from an induction of receptor internalization to the generation of reactive oxygen species. 
Ultimately, cell-penetrating molecules with such biological side effects might evolve into 
new bioactive agents that combine delivery capacity and pharmacophore in a single 
molecular entity. First examples for such molecules will be presented. 
2.1 Introduction 
As research provides an ever greater understanding of disease at a molecular level, the 
number of potential therapeutic targets is increasing steadily. The challenge is to translate 
these targets into therapies [1]. Progress with classical, small-molecule based drug 
development has been slow. Underlying reasons include the need to target protein-protein 
interactions, reach targets inside cells and the difficulty to achieve specificity [2, 3].  
Therefore, attention is shifting towards alternative approaches that enable a rapid 
rational design of active and specific molecules. Oligonucleotides, including siRNA, 
proteins and peptidomimetics are prominent examples [4-6]. However, for these molecules, 
a rapid and rational design is set off by poor bioavailability, which prevents them from 
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reaching their intended targets in vivo. The successful implementation of these molecules 
into new therapies therefore critically depends on delivery and targeting strategies [7], 
which generally involve the use of peptides, proteins, lipids, or polymers. Although the 
specific molecular design underlying these delivery strategies may vary in detail, the 
incorporation of positive charge is a common denominator [8-10]. The positive charge 
mediates the interaction with negatively charged sugar moieties and lipids on the outer 
leaflet of the plasma membrane which promotes cellular uptake.  
Ideally, these carriers act exclusively as pharmacokinetic modifiers with no biological 
activity of their own. However, an increasing body of evidence indicates that these carriers 
may influence cellular activity in multiple ways [11-19]. Testing of carriers should 
therefore extend beyond mere cytotoxicity and delivery efficiency. In this review, we will 
therefore summarize recent results on biological responses towards cationic carriers. The 
focus will be on cationic cell-penetrating peptides (CPPs) and related transporters.  
Research into the biological side effects of cationic and amphiphilic membrane-active 
peptides has a long tradition in the area of peptide toxins, with melittin and mastoparan 
being the paradigmatic examples. Extensive studies on structure-activity relationships have 
been conducted for induction of mast cell degranulation [20] and hemolysis [21]. Mast cell 
degranulation has been related to the interaction of the positive charges of the cationic 
peptides with sialic acids present on the plasma membrane and a G protein-coupled 
receptor (GPCR)-independent G-protein activation [20].  
Many membrane-active peptides also have cell-penetrating activity. Therefore, it is 
difficult to make a clear distinction between both types of peptides [22]. CPPs might be 
considered membrane-active peptides with little toxicity. As a consequence, for CPPs 
research has focused on mechanisms of uptake and biomedical applications, rather than 
potential side effects. Especially because of the other activities that were reported to occur 
in the absence of acute toxicity, they may be very relevant in future clinical applications. In 
this review, we will present an overview of the in vitro and in vivo biological responses that 
have been reported for the interaction of cells and organisms with cationic carrier systems 
and especially cationic CPP. Frequently, these responses directly relate to uptake. Finally, 
we will provide examples of CPPs that have an intended intrinsic biological activity.   
2.2 Cell-Penetrating Peptides: Promising Molecules For The Intracellular Delivery 
of Therapeutics 
CPPs are characterized by their ability to promote the receptor-independent cellular uptake 
of membrane-impermeable macromolecules, such as peptides, proteins, nucleic acids and 
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nanoparticles [23]. CPP contain fewer than 30 amino acids and are mostly cationic, or 
cationic and amphipathic. Cationic and amphipathic CPP show some differences in their 
internalization mechanisms [24] which may be attributed to the ability of amphipathic CPP 
to more directly interact with membrane lipids [25]. Early CPP include the Drosophilia 
melanogaster-derived penetratin [26], the protein transduction domain from the tat protein 
[27] and the more hydrophobic CPP transportan, which is a chimeric molecule designed 
from parts of the neuropeptide galanin and the wasp venom mastoparan [28].  
Cellular internalization is observed for virtually all cells, albeit with different 
efficiencies that depend on the CPP, the cargo and the cell type [29, 30]. Especially for 
large molecular weight complexes, internalization occurs mainly through endocytosis. 
Therefore, even though the ultimate target compartments typically are cytosol and nucleus, 
in many (if not most) cases the major part of the imported cargo is trafficked to the 
endolysosomal compartment [24]. Endocytic pathways that have been reported to 
contribute to CPP uptake include macropinocytosis and the clathrin-dependent and 
caveolae-dependent pathways [31]. It has been shown that a given CPP is not necessarily 
restricted to only one import pathway. Instead, CPPs might exploit multiple entry routes at 
the same time [32].  
2.2.1 Biological interactions involved in the internalization of cationic CPPs  
A CPP approaching a cell first encounters glycosaminoglycans (GAGs), negatively charged 
carbohydrate polymers on the surface of the plasma membrane. It is therefore no surprise 
that GAGs have been implicated in the cellular uptake of CPPs [33]. Affinity 
measurements typically show Kd values between 100 nM and 1 M for the interaction of 
cationic peptides with GAGs, which provides evidence for their role as primary cellular 
interaction partner [34]. 
Conflicting evidence has been obtained on whether interaction with GAGs also triggers 
import or not. The role of GAGs as a direct trigger for uptake has been supported by a 
report from Letoha et al, who found that the proteoglycan syndecan-4 bound the cationic 
CPP tat, penetratin and octaarginine and facilitated their internalization in a PKC α-
dependent manner [35]. Conversely, a role of GAGs in CPP import has been questioned 
entirely by research showing only minor differences in cellular delivery of a Tat-Cre 
recombinase into GAG-deficient or wild type cells [36].  
In addition to studies addressing interactions with GAGs, research on lipid bilayer 
model systems has given ample indications for the potential of CPPs to interact with lipids, 
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though affinities are substantially lower [34]. It has been shown that cationic CPPs directly 
affect lipid bilayer organization in model systems. Disturbance of bilayer organization is a 
major requirement for uptake-related membrane processes such as fusion, fission or pore 
formation [37, 38]. In these processes, changes in membrane curvature are involved [37]. 
As an example, the CPP tat was found to induce negative curvature in artificial vesicles 
[39], which is a necessary condition for pore formation, dimple formation in caveolae-
based endocytosis and for membrane protrusions in macropinocytosis [37]. Induction of 
vesicle fusion has also been observed for cationic CPP [40]. 
To this point structure-activity relationships of CPPs have been explored in rather 
simplistic model systems. Even though these systems have succeeded in identifying lipid 
composition, transbilayer potential and vesicle size as important determinants for peptide 
translocation, even the most complex of these models has failed to account for cellular 
responses that dynamically remodel the lipid composition. 
2.3 Biological Activity of Cationic CPPs 
Cationic CPPs were originally considered as „Trojan Horse‟ delivery vehicles that enter 
cells without eliciting a cellular response [41]. However, CPPs can induce a wide range of 
side effects that may be more subtle than cell death. These side effects have been related to 
the uptake itself as well as to interactions inside the cell.  
2.3.1 Effects of cationic CPPs on membrane integrity and cell viability 
Cationic CPPs (for peptide sequences, see table 2.1) have a sound track record with respect 
to toxicity, both in vitro and in vivo. In vitro, the low toxicity holds for both acute 
membrane toxicity (as determined by a variety of membrane integrity assays) and for cell 
viability (as determined mainly by assays probing for mitochondrial activity) [32, 42, 43]. 
Tat and penetratin (with or without cargo) at concentrations of up to 50 M had only minor 
effects on cell proliferation and membrane integrity [42]. By comparison, the more 
amphipathic CPPs MAP and TP10 affect proliferation at lower concentrations and show 
considerable membrane destabilization. For example, MAP and TP10 induce lactate 
dehydrogenase leakage at concentrations of 10 M [42, 43].  
At the high concentration of 50 M, little hemolysis was observed for penetratin and 
none for tat, further supporting the lack of acute membrane toxicity for cationic CPPs [43]. 
Although amphipathic peptides were somewhat more hemolytic, none of the tested CPPs 
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had a hemolytic activity comparable to the one of membrane-active peptides such a 
mastoparan, which clearly distinguishes CPPs from other membrane-active peptides [43].  
2.3.2 Novel methods to detect subtle side effects of cationic CPP  
Now that cationic CPP are moving steadily towards preclinical and clinical development, 
the traditional toxicity analysis methods are being complemented with ”-omics” assays that 
globally profile cell activities. These assays are more sensitive in profiling potential side 
effects of CPP-based therapeutics than the traditional assays. Consistent with results on 
membrane integrity and viability, a toxicity analysis based on metabolomic profiling also 
demonstrated that amphipathic peptides such as TP affect cellular metabolism at 
concentrations of 5 to 10 M, whereas the cationic CPP penetratin, tat and nonaarginine 
had little effect at 10 M [44]. No specific enzymes were identified as being directly 
affected by TP. Instead, reduced levels of GSH, glucose, purines, pyrimidines and related 
molecules led the authors to hypothesize that the cells countered oxidative stress caused by 
the peptide [44]. 
A transcriptome analysis for H1299 lung adenocarcinoma cells treated with a tat-
conjugated dsRNA-binding domain (DRBD) indicated very few changes both after 12 h 
and 24 h [45]. None of the upregulated or downregulated genes clustered into a specific 
genetic pathway. Similarly, a transcriptome analysis in HeLa cells found that several 
unrelated genes were affected by penetratin, while for tat hardly any effects were observed 
[46].  
To detect possible subtle side effects of CPPs on the immune system, Kuo et al. 
performed genome-wide profiling of gene expression with U-937 macrophages treated with 
octaarginine [47]. Although these researchers found an increase in the expression of several 
immune-related genes, this response did not result in cytokine release or reduced viability 
for concentrations of up to 40 M. They did, however, find elevated superoxide levels 30 
min after peptide addition, which normalized after 8 hours [47].  
 
Table 2.1 Sequences of cationic peptides 
Peptide Sequence Class Origin Reference 
R9 RRRRRRRRR-NH2 Cationic CPP N/A [48] 
TAT C-(acetamidomethyl) 
GRKKRRQRRRPPQQ 
Cationic CPP HIV TAT protein (48-
60) 
[27] 
hLF KCFQWQRNMRKVRGPP
VSCIKR-NH2 
Cationic CPP Human lactoferrin [49] 
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(RXR)4 (R-Ahxa-R)4-PMO Cationic CPP N/A [50] 
Penetratin RQIKIWFQNRRMKWKK Cationic/ 
Amphipathic CPP 
Antennapedia 
homeodomain 
[26] 
Transportan GWTLNSAGYLLGKINLK
ALAALAKKIL-NH2 
Amphipathic CPP Galanin and mastoparan [28] 
TP10 AGYLLGKINLKALAALA
KKIL-NH2 
Amphipathic CPP Galanin and mastoparan [51] 
Maurocalcine GDCLPHLKLCKENKDCC
SKKCKRRGTNIEKRCR-
COOH 
Bioactive CPP Scorpion venom [52] 
Vasostatin 1 MRSAAVLALLLCAGQV
TALPVNSPMNKGDTEV
MKCIVEVISDTLSKPSPM
PVSQECFETLRGDERILSI
LRHQNLL-COOH 
Bioactive CPP Vasostatin 1 (1-76) [53] 
p14ARF MVRRFLVTLRIRRACGP
PRVRV-NH2 
Bioactive CPP p14ARF protein (1-22) [54] 
M511 FLGKKFKKYFLQLLK-
NH2 
Bioactive CPP Rodent angiotensin 
receptor 
[55] 
TBX2 GKMADWFRQTLLKKPK
KRPNSPESTLQLRD 
ATPGGAIVS-NH2 
Bioactive CPP Toll-receptor 4 adaptor 
protein (19-43) 
[56] 
Cyt c GTKMIFVGIKKKEERAD
LIAYLKKA-NH2 
Bioactive CPP Human cytochrome C 
(77-101) 
[57] 
mPrP MANLGYWLLALFVTM
WTDVGLCKKRPKP-NH2 
Bioactive CPP Mouse prion protein (1-
28) 
[58] 
SAHBA EDIIRNIARHLAX
bVGDXb
NL
cDRSIW-NH2 
Chemically 
modified bioactive 
CPP 
BID BH3 [59] 
Lactoferricin 
B 
FKCRRWQWRMKKLGAP
SITCVRRAFd 
Host defense 
peptide 
Bovine lactoferrin (17-
41) 
[60] 
Buforin IIb TRSSRAGLQWPVGRVHR
LLRKd 
Host defense 
peptide 
Histone H2A (Toad 
stomach) 
[61] 
a) Ahx stands for 6-aminohexanoic acid 
b) X refers to the position of , -disubstituted non-natural amino acids containing olefin-bearing tethers. These 
amino acids were used for the formation of a hydrocarbon staple (cyclic alkene) 
c) NL corresponds to the non-natural amino acid norleucine 
d) No information was available regarding the amidation status  
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2.3.3 Biological mechanisms of side effects of cationic CPPs  
Even though scientific understanding of the biological effects of CPP is far from complete, 
individual molecular mechanisms along the route of uptake and inside cells have been 
identified (Figure 2.1). At the first step of cellular entry, an interaction between heparan 
sulfate proteoglycans and the CPP tat has been found to affect the cell by reducing its 
responsiveness to exogenous polyamines via a competition for heparan sulfate binding sites 
[17]. 
Following their interaction with heparan sulfates, a principal effect of cationic CPPs is 
their ability to induce endocytosis of unconjugated constituents and transmembrane 
receptors, as detected by an increased uptake of fluorescently labeled dextran via fluid-
phase endocytosis [15] and the internalization of TNF-receptors [14], respectively. 
Although the precise trigger has not yet been identified, this endocytosis induction can have 
profound effects on the capacity of a cell to respond to extracellular signals. Internalization 
of TNF-receptors occurred without receptor activation. As a consequence, the 
downregulation resulted in a reduced capacity to respond to TNF-α by up to 50 % [14]. 
Downregulation was also observed for epidermal growth factor receptor and was induced 
by penetratin, tat and nonaarginine [14]. 
Cationic CPP also evoke side effects by remodeling the plasma membrane. TAT-GFP 
fusion proteins were found to induce phosphatidylserine (PS) exposure, though without 
initiating apoptosis or necrosis. Recently, we confirmed and extended this observation by 
showing that cationic CPPs have the ability to not only alter the distribution of lipids in the 
bilayer, but also to induce changes in the lipid composition of the plasma membrane that 
depend on enzymatic activity [19]. The mechanism involves the induction of acid 
sphingomyelinase (ASMase), which converts sphingomyelin to ceramide at the outer 
leaflet of the plasma membrane. Because ceramide is a lipid with important second-
messenger functions, this finding may have important implications for the interpretation 
and design of studies using CPP-based therapeutic strategies (Box 1). ASMase was 
identified as a key player in the plasma membrane repair response [62], which is known to 
be induced by several CPPs including TP10 and penetratin [63].  
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Arginine-rich peptides also induce actin rearrangement in a proteoglycan-dependent 
manner [64]. Given the central role of the cytoskeleton in signaling processes, it remains to 
be determined to what extent this activity affects signaling cascades [65]. Very 
interestingly, differential effects on healthy and malignant fibroblasts were observed for 
several arginine (R9) and arginine/tryptophan-based (R/W)9 peptides [13]. Whereas these 
peptides restored a disrupted actin cytoskeleton in malignant fibroblasts, the peptides did 
not affect actin organization in untransformed fibroblasts. Furthermore, the CPPs reduced 
cell motility and wound healing. These activities were only observed with CPPs that had 
the ability to bind actin in vitro as determined by isothermal titration calorimetry [13]. The 
effects were not observed upon treatment with non-actin binding peptides, such as an 
Box 1. The many faces of acid sphingomyelinase and ceramide 
Acid sphingomyelinase (ASMase) and ceramide are subjects of intense research due to 
their recently discovered roles in the pathophysiology of common diseases [100] and 
the multifaceted roles of ceramide as a second messenger in several antiproliferative 
and/or apoptotic responses, in the arrangement of the cellular cytoskeleton and in 
motility. Currently, there is increasing interest in ceramide metabolism as a potential 
target for cancer therapy [101]. 
In lipid membranes, ceramide segregates into rigid domains and induces negative 
monolayer curvature [102], which has been associated with the internalization of 
several pathogens [103] and cationic CPP [19]. The initial trigger for ASMase 
translocation and ceramide formation is poorly understood, though reactive oxygen 
species have been implicated independently by various groups [104]. Although 
octaarginine also induced superoxide in U-937 macrophages [47], a direct link to 
ASMase activation has not been established. 
The observation that cationic CPPs have the potential to influence ceramide 
metabolism may have important implications for cancer therapy. CPPs could serve to 
enhance the sensitivity of tumor cells to chemotherapeutic drugs. In fact, ceramide 
generation induced by cationic CPP might be part of the mechanism of enhanced 
toxicity of CPP-based chemotherapeutic approaches [105]. CPP-drug conjugates 
enhanced cytotoxicity and induced ceramide formation through acid sphingomyelinase, 
whereas the drugs by themselves did not. Although the mode of drug delivery was seen 
as the probable reason, the bioactivity of the cationic CPP could very well have 
contributed to the increased cytotoxicity. 
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(R/W)9 peptide consisting of D-amino acids or penetratin, which both had a comparable 
capacity to enter the fibroblasts.  
In addition to these activities, oligoarginines also act as protease inhibitors. 
Octaarginine reduced proteasome activity, leading to the accumulation of high-molecular-
weight ubiquitin-conjugated proteins inside the cells as determined by analysis of whole 
cell lysates [16]. Oligoarginines more generally acted as furin inhibitors [11]. As again 
another mechanism-of-action, HIV replication was inhibited by tat, which is achieved 
through competition with the full HIV-1 tat protein for binding to the TAR element in the 
nucleus [18]. 
Given all these biological activities, cationic CPPs are thus far from true Trojan horses. 
Because arginine and tryptophan are residues enriched on protein interaction surfaces and 
because of the high energy contribution of these residues to protein-protein interactions 
[66], it should come as no surprise if next to the demonstrated interactions with actin and 
proteases, arginine- and trypophan-rich peptides had further proteinaceous interaction 
partners inside the cell. As we will detail more extensively below, many other specific 
intracellular interaction partners have been identified for particular bioactive cell-
penetrating peptides.  
2.3.4 Toxicity and bioactivities of cationic drug delivery systems  
The scientific focus for other cationic carriers is also shifting from the application of 
standard toxicity assays towards a more complete understanding of the side effects through 
the analysis of specific biological interactions and global gene expression profiling [67, 
68]. Selected examples that are pertinent to the discussion of cellular responses towards 
cationic carriers are presented. For the cationic polymer polyethyleneimine (PEI), two 
distinct phases in cytotoxicity were detected [68]. First, PEI induced lactate dehydrogenase 
leakage and PS externalization in a caspase-3 independent manner, which was then 
followed by the induction of caspase-3-dependent mitochondrial apoptosis, most likely 
caused by a direct interaction of PEI with the negatively charged mitochondrial membrane. 
A role for lysosomal destabilization could not be ruled out because PEI has been shown to 
disrupt lysosomes [69]. A similar caspase-3 independent PS externalization was observed 
for poly-L-lysine (PLL), which was also followed by a caspase-3 dependent apoptosis [70]. 
Another bioactivity that may be implicated in PLL-mediated apoptosis, but that has also 
been observed for poly-L-arginine, was the induction of phospholipase D through protein 
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kinase C [71]. Like PEI and PLL, chitosan and chitosan-derivates also induce apoptosis 
through caspase-3 [72].  
 
 
Figure 2.1. Common side effects elicited by multiple cationic CPPs. In recent years, multiple side effects of 
cationic CPPs have been described that can in some instances directly be related to their internalization 
mechanisms. The first step of internalization, the high-affinity interaction with heparan sulfates, is the primary 
reason for the reduced responsiveness to polyamines (a). The induction of internalization of fluid-phase markers 
and receptors are related to the ability of cationic CPPs to activate the endocytic machinery (b,c). The molecular 
triggers that lead to plasma membrane remodeling (d) or affect the redox status and/or gene transcription (e) have 
not yet been identified, whereas interactions with sialic acid residues and G proteins are thought to be responsible 
for mast cell degranulation (f). A direct interaction with intracellular actin has been proposed to underlie the 
ability to mediate stress fiber reorganization in malignant fibroblasts (g). HSPG, heparan sulfate proteoglycan; 
PM, plasma membrane. 
Cholesterol-based cationic lipids, which are being investigated for gene delivery, have 
the potential to inhibit protein kinase C activity [73]. Factors that affect the inhibition are 
charge, the presence of steroid versus linear hydrocarbons and the presence of a quaternary 
ammonium cation versus a tertiary amine headgroup [73]. Reminiscent of the induction of 
receptor internalization by cationic CPPs, the transfection agent lipofectamin, which has 
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similarities with cationic lipids that are being developed into drug-delivery constructs, 
activates the insulin receptor at higher concentrations. This leads to a subsequent 
downregulation of insulin receptors and a lack of responsiveness to insulin in transfected 
cells [74].  
2.3.5 Toxicity and side effects of cationic CPP in vivo  
As very recently reviewed by Järver et al., there is currently little information regarding the 
in vivo toxicology of cationic CPPs [75]. Despite numerous preclinical studies that indicate 
activity of CPP-based therapeutics (for examples, see below), few dedicated toxicity 
assessments of therapeutic CPP-constructs in preclinical or clinical development have been 
published. Nevertheless, the absence of obvious toxic effects in most of the studies 
assessing therapeutic effects is promising. Several notable constructs that are or have been 
in clinical development include: PsorBan, which is cyclosporin A coupled to heptaarginine 
via a pH-dependent linker [76]; KAI-9803, a tat-coupled peptide inhibitor of PKC [77]; 
(RXR)4 peptides coupled to anti-c-myc phosphorodiamidate morpholine oligomers (PMO) 
[78]; and XG-102, a tat-coupled c-Jun N-terminal kinase inhibitor [78-82]. In multiple 
studies with these compounds in rat, mouse and porcine models, but also in an exploratory 
study in humans (KAI-9803) [83], no apparent signs of acute or long-term toxicity were 
reported at therapeutic doses. Administration through various routes was well-tolerated, 
including: the topical administration of PsorBan (Psorban; 
http://goliath.ecnext.com/coms2/gi_0199-2736134/CellGate-Announces-Phase-IIa-
Study.html); the intracoronary administration of KAI-9803 [77, 83]; the intravenous 
administration of ((RXR)4-PMO) [78] and XG-102 [81]; and the intraperitoneal (IP) 
administration of XG-102 [80, 82]. Similarly, direct stereotactic delivery into the brain of 
tat coupled to a dsRNA-binding domain, a platform which is also being developed for 
clinical trials, seems to be well-tolerated at therapeutic levels in a glioblastoma mouse 
model [84].  
In line with the aforementioned findings, 14 subsequent days of IP injection of 20 nmol 
of a Tat-PKC peptide conjugate in rats did not result in organ toxicity, despite a widespread 
biodistribution [85]. Frequent IP injections of tat coupled to the enzyme purine nucleoside 
phosphorylase at a dose of 80 mg/kg body wt/wk in mice also did not result in any 
detectable toxicity, as determined by blood-based parameters of liver, kidney and 
hematological function [86]. By contrast, tat and penetratin were found to induce by 
themselves a reduction in the expression of the kinase p38 in a mouse lung delivery study 
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after intratracheal administration at 10 nmol [87], however, it was not investigated in more 
detail if the expression of other genes was affected as well. When coupled to siRNA, 
penetratin also activated innate immunity [87]. The mechanisms are not understood. 
A recent report from Aguilera et al. described the in vivo distribution and toxicity of C-
terminally amidated r9 (all D-amino acids) following intravenous administration in mice. 
The peptide was found to bind rapidly to the local vasculature and to redistribute within 30 
min, with over 90 % localized to the liver [88]. These researchers observed that mice went 
into shock with dilated blood vessels and died of respiratory collapse within one minute 
after an injection of 100 nmol r9 (5 μmol/kg, which is ~7 mg/kg), though 4 out of 5 mice 
survived an injection of 50 nmol. The toxicity of r9 could be reduced by masking the 
arginine moieties in the bloodstream via a glutamic acid-based polyanion stretch coupled to 
the CPP via a protease-cleavable linker. A suspected reason for this adverse effect is 
massive mast cell degranulation, leading to a fatal vasodilation. These strong adverse 
effects of r9 in mice were in contrast to the results observed with peptide-PMO constructs 
in rats, where no adverse effects occurred at 15 mg/kg, and the LD50 lay between 210 and 
250 mg/kg. Of note is that the total amount of positive charge at 15 mg/kg is about half of 
that for r9 at 7 mg/kg. The conjugate (RXR)4-PMO has one positive charge less than r9 
and its molecular weight is about fourfold higher. Moreover, the charge density is 
substantially lower due to the insertion of four 6-aminohexanoic acid moieties in the octa-
arginine sequence [78]. In the exploratory study in human volunteers with tat-PKC , 
corrected-for-weight quantities of the peptides were around 100-fold lower (~7 mg/kg in 
the mice study [88] vs. max. 70 g/kg in the human study [83]). Other reasons that may 
contribute to the diverse biological responses include the different route of administration 
(intravenous vs. intracoronary), the difference in CPP and the conjugation to a peptide 
inhibitor (PKC  Typically, the studies at therapeutic doses use far lower concentrations, 
which makes toxicity comparisons difficult, if not impossible. 
Another consideration regarding the toxicity of CPPs in vivo is their lack of specificity. 
The implementation of targeting strategies to direct the CPP to the site of action may 
therefore help to avoid side effects in multiple tissues [75, 89]. So far, targeting strategies 
to improve specificity have focused on targeting CPP-conjugates to tumors. These 
strategies either exploited the tumor microenvironment [90, 91] or tumor-specific antigens 
[92, 93]. For instance, Whitney et al. increased specificity through a phage display-based 
selection of tumor-homing activatable CPPs, which incorporate a tumor protease-cleavable 
linker attached to an arginine-masking polyanion chain [91]. As indicated above, this 
strategy also decreases toxicity. The group of Torchilin made use of hydrazone-linked PEG 
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shells on liposomes, which shield the tat-moiety at physiological pH, but expose tat at 
lower pH values [90], which are normally encountered in the tumor microenvironment 
[94]. Myrberg et al. and Miyamoto et al. achieved enhanced specificity of CPPs through 
coupling to tumor-targeting peptides or antibodies, respectively [92, 93]. In the near future, 
cell-targeting peptides with an intrinsic cell-penetrating activity may expand the repertoire 
of strategies available to increase specificity [95]. 
2.4 CPPs with Intrinsic Bioactivity  
In addition to the traditional cationic CPP that are applied as vectors for cargo-delivery, 
CPPs with intrinsic activities are rapidly gaining interest (Figure 2.2). This class of peptides 
demonstrates that cell entry and intracellular function can be combined effectively (for 
examples, see table 2.1).  
One example of a bioactive cell-penetrating peptide is a seven arginine residue-
containing CPP derived from the p14 ARF protein [54]. Internalization of this peptide is as 
efficient as uptake of the CPP TP10 and is associated with little membrane disturbance. 
Inside the cells, this peptide activates the apoptotic machinery by mimicking the function of 
the intact p14ARF protein, most likely by increasing p53 activity through inhibition of 
HMD2. In a similar vein,  bioactive CPPs derived from cytochrome C were developed, 
which also combine efficient cellular internalization with the induction of tumor cell 
apoptosis.  Another example is maurocalcine, which is a CPP derived from a scorpion 
venom that induces intracellular Ca(2+) release through activation of ryanodine receptors 
[52]. The peptide vasostatin 1 also shares multiple characteristics with cationic CPP, 
because it also binds to heparan sulfate proteoglycans (HSPGs) and is internalized via 
endocytosis. In addition, vasostatin 1 activates endothelial nitric oxide synthase (eNOS) 
phosphorylation in a PI3K- and proteoglycan-dependent manner, which stimulates 
caveolae-dependent endocytosis [53]. The increase in caveolae-dependent endocytosis is 
somewhat surprising, because PI3K is commonly associated with macropinocytosis [96]. A 
highly interesting finding has been presented for prion-derived peptides, which successfully 
entered cells and also caused a reduction of intracellular levels of the pathogenic prion 
isoform [58].  
Furthermore, the G protein-binding parts of GPCRs have been employed as a source for 
CPP with an intrinsic bioactivity [55]. A CPP prediction algorithm was used to identify 
CPPs from various GPCRs. One of the peptides (M511) induced blood vessel contraction. 
This indicates that the peptide successfully mimicked the respective domain of its parent 
protein [55]. By contrast, a peptide derived from the Toll-receptor 4 (TLR-4) adaptor 
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protein blocked parent protein activity [56]. This peptide, TBX2, penetrated the plasma 
membrane and eliminated lipopolysaccharide-induced production of pro-inflammatory 
cytokines. Presumably it prevents TLR-4-mediated activation of downstream signaling 
events by competition for TLR-4 binding sites [56].  
Walensky et al. followed a different route to confer cell-penetrating capacity to a cell-
impermeable BID BH3 peptide, which is the conserved BH3 α-helical domain of the pro-
apoptoic protein BID (a member of the Bcl-2 family). Unlike the aforementioned examples, 
cell-permeability of this peptide was not a function of its primary sequence, but instead the 
result of the inclusion of a cyclic alkene using , -disubstituted non-natural amino acids 
that constrains the molecule to assume an -helical conformation. This chemical 
modification is referred to as stapling. The authors attributed the enhanced cell-penetrating 
capacity to the increased lipophilicity of the derivate. The stapled BID-BH3 peptide enters 
cells through macropinocytosis, localizes to mitochondria and binds to and activates Bcl-2-
associated protein X (BAX), thereby initiating the apoptotic machinery [59]. In vivo, this 
peptide analog slows the growth of human leukemia xenografts.  
2.4.1 Host defense peptides 
A separate class of bioactive peptides that also comprises cell-penetrating members are the 
host defense peptides (see table 2.1). Although some of these peptides act by being 
preferentially membranolytic for cancer cells or bacteria, others have the ability to 
translocate into cells without major membrane disturbance. An example is the 7 arginine-
residues-containing buforin IIb, a 22 amino acid peptide derive from histone H2A [61]. In 
studies, this peptide required cell surface gangliosides or sialic acids for efficient entry into 
cancer cells. Remarkably, buforin IIb did not enter healthy cells even at high 
concentrations, despite being very arginine-rich. After cell entry, buforin IIb causes 
mitochondria-dependent apoptosis through the activation of pro-caspase 9 and pro-caspase 
3. It has not been established whether a direct interaction is involved. Mitochondria-
dependent apoptosis has also been described for bovine lactoferricin B [60], a host defense 
peptide that also has the capacity to enter cells [97]. For bovine lactoferricin B, generation 
of reactive oxygen species has been implicated in the mechanism of apoptosis induction. 
Notably, the cyclic structure, while being essential for internalization of the human 
lactoferrin (hLF)-derived CPP (which is a part of human lactoferricin H), was not required 
for the cancer cell-selective induction of apoptosis of bovine lactoferricin B, emphasizing 
the distinct structure-activity relationship of these two peptides [49, 60].  
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Figure 2.2. Examples of CPPs with intrinsic bioactivity. Cationic CPPs can have diverse effects on cellular 
physiology. At the plasma membrane, binding of vasostatin 1 to heparan sulfate proteoglycans is involved in 
eNOS phosphorylation [53]. In the cytosol, diverse activities have been described that include a reduction in the 
pathogenic isoform of the prion protein by prion-derived peptides [58] and blood vessel contraction through G 
proteins [55]. A cell-penetrating BH3 domain with a stabilized -helical conformation acts by recruiting BAX to 
the mitochondria, where it is activated [59]. Several host defense peptides have been shown to cause 
mitochondrial apoptosis in cancer cells after having traversed the plasma membrane without major disturbances 
[60, 61]. Ryanodine receptors, located in the membrane of the ER, are modulated by a bioactive CPP derived from 
scorpion venom [52]. In the nucleus, a p14ARF-derived peptide is proposed to sequester HDM2 to the nucleolus, 
which leads to p53 activation and apoptosis [54]. ER, endoplasmic reticulum. 
2.5 Concluding Remarks and Future Perspectives  
The data reviewed in this article indicate that side effects of cationic delivery agents can be 
diverse and are not necessarily directly related to cellular uptake. Therefore, when 
screening for side effects, a comprehensive analysis of the interactions between the 
delivery agent and the biological system is required. Global gene expression profiling is the 
most straightforward screen. Ideally, such a screen should be complemented with a more 
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directed search for side effects based on available precedents. Testing procedures could 
encompass diverse assays for the detection of superoxide levels, receptor internalization, 
mast cell degranulation or the effect on lipid composition.  
At present, it is difficult to foresee which side effects that were observed in vitro will be 
relevant in vivo. There are still very limited data to translate in vitro peptide concentrations 
into relevant in vivo concentrations. Nevertheless, we predict the start of an exciting new 
era in which it will be possible to use knowledge regarding molecular interactions of cell-
entering peptides to design delivery agents that have themselves desired pharmacodynamic 
activity. Alternatively, the fundamental knowledge could be used to rationally engineer 
delivery agents without undesired side effects. A notable example is the (R/W)9 
synthesized with either D- or L-amino acids, which have equal internalization efficiencies, 
but remarkably different molecular interactions and activities inside the cell [13]. A further 
example is the recent design of a pharmacologically inert D-maurocalcine, which, unlike its 
L-counterpart, does not affect calcium signaling inside the cell [98]. Another emerging 
trend is to identify cell-permeant proteomimetic peptides using quantitative structure-
activity relationship-based algorithms [99], which has already provided several interesting 
new bioactive agents in which the delivery capacity and pharmacophore are present in the 
primary sequence in overlapping, but not identical, regions [55-57]. 
In conclusion, cationic peptides and cationic drug carriers show a large variety of side 
effects that might be related or unrelated to their internalization mechanisms. If 
bioactivities are associated with the internalization mechanisms of this type of carrier, then 
the choice of the class of delivery system should be compatible with or contribute to the 
therapeutic goal, such as for example the import of anti-cancer drugs with apoptosis-
inducing peptides. Ultimately, the understanding of the structural determinants underlying 
these effects should allow us to rationally engineer new bioactive agents that only possess 
the properties that are deliberately introduced.   
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Abstract 
Cationic cell-penetrating peptides (CPP) are receiving increasing attention as molecular 
transporters of membrane-impermeable molecules. Import of cationic CPP occurs both via 
endocytosis and – at higher peptide concentrations – in an endocytosis-independent manner 
via localized regions of the plasma membrane. At present, this endocytosis-independent 
import of cationic CPP is not well understood, but has been shown to be sensitive to 
various pharmacological inhibitors, suggesting a role of an unidentified enzymatic activity. 
Here, we demonstrate that the direct translocation of cationic CPP depends on a CPP-
induced translocation of acid sphingomyelinase (ASMase) to the outer leaflet of the plasma 
membrane and ceramide formation. The involvement of ASMase in uptake was confirmed 
by a pharmacological inhibition of ASMase by imipramine and a subsequent rescue of 
uptake through external addition of sphingomyelinase, and by using ASMase-deficient 
cells. We also found that the threshold for direct CPP translocation can be lowered through 
addition of sphingomyelinase and that sphingomyelinase enhances the translocation of R9 
coupled to low-molecular weight cargos, but not high-molecular weight cargos. In 
conclusion, we show that a previously poorly understood mechanism of cationic CPP 
import depends on the ASMase-dependent formation of ceramide on the outer leaflet of the 
plasma membrane. To our knowledge, this is the first illustration that a class of delivery 
vectors operates through the induction of an enzymatic activity that changes the lipid 
composition of the plasma membrane.  
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3.1 Introduction 
Interest in cell-penetrating peptides (CPP) as tools to deliver membrane-impermeable 
therapeutic molecules continues to increase. This development is illustrated by the 
increasing efforts of the scientific community to elucidate the chemical, physical and 
biological principles underlying the activity of CPP and CPP-based delivery systems [1-4] 
and the steep rise in the number of therapeutic strategies that are being pursued with these 
systems [5, 6]. It is becoming progressively clear that instead of a single mechanism that is 
valid for all CPP, multiple modes-of-action exist with respect to the route of internalization 
and intracellular trafficking, that depend on the cell line [7], the CPP [8], and the cargo [9, 
10]. Although endocytosis is now considered the major internalization route of cationic 
CPP, [1, 11-14] direct translocation for cationic CPP has also been observed, mainly at 
high [8, 15-17], but also at low concentrations [18, 19].  
For arginine-rich CPP the potential for direct translocation is thought be related to the 
ability of the guanidinium moieties of arginines to form bidentate hydrogen bonds with 
membrane lipids [20] and is underscored by the ability of the arginine-rich TAT peptide to 
induce pores in artificial membranes, as was observed by small angle X-ray scattering [21]. 
Moreover, molecular-dynamics simulations indicate the potential of arginine-rich peptides 
to form transient pores in plasma membranes in the presence of an electrochemical gradient 
and provide a mechanistic hypothesis for direct membrane translocation [22].  
Nevertheless, biological details remain poorly understood and it is not clear to which 
degree in vitro models manage to reflect the complex molecular environment of a cell. At 
higher concentrations, direct cytoplasmic import of cationic CPP has been shown to depend 
on spatially confined nucleation zones. This rapid import is sensitive to the PKCδ inhibitor 
rottlerin and to chlorpromazine [8]. Available evidence indicates that the plasma membrane 
remains intact. In a search for a common denominator of the observed pharmacological 
profile, we discovered that both molecules act as inhibitors of acid sphingomyelinase 
(ASMase) activity [23-25]. This finding provided us with a rationale for investigating a 
possible involvement of ASMase in the CPP uptake via direct translocation. 
Acid sphingomyelinase has traditionally been known in relation to Niemann-Pick 
disease, a lysosomal storage disorder [26]. More recently, an important role for this enzyme 
in ceramide-mediated signal transduction pathways has emerged, linking its activity to a 
variety of common diseases, among which are cancer, cardiovascular diseases and diabetes 
[27]. A major function of this enzyme is the hydrolysis of sphingomyelin to ceramide and 
phosphorylcholine following a trigger-initiated translocation from lysosomes to the outer 
leaflet of the plasma membrane. The details of the translocation mechanism are unknown at 
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present. Ceramide is a lipid with a well-established role in the induction of antiproliferative 
and apoptotic responses in a variety of cancer cells [28]. As a part of this role, ceramide 
greatly affects the structure and properties of cellular membranes. In the plasma membrane 
ceramide-enriched membrane domains modulate signaling [29, 30]. In the mitochondrial 
outer membrane ceramide increases permeability [31]. Here, we provide evidence for a role 
of ceramide formation by ASMase at the plasma membrane in the rapid cytoplasmic import 
of cationic CPP. This finding gives rise to the concept that cationic CPP enhance their own 
uptake by initiating a positive feed-back loop that involves an enzymatic alteration of the 
lipid composition of the plasma membrane.  
3.2 Materials and methods 
3.2.1 Materials  
C-terminally amidated peptides were purchased from EMC microcollections (Tübingen, 
Germany). Fluorophore-labeled peptides were synthesized with an N-terminal 
carboxyfluorescein-label. Purity was evaluated by high-performance liquid 
chromatography (HPLC) and identity confirmed by mass spectrometry. If required, 
peptides were further purified to a purity of > 95 % using reversed-phase HPLC. The CPP 
hLF was oxidized before use as described previously [32]. Bovine serum albumin (BSA), 
glucose, imipramine, rottlerin and bacterial sphingomyelinase (from Bacillus Cereus, 
specific activity was 100 units/mg based on the Lowry protein assay) were from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Alexa-647 labeled annexin-V was from Invitrogen 
(Eugene, U.S.A.) and phenylmethylsulfonyl fluoride (PMSF) was from Research Organics 
(Cleveland, U.S.A). Standard chemicals were from Sigma-Aldrich and Merck (Darmstadt, 
Germany). HPMA-R9 conjugates were prepared as described previously [33]. 
3.2.2 Cell culture 
HeLa cells were maintained in RPMI 1640 (PAN Biotech, Aidenbach, Germany) 
supplemented with 10 % fetal calf serum (FCS; PAN Biotech) and incubated at 37°C in a 5 
% CO2-containing, humidified incubator. Cells were passaged every 2 to 3 days. Primary 
mouse fibroblasts were obtained from lung or orbital tissue explants from wild-type (WT) 
and Asm-/- mice [34]. Mice were raised for 8-10 weeks before they were sacrificed. Primary 
fibroblasts were cultured in 6-cm dishes in minimum essential medium supplemented with 
10 % FCS, penicillin and streptomycin, 1 % non-essential amino acid, 1 % sodium 
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pyruvate, 1 % 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, and 1 
% L-glutamine (all from GIBCO, Invitrogen), at 37°C in a 10 % CO2-containing 
humidified incubator and passaged every week. For experiments, passages 2 and 3 were 
used. For experiments with imipramine using primary cells, primary mouse feet fibroblasts 
were kindly provided by F. Valsecchi (Radboud University Nijmegen Medical Centre). 
3.2.3 Confocal laser scanning microscopy 
Confocal laser scanning microscopy was performed on a TCS SP5 confocal microscope 
(Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 x N.A. 1.2 
water immersion lens. Cells were maintained at 37°C on a temperature-controlled 
microscope stage. Images of ASMase-deficient cells were also taken with an HCX PL APO 
63 x N.A. 1.4 oil immersion lens (Leica Microsystems) at room temperature (RT), as 
indicated. For all microscopy images, one confocal slice is shown. 
3.2.4 Peptide uptake 
For confocal microscopy, HeLa cells or primary mouse fibroblasts were seeded in 8-well 
microscopy chambers (Nunc, Wiesbaden, Germany) and grown to 75 % confluence. Cells 
were incubated with peptides in RPMI 1640 supplemented with 10 % FCS for durations 
and concentrations as indicated for the individual experiments. Imipramine pre-treatment to 
reduce ASMase activity was conducted by incubating cells for 30 min with 30 M 
imipramine in RPMI 1640 without FCS. 30 M imipramine and 10 % FCS were included 
during peptide incubations. In experiments with bacterial sphingomyelinase, imipramine 
was only present before, but not during the peptide incubations. Cells were washed twice 
after the incubation and living cells were analyzed immediately by confocal microscopy.  
Modifications for uptake experiments by flow cytometry were the use of 24-well plates 
(Sarstedt, Numbrecht, Germany) and a trypsinization step, which was followed by 
centrifugation and resuspension in 200 l HEPES-buffered saline (HBS; 10 mM HEPES, 
135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4). Cellular fluorescence of 
10,000 cells, gated on the basis of forward and sideward scatter, was measured using a BD 
FACScan flow cytometer equipped with a 488 nm laser (BD Biosciences, Erembodegem, 
Belgium) and analyzed using Summit software (Fort Collins, USA).  
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3.2.5 Immunofluorescence 
HeLa cells were seeded in 8-well microscopy chambers and grown to 75 % confluence. 
Cells were incubated with 20 M R9 for 20 min at 37°C, washed twice with pre-warmed 
HBS containing 0.1 % (w/v) BSA and 5 mM glucose (HBS+) supplemented with 0.025 % 
Tween-20 and fixed for 15 min at RT with 3 % paraformaldehyde in HBS. Then, cells were 
washed twice with HBS+ supplemented with 0.025 % Tween-20 and blocked for 15 min at 
RT with the same buffer. Incubation with the primary antibody took place for 1 h at RT in 
150 l HBS containing 0.1 % (w/v) BSA (HBS/BSA) per well. The rabbit polyclonal IgG 
anti-ASMase antibody sc11352 (dilution 1:50, Santa Cruz Biotechnology, Santa Cruz, 
U.S.A.) was used for ASMase detection. A rabbit polyclonal IgG against NF B was used 
as an isotype control (Santa Cruz Biotechnology). Ceramide was detected with a 1:50 
dilution in HBS/BSA of a monoclonal mouse anti-ceramide IgM antibody 15B4 (Alexis 
biochemicals, Lausen, Switzerland). A b allotype, anti-KLH mouse IgM antibody (BD 
Pharmingen, San Diego, U.S.A.) was used as an isotype control for ceramide detection. 
After incubation with the primary antibody, cells were washed 2 x 5 min with HBS+ 
supplemented with 0.025 % Tween-20. Incubation with secondary antibodies was for 45 
min in HBS/BSA, after which cells were washed twice. Confocal images were taken 
immediately. For detection of ASMase and isotype control, an Alexa-633-conjugated goat-
anti-rabbit IgG (H+L) antibody (Invitrogen, 1:100 dilution) was used. For detection of 
ceramide and isotype, an Alexa-633-conjugated goat-anti mouse IgG (H+L) antibody 
(Invitrogen, 1:100 dilution) was used. 
3.2.6 ASMase activity assay 
HeLa cells were seeded at a density of 80,000 cells in 24-well plates one day before the 
experiment. Cells were treated for 30 min with 30 M imipramine or for 20 min with 
unlabeled R9 at 5 or 20 M. Then, cells were lysed and scraped in cold distilled water 
containing 1 mM PMSF, followed by three freeze-thaw cycles using liquid nitrogen. The 
lysate was centrifuged for 10 min at 18,000 g and the ASMase activity in the supernatant 
was assayed using an ASMase activity kit (Echelon Biosciences, Salt Lake City, U.S.A.) 
according to the manufacturer‟s instructions.  
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3.3 Results 
3.3.1 Inhibition of direct translocation of nona-arginine (R9) after inhibition of ASMase 
Previously, we and others described the direct cytoplasmic import of cationic CPP through 
localized plasma membrane regions, which we termed nucleation zones [8, 15, 17]. This 
import has a particular pharmacological profile, being sensitive to rottlerin, and 
chlorpromazine. In a search for a common denominator of these findings, we found that 
both compounds have the potential to interfere with the activation of ASMase. Among 
other activities, rottlerin has been shown to directly prevent the activation of ASMase [25], 
whereas chlorpromazine accumulates in acidic compartments in living cells, leading to the 
displacement of ASMase from the membranes of acidic vesicles into the lumen, after which 
the enzyme is susceptible to proteolytic degradation by lysosomal proteases [23, 24]. Both 
compounds are no specific ASMase inhibitors. Nevertheless, given their shared effect on 
ASMase activity, we hypothesized that the rapid cytoplasmic import might depend on the 
activation and translocation of ASMase from an intracellular compartment to the 
extracellular leaflet of the plasma membrane, where it would change the plasma membrane 
composition by hydrolyzing sphingomyelin to ceramide [30]. To probe for the involvement 
of ASMase in the direct translocation of R9 in HeLa cells, we decided to first use 
imipramine as a pharmacological ASMase inhibitor. Like chlorpromazine, imipramine is a 
cationic amphiphile that accumulates in lysosomal compartments. With respect to ASMase 
inhibition, the mode of action of imipramine very likely corresponds to that of 
chlorpromazine [24]. We confirmed the inhibitory activity in our HeLa cells by probing for 
ASMase activity after treatment of cells with the compound (Figure 3.1A). 
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Figure 3.1. Effect of imipramine and unlabeled R9 on ASMase activity in HeLa cells. (A) HeLa cells were 
seeded at a density of 80,000 cells/well in a 24-well plate one day before the experiment. Cells were incubated 
with 30 M imipramine in serum-free RPMI, detached by scraping in distilled water containing 1 mM PMSF and 
lysed by three freeze-thaw steps using liquid nitrogen. ASMase activity was determined using a commercially 
available ASMase activity kit according to the manufacturer‟s instructions and normalized to the ASMase activity 
of the control. Error bars denote the standard error of the mean of two independent experiments performed in 
triplicate. (B) HeLa cells were seeded at a density of 80,000 cells/well in 24-well plates, incubated with the 
indicated concentrations of unlabeled peptide for 20 min at 37°C in RPMI + 10 % FCS, washed and assayed for 
ASMase activity using a commercially available kit according to the manufacturer‟s instructions. Error bars 
denote the standard error of two independent experiments. In this assay, unlabeled R9 was employed in order to 
avoid interference with the fluorescence-based activity assay. 
As predicted, imipramine greatly decreased the cytoplasmic uptake of the cationic CPP 
R9 to a similar degree as rottlerin (Figure 3.2A). By confocal microscopy no significant 
effects of both inhibitors were observed at a peptide concentration of 5 M, suggesting that 
endocytosis was unaffected by these molecules. A quantitative analysis by flow cytometry 
confirmed that internalization of R9 was reduced by 64 % at 10 M and even by 81 % at 20 
M R9 (Figure 3.2B-C). At 5 and 2.5 M, the reduction of the median fluorescence was 
only 19 % and 22 %, respectively. The use of the human lactoferrin (hLF) peptide, a 
cationic CPP derived from human lactoferrin [32], demonstrated that imipramine-
sensitivity of direct uptake was not restricted to R9. For hLF at 20 M cytoplasmic 
fluorescence was also almost completely absent (Figure 3.2D). As for R9, hLF uptake via 
endocytosis at 5 M was unaffected. 
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Figure 3.2. Uptake of cationic cell-penetrating peptides is sensitive to imipramine and rottlerin. (A) Effect of 
a pre-treatment with imipramine or rottlerin on the uptake of R9 in HeLa cells. HeLa cells were pre-treated for 30 
min with imipramine or rottlerin and incubated for 20 min at 37°C with the indicated concentrations of R9 in the 
presence or absence of the inhibitors, washed and analyzed by confocal microscopy. 0.1 % Dimethyl sulfoxide 
(DMSO) was included as a vehicle control. Settings for image acquisition were optimized for the individual 
concentrations to avoid saturation or too poor detection (please note the logarithmic scale in panel C). Here, and 
for all other microscopy images, one confocal slice is shown. The scale bar corresponds to 20 m. (B) 
Quantification of cellular fluorescence by flow cytometry. HeLa cells seeded in 24-wells plates were incubated 
with 20 or 10 M R9 for 20 min at 37°C with (no fill) or without (grey) imipramine pre-treatment. (C) Median 
fluorescence intensity of uptake of R9 with (+) or without (-) imipramine as derived from flow cytometry 
performed as described in (B). Error bars indicate standard error of the mean of two independent experiments. (D) 
Effect of imipramine on the uptake of the cationic CPP hLF at 5 and 20 M. Experimental conditions were similar 
as described in (A). The scale bar indicates 20 m. 
Our hypothesis implicated a role of ceramide formation at the plasma membrane 
following ASMase translocation in CPP uptake. Therefore, we reasoned that a direct 
translocation of cationic CPP after an imipramine pre-treatment may be rescued by addition 
of exogenous bSMase from Bacillus cereus, which is known to have a high specificity 
towards sphingomyelin [35]. Moreover, because the enzyme has a high specific activity 
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(100 units/mg), aspecific interactions between the enzyme and the peptide or plasma 
membrane are unlikely to influence peptide uptake. As can be seen in Figure 3.3A, the 
addition of bSMase rescued the cytoplasmic import of R9 in HeLa cells in a dose-
dependent manner, providing more direct evidence for the notion that ceramide formation 
at the plasma membrane is required for the direct cytoplasmic import. This bSMase-
dependent induction of uptake was not due to a compromise of membrane integrity. No 
uptake of propidium iodide (PI) was observed (Figure 3.3B). Only after addition of 
detergent, PI entered cells, while peptide rapidly leaked out. This result indicates that the 
capacity for rapid cytoplasmic uptake is a characteristic of R9, even if ceramide formation 
is induced by exogenously added enzyme. 
 
Figure 3.3. Reduced uptake of R9 in imipramine-treated HeLa cells can be rescued by external 
sphingomyelinase, while preserving membrane integrity. (A) HeLa cells were seeded in 8-well microscopy 
chambers and grown to 75 % confluence. Cells were pre-treated with 30 M imipramine (+) for 30 min or left 
untreated (-). The effect of addition of the indicated concentrations (in mU) of bacterial sphingomyelinase 
(bSMase) on uptake of 20 M R9 was evaluated by incubation of cells with peptide and bSMase for 20 min at 
37°C, followed by a wash, and immediate analysis by confocal microscopy. (B) Bacterial sphingomyelinase 
(bSMase) treatment preserves membrane integrity. HeLa cells were seeded in 8-well chambered coverslips as 
described above and incubated with 10 M R9 for 20 min at 37°C, in the presence of propidium iodide (PI, 5 
g/ml) and, bSMase (1000 mU) as indicated. Analysis by confocal microscopy was performed without a wash 
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step. As a positive control for PI uptake, Tween-20 was added to a concentration of 0.5 % in a sample treated with 
peptide and bSMase 20 min after the start of the incubation. This sample was analyzed 15 min later. The scale bars 
denote 40 m. 
3.3.2 Translocation of ASMase and the formation of ceramide-enriched membrane 
platforms  
We then pursued the visualization of the translocation of ASMase to the extracellular 
leaflet of the plasma membrane. For this purpose, fixed but unpermeabilized HeLa cells 
that had been treated with 20 M R9 or left untreated were probed for ASMase by 
immunofluorescence (Figure 3.4A). Translocated ASMase was detectable at the plasma 
membrane in confocal images of cells treated with R9 in some, but not all, cells. Although 
translocated ASMase is thought to be derived from intracellular vesicles, the enzyme was 
not only localized in punctate structures at the plasma membrane, but also across larger 
platforms, most likely due to rapid lipid raft clustering [36] (Figure 3.4A). In some 
locations, ASMase immunofluorescence colocalized with fixed nucleation zones 
(illustrated by arrows in Figure 3.4A), but this was not always evident. As fixation may 
lead to a redistribution of intracellular peptides, colocalization with fixed CPP should be 
interpreted with caution [37]. 
Translocated ASMase was only observed in cells that were brightly stained with 
fluorescein. To assess whether lower concentrations of R9 also induced ASMase activity, 
HeLa cells were assayed for total ASMase activity after a 20 min treatment with 5 or 20 
M unlabeled R9 at 37°C using a commercially available ASMase activity kit. However, 
using this kit, for both concentrations we could only observe a modest trend towards a 
slightly higher total ASMase activity at both concentrations (Figure 3.1B). 
When the formation of ceramide-enriched membrane platforms was investigated by 
immunofluorescence (Figure 3.4B), we observed a more pronounced colocalization 
between fixed nucleation zones and ceramide-enriched membrane platforms. No ceramide 
platforms were identified on untreated cells. Because ceramide affects the membrane 
architecture in multiple ways, including facilitating the exposure of phosphatidylserine (PS) 
through transbilayer lipid flip-flop [38], we also probed for an enhanced PS-exposure 
following an R9 treatment, which was indeed found in a time-lapse experiment (Figure 
3.5A). 
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3.3.3 Reduced uptake in ASMase-deficient (Asm-/-) primary fibroblasts 
To further validate that the reduced uptake after imipramine treatment was due to a 
reduction in ASMase activity, the cytoplasmic uptake of R9 was investigated in ASMase-
deficient (Asm-/-) primary mouse fibroblasts. Again, cytoplasmic fluorescence was strongly 
reduced for higher peptide concentrations (Figure 3.6A), thereby corroborating the role of 
ASMase for the direct cytoplasmic uptake of cationic CPP. At 10 M peptide only little 
difference in ASM-deficient and wild-type cells was observed. In these fibroblasts 
cytoplasmic uptake led to a filamentous distribution of fluorescence, very likely reflecting 
binding to actin which has been reported for cationic peptides [39]. The effect of ASMase 
deficiency was similar to the effect of an imipramine treatment in primary mouse 
fibroblasts (Figure 3.5B), demonstrating that the decreased peptide uptake is due to a lack 
of ASMase activity and not due to compensatory changes in these cells. Consistently, for 
the ASM-/--cells, rapid uptake could also be rescued by addition of exogenous bSMase 
(Figure 3.6B).  
Chapter 3 – Cationic CPP induce ceramide formation via ASMase 
59 
 
 
Figure 3.4. R9 induces the translocation of ASMase and formation of ceramide platforms at the plasma 
membrane. HeLa cells were seeded in 8-well microscopy chambers and grown to 75 % confluence. Cells were 
treated with 20 M R9 for 20 min at 37°C or left untreated. Immunofluorescence without permeabilization was 
performed using A) anti-ASMase (IgG) and B) anti-ceramide (IgM) antibodies, including isotype controls. Alexa-
633 conjugated secondary antibodies were visualized by confocal microscopy. The scale bar corresponds to 15 (A) 
or 10 m (B). The staining of nucleoli by R9 is typically observed upon fixation. Arrows indicate colocalization 
between nucleation zones and ASMase or ceramide. 
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Figure 3.5. Time-lapse of R9-induced phosphatidylserine (PS) exposure and effect of a pre-treatment with 
imipramine on the uptake of R9 in primary mouse fibroblasts. (A) HeLa cells were seeded one day before the 
experiment at 40,000 cells/well in 8-well chambered coverslips. Cells were incubated with 20 M R9 in the 
presence of Alexa-647 labeled annexin-V as a probe for PS (1:50 dilution) and images were acquired directly. A 
notable increase in punctate PS exposure following R9 treatment was observed, with all areas corresponding to 
nucleation zones showing overlap with PS exposure. Besides PS exposure at areas of nucleation zones, punctate 
PS exposure was also detected at many other areas. The scale bar indicates 20 m. (B) Primary mouse feet 
fibroblasts were seeded one day before the experiment in 8-well chambered coverslips and grown to confluence in 
minimal essential medium supplemented with 10 % FCS. Fibroblasts were pre-treated for 30 min with 30 M 
imipramine and incubated for 30 min at 37°C with the indicated concentrations of R9 in the presence (imipramine) 
or absence (control) of imipramine, washed and analyzed by confocal microscopy. The scale bar denotes 20 m. 
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3.3.4 Effect of exogenous SMase activity on the threshold for peptide uptake via direct 
translocation 
The results shown above suggested that high concentrations of peptide were required to 
induce sufficient ASMase activity to initiate rapid cytoplasmic import. We then 
investigated whether the concentration threshold for rapid cytoplasmic uptake could be 
lowered by treatment of HeLa cells with bSMase. Cells were incubated with 5 M R9, a 
concentration at which direct translocation is not observed, in the presence of 1000 mU 
bSMase. This experiment would provide information on whether peptide concentration or 
the induction of sphingomyelinase activity is the limiting factor for uptake via direct 
translocation. As expected, in the untreated cell population rapid uptake of R9 was virtually 
absent. In contrast, many cells with intense cytoplasmic and nuclear fluorescence were 
detected in the sphingomyelinase-treated cell population (Figure 3.7A). Similar 
observations were made in mouse fibrosarcoma MC57 cells (data not shown).  
To assess the size limit for this sphingomyelinase-induced uptake of direct 
translocation, HeLa cells were incubated with R9 coupled to differently sized cargos. In the 
presence of sphingomyelinase, we found an increased direct translocation of R9 conjugated 
to a short 7 amino acids apoptosis-enhancing smac-derived peptide derived from the 
proapoptotic smac protein [40-42] though only at higher peptide concentrations than for R9 
(Figure 3.7A). For R9 coupled to 28 kDa N-(2-hydroxylpropyl) methyl acrylamide 
(HPMA) polymers [33] no direct translocation was observed at concentrations up to 20 M 
of the HPMA polymer, indicating that the sphingomyelinase-mediated uptake was 
restricted to low-molecular weight molecules.  
Previously, we had established that rapid uptake at high R9 concentrations occurred 
through spatially confined nucleation zones [8]. We were now interested to learn whether 
external addition of bSMase led to a similar internalization mechanism via localized plasma 
membrane domains or whether uptake occurred homogeneously distributed over the plasma 
membrane because of the ubiquitous presence of bSMase. Therefore, a time-lapse 
experiment was conducted. Peptide uptake was followed in real-time at low concentrations 
in the presence or absence of bSMase, and at high concentrations in the absence of 
bSMAse (Figure 3.7B). Also for the externally added bSMase entry was restricted to 
confined zones at the plasma membrane. Uptake occurred minutes after the start of the 
incubation and had the same morphological characteristics as the uptake observed for 20 
M R9 in the absence of bSMase. Without bSMase, no rapid cytoplasmic uptake was 
observed at 5 M. 
Chapter 3 – Cationic CPP induce ceramide formation via ASMase 
62 
 
 
Figure 3.6. Cytoplasmic import of R9 is inhibited in ASMase-deficient primary fibroblasts. Primary mouse 
fibroblasts were seeded one day before the experiment in 8-well microscopy chambers. (A) R9 was added to wild-
type (WT) and ASMase-deficient primary mouse fibroblasts at the indicated concentrations and incubated for 30 
min at 37°C in serum-containing medium. Cells were then washed twice and analyzed immediately by confocal 
microscopy. Image acquisition parameters were optimized for the individual peptide concentrations. (B) ASMase-
deficient fibroblasts were incubated with 20 M R9 for 30 min at 37°C in the presence or absence of 1000 mU 
bSMase, washed and analyzed immediately by confocal microscopy. Scale bars correspond to 40 m.  
 
Figure 3.7. Effects of bacterial sphingomyelinase (bSMase) on the uptake of R9 and R9-conjugates. (A) 
HeLa cells were seeded in 8-well microscopy chambers and grown to 75 % confluence. Cells were incubated for 
30 min with the indicated concentrations of R9 or R9-conjugates +/- 1000 mU bSMase, washed and analyzed by 
confocal microscopy. Settings were optimized for the individual samples. The scale bar corresponds to 20 m. (B) 
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Time-lapse experiment of uptake of R9 after bSMase treatment. HeLa cells were seeded in 8-well microscopy 
chambers, grown to confluence and incubated with the indicated peptide concentrations and bSMase (1000 mU) as 
indicated. Uptake was followed in real-time by confocal microscopy at 37 °C on a temperature-controlled stage. 
The timepoint t = 0 corresponds to the first image acquired, which was taken as soon as possible after peptide 
addition. The scale bar indicates 20 m. 
3.4 Discussion 
CPP hold a great potential for the delivery of membrane-impermeable molecules. To 
exploit this potential to the fullest, it is imperative that the import mechanisms and the 
associated effects on the cells are well understood. Despite various reports of direct 
translocation of arginine-rich CPP [8, 15-17, 20], and biophysical [21] and molecular 
dynamics [22] studies supporting this ability, the biology behind these observations has 
proven elusive. Here, we demonstrate that the previously poorly understood mechanism of 
rapid cytoplasmic entry of cationic CPP via nucleation zones strongly depends on the 
induction of translocation of ASMase to the plasma membrane and ceramide formation.  
We verified the involvement of ASMase activity in the rapid import mechanism a) by a 
pharmacological inhibition of ASMase using imipramine, b) by a rescue of the cytoplasmic 
CPP uptake via exogenous addition of bSMase, c) by showing a reduced cytoplasmic 
import in ASMase-deficient primary mouse fibroblasts and d) the corresponding rescue of 
efficient uptake by exogenously added bSMase. The cellular events involved in the process, 
a translocation of ASMase to the outer leaflet of the plasma membrane and the formation of 
ceramide-enriched membrane platforms, were visualized by immunofluorescence 
microscopy. While phosphatidylserine exposure is only indirect evidence for ceramide 
formation, our time-lapse experiments nevertheless provide further evidence for an impact 
of the peptides on membrane architecture [43].  
We also showed that the threshold for direct translocation can be lowered by co-
incubation of R9 with bSMase. Finally, by real-time confocal microscopy, we 
demonstrated that the uptake mechanism of R9 at 20 M is similar to the uptake of 5 M 
R9 in the presence of bSMase: both lead to rapid cytoplasmic entry of peptide through 
spatially confined nucleation zones. To our knowledge, this is the first demonstration of a 
CPP-mediated induction of enzymatic activity that changes the lipid composition of the 
plasma membrane, which then stimulates CPP uptake. A schematic representation of the 
proposed import mechanism is presented in Figure 3.8. Our data suggests the presence of a 
positive feed-back mechanism: an initial induction of ASMase translocation, followed by a 
remodeling of the plasma membrane and subsequent cytoplasmic entry. Peptide 
concentration is limiting for the first step, but not for rapid entry, as demonstrated by 
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cytoplasmic entry at low peptide concentrations in the presence of exogenously added 
bSMase. It is interesting to note, that even in the presence of exogenously added bSMase 
entry is confined to nucleation zones. At this point, we can only speculate that this 
localized entry reflects the tendency of ceramide-rich microdomains to coalesce to larger 
structures referred to as ceramide-enriched membrane platforms [44]. Nevertheless, despite 
these clear indications for a direct role of ceramide in enhancing peptide translocation, the 
involvement of ceramide-dependent signaling pathways or ceramide-derived metabolites in 
peptide uptake cannot be excluded. 
 
Figure 3.8. Schematic overview depicting the proposed import mechanism of cationic CPP via direct 
translocation through nucleation zones. (A) First, CPP induce the translocation of ASMase from intracellular 
compartments to the outer leaflet of the plasma membrane via an unknown mechanism. (B) Second, ASMase 
hydrolyzes sphingomyelin, resulting in the formation of ceramide-enriched microdomains that may fuse to form 
larger platforms. (C) Third, cationic CPP enter the cytosol directly across the plasma membrane, most likely at the 
border region of segregated gel-like ceramide-rich domains and more fluid domains, as this border region is 
expected to be the most permeable part of the plasma membrane [45]. In their combination, these steps constitute a 
positive feed-back loop. 
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It still remains to be resolved by which mechanism the cationic CPP activate ASMase. 
It is known that, next to apoptosis-inducing growth factors, ASMase is activated by a 
variety of stressors [25, 46], with a possible role for reactive oxygen species [47-49]. Of 
note is that superoxide formation induced by octa-arginine was recently described in 
macrophages [50], although it is currently unclear whether there is a relationship with our 
present findings. It is also attractive to speculate that CPP-induced exocytosis-dependent 
membrane repair mechanisms, through release or translocation of lysosomal enzymes [51] 
lead to an enhanced sphingomyelinase activity at the plasma membrane. However, one 
should note, that the molecular mechanism underlying the cellular translocation of ASMase 
is poorly understood in general [52]. 
Our results are not the first to implicate ceramide in membrane permeability. Even 
though such effects have been mainly described in model systems [53], an effect of 
ceramide on the release of pro-apoptotic proteins with a size of up to 57 kDa from 
mitochondria has also been described [54]. More recently, increases of ceramide 
concentration in the mitochondrial outer membrane were found to correlate directly with 
cytochrome C (12 kDa) release [31]. Nevertheless, our data did not support a general 
increase in membrane permeability as the source of the ASMase-induced rapid peptide 
uptake. An increased uptake was confined to small molecules directly conjugated to a CPP. 
No increased uptake was observed if the small molecule was applied by co-administration. 
In mammalian cells, many other lipids influence plasma membrane properties. Of 
special interest in the relationship between cholesterol and ceramide. Cholesterol prevents 
both ceramide-induced membrane changes through a competition with ceramide for 
association with lipid rafts [55, 56] and inhibits ASMase activity directly [56], which might 
explain our previous finding that methyl- -cyclodextrin enhances peptide uptake [8].  
It has been demonstrated that at 4°C direct membrane translocation may be induced in 
suspension cells, although the mechanism does not involve nucleation zones [15, 19]. It is 
tempting to speculate that lowering of temperature may affect membrane fluidity or 
microdomain organisation in a similar way as does ceramide formation, which could create 
a common denominator for these observations.  
Our findings show that cationic CPP do not function as inert delivery vectors, but have 
significant biological effects instead. Besides its effects on membrane physical properties, 
ceramide and ASMase are also a major players in widely differing pathological conditions, 
ranging from Niemann-Pick disease [26] to heart disease and cancer [27]. Given their effect 
on ceramide and ASMase, the pharmacodynamic properties of cationic CPP should 
evidently be taken into account when designing CPP-based therapeutic strategies and 
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evaluating their outcomes. For instance, multiple cationic CPP-drug conjugates were shown 
to induce ceramide, whereas the drugs did not do so by themselves [57]. This activity was 
attributed to the mode of drug delivery rather than the vector itself. Our results indicate that 
the bioactive properties of the cationic CPP may have contributed to the enhanced 
cytotoxicity. Nevertheless, it should be pointed out that the CPP by themselves were well 
tolerated, also at concentrations at which nucleation zone-dependent entry was observed [8, 
32]. In future studies, it will be highly interesting to investigate whether cationic CPP 
preferentially induce ceramide in tumor cells, which might be useful for enhancing 
cytotoxic effects of chemotherapeutic drugs [58]. Noteworthy is also that ASMase 
activation is not just required for apoptosis initiation or sphingomyelin turnover. Being at 
the center of sphingolipid catabolism, ASMase is, through its impact on ceramide 
generation, implicated in numerous other physiological processes [52, 59]. The exact effect 
of generated ceramide depends on the cellular context and is affected by multiple factors 
including the presence of ceramidases and effector proteins such as ceramide-activated 
protein phosphatases. The activation of the ASMase/ceramide pathway is also associated 
with other pathophysiologically relevant phenomena, as is illustrated by recent findings 
showing that measles virus-induced membrane ceramide accumulation targets specific 
processes in T cell activation and function [29]. To what degree there is a physiological 
mechanism coupling membrane-active peptides to ceramide formation is unknown, 
although pathological amyloid peptides were found to be able to induce apoptosis in an 
ASMase-dependent manner [60]. 
By shedding light on a biological mechanism involved in membrane translocation, our 
findings regarding membrane remodeling will also be relevant for the choice of a model 
system for biophysical studies. Ideally, such model systems should have a capacity to 
reflect the effect ceramide has on the membrane properties in order to be an accurate model 
system. It will therefore be highly interesting to include ceramide in such experiments or 
perform experiments with sphingomyelin-containing model membranes in the presence of 
bSMase.  
In conclusion, we show that the previously poorly understood direct cytoplasmic uptake 
of the cationic CPP depends on a specifically induced enzymatic alteration of the 
composition of the plasma membrane, namely sphingomyelin hydrolysis to ceramide by 
ASMase. To our knowledge, no earlier studies have shown that delivery vectors can 
operate through actively changing the composition of the plasma membrane via an induced 
enzymatic activity. The finding that cationic CPP by themselves induce ASMase is a 
further example of the notion that cationic CPP do not act as true Trojan horses, i.e. purely 
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pharmacokinetic modifiers, but have their own pharmacodynamic activity. Together with 
the induction of receptor internalization [41], the activation of ASMase is another 
important factor that requires scrutiny in the application of CPP. 
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Abstract 
The use of protease-resistant D-peptides is a prominent strategy to overcome proteolytic 
sensitivity in the use of cell-penetrating peptides (CPPs) as delivery vectors. So far, no 
major differences have been reported for the uptake of L- and D-peptides. Here, we report 
that cationic L-CPPs are taken up more efficiently than their D-counterparts in MC57 
fibrosarcoma and HeLa cells, but not in Jurkat T leukemia cells. Reduced uptake of D-
peptides co-occurred with persistent binding to heparan sulfates (HS) at the plasma 
membrane. In vitro binding studies of L- and D-peptides with heparan sulfate indicated 
similar binding affinities. Our results identify two key events in the uptake of CPPs: 
binding to HS chains and the initiation of internalization. Only the second event depends on 
the chirality of the CPP. This knowledge may be exploited for a stereochemistry-dependent 
preferential targeting of cells. 
4.1 Introduction 
The use of cell-penetrating peptides (CPPs) such as nona-arginine (R9), TAT or penetratin 
as delivery vectors for molecules that otherwise do not cross the plasma membrane is 
gaining significance in biomedicine [1]. Although different strategies are pursued for the 
optimization of CPP-based delivery, premature degradation of CPPs before they reach their 
target in vivo remains a common concern for therapeutic applications [2]. The relevance of 
this concern is exemplified by the rapid degradation of CPPs when they are in contact with 
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various cell lines [2-4] or when they are exposed to serum [5, 6]. A common strategy to 
combat this issue is to employ CPPs consisting of D-amino acids (D-CPPs). The altered 
stereochemistry of peptides containing D-amino acids renders D-CPPs much more protease 
resistant than their L-amino acid counterparts [5-7].  
The increased stability in serum is not limited to peptides composed entirely of D-
amino acids, but was also observed for partial D-amino acid substitutions at the termini in 
small peptides [8] and for CPPs conjugated to morpholino-nucleotide oligomers [7].  
For penetratin uptake was observed for the reverse L-amino acids sequence, the D-
peptide and a retro-inverso analog, suggesting that backbone chirality is not important for 
uptake of this CPP [9, 10]. Since uptake was also observed at 4°C, the authors suggested 
that internalization occurred via a receptor-independent mechanism, most likely involving 
direct interactions with membrane phospholipids [10]. Later studies corroborated this 
hypothesis for inverso and retro-inverso analogs of poly-arginines and the arginine-rich 
TAT peptide [11, 12], which together have led to the prevailing paradigm that cellular 
uptake of CPPs is a chirality-independent process. Studies using these and other CPPs, 
including pVEC and sweet arrow peptide provided additional support for this current 
paradigm [5, 13, 14]. A higher uptake efficiency of D-TAT and D-poly-arginines in the 
presence of serum [12] was attributed to an increased proteolytic stability [15].  
While the available studies thus appear to sketch a uniform picture, one should 
acknowledge that these studies were conducted with a rather limited number of cell-types. 
It is well established, however, that different mechanisms for CPP uptake are operating in 
different cell types [16]. Moreover, some of the earlier studies did not distinguish between 
membrane-bound and internalized peptides. Nowadays, the distinction between internalized 
and membrane-associated peptide is considered a vital aspect for the quantification of CPP 
uptake [17-19] and is generally accomplished by a specific modification of the membrane-
bound fraction [17, 18] or by a trypsin and/or heparin treatment of cells. Since trypsin does 
not degrade D-peptides, in studies comparing the uptake of D- and L-CPP an incubation of 
cells with heparin is the appropriate treatment for removal of membrane-bound peptides.  
Recent advances in the quantification of internalization, and the introduction of 
protocols to study CPP uptake using live cell confocal microscopy warrant a new analysis 
of L- and D-CPP uptake. Therefore, the goal of the present study was to study in detail 
possible differences in the cellular uptake of arginine-rich as well as cationic amphiphilic 
all-L-CPPs and their all-D counterparts, using a panel of cell types for which we had 
previously noted differences in the intracellular distribution of CPPs. The CPPs used were 
nona-arginine (R9), which is considered to be conformationally unstructured, and the 
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amphiphilic CPP penetratin, which adopts different conformations depending on the local 
environment and also contains several arginine residues. Furthermore, the human 
lactoferrin-derived peptide hLF(38-59) was included [20]. Being entirely composed of D-
amino acids, the inverso peptide D-nona-arginine (r9) is at the same time also the retro-
inverso analog of R9, and as such it is topologically essentially equivalent to R9 with 
respect to the absolute side-chain orientation. For hLF, uptake efficiency is conformation-
dependent. Presence of a disulfide bridge is required for activity [20]. 
Surprisingly, we found significant differences in the uptake of all-L- and all-D CPPs in 
HeLa and MC57 cells, but not in Jurkat cells. In cells with reduced uptake of D-peptides, a 
persistent binding to heparan sulfates (HS) was observed. These differences in uptake were 
restricted to uptake via endocytosis. In contrast, rapid cytoplasmic uptake by nucleation 
zones, which occurs for R9 and hLF at higher concentrations [21], was even more effective 
for r9. Detailed binding studies by surface plasmon resonance (SPR) and isothermal 
titration calorimetry (ITC) indicated that D- and L-peptides bound to HS with similar 
affinities, indicating that they also bind cellular heparan sulfates with similar propensity, 
but differ in their capacity to trigger their endocytic uptake. Results obtained for a series of 
peptides with partial D-amino acid substitutions suggest that a consecutive stretch of L-
amino acids is required to trigger uptake. The cell type dependence of the L versus D 
preference suggests that the stereochemistry of cationic CPPs may be exploited as a new 
principle for a cell type selective targeting. 
4.2 Results 
4.2.1 Cellular uptake of R9 and r9 
 To address potential differences in the cellular uptake and intracellular trafficking of CPP 
(for peptide sequences, see table 4.1), we analyzed the uptake and intracellular distribution 
of R9 and r9 by confocal microscopy in MC57 fibrosarcoma [22], HeLa, and Jurkat cells. 
The selection of cell lines was motivated by previously observed differences in cytoplasmic 
fluorescence at low peptide concentrations, at which uptake via endocytosis occurs. In 
MC57 fibrosarcoma cells, fluorescence was to a larger extent cytoplasmic, while in HeLa 
cells fluorescence was more restricted to vesicular structures [23]. At low concentrations, 
fluorescence was also strongly cytoplasmic in Jurkat cells and other leukocytes [13]. 
Uptake and intracellular distribution were compared after a 45-min incubation with the 
peptides at a concentration of 5 M (Figure 4.1A-C).  
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Table 4.1 Peptide sequences 
 Sequence MW Ref 
R9 1Fluo-RRRRRRRRR-NH2
2 1781 [12]  
r9 Fluo-rrrrrrrrr-NH2 1781 [12]  
r9-fluo Ac-rrrrrrrrrk-fluo 1955 n/a 
R9 (1,9) Fluo-rRRRRRRRr-NH2 1781 n/a 
R9 (1,3,5,7,9) Fluo-rRrRrRrRr-NH2 1781 n/a 
L-penetratin Fluo- RQIKIWFQNRRMKWKK-NH2 2605 [10]  
D-penetratin Fluo-rqikiwfqnrrmkwkk-NH2 2605 [10]  
L-hLF Fluo-KCFQWQRNMRKVRGPPVSCIKR-NH2 3076 [20]  
D-hLF Fluo-kcfqwqrnmrkvrgppvscikr-NH2 3076 n/a 
1 Fluo = fluorescein; 2 NH2 indicates C-terminal amide 
 
Unexpectedly, major differences were observed in the uptake of r9 and R9 in both HeLa 
and MC57 cells (Figure 4.1A-B). Punctate vesicular structures inside cells were more 
numerous and brighter for R9 compared to r9. Next to this punctate staining, a cytosolic 
fluorescence was observed for R9 but not for r9 in MC57 and, to a lesser extent, also in 
HeLa cells for R9. In contrast, for r9 there was a more intense staining of the plasma 
membrane (Figure 4.1A-B). This staining was more pronounced for MC57 than for HeLa 
cells. For Jurkat cells, no membrane staining was observed (Figure 4.1C). Instead, only 
differences in the intracellular localization of R9 and r9 were observed. The distribution of 
r9 differed from the one of R9 in that the former strongly stained the nucleoli, in 
accordance with previous observations [13].  
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Figure 4.1. Cellular distribution and uptake of R9 and r9 in HeLa (A), MC57 (B), and Jurkat cells (C). 
HeLa and MC57 cells were seeded in 8-well microscopy chambers, grown to 75 % confluence and incubated with 
5 M of the peptides for 45 min. Jurkat cells were similarly incubated with peptide for 45 min, washed, and then 
transferred into the microscopy chambers. All cells were washed after incubation with heparin. Confocal images 
were acquired immediately. (D) Illustration of the heparin-induced removal of cell-associated fluorescence of r9 in 
living MC57 cells. Following peptide uptake, cells were incubated 2 x 5 min with 100 g/ml heparin. The scale 
bar represents 10 m. 
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We and others had previously described that at higher peptide concentrations, an 
alternative internalization mechanism occurs that rapidly leads to cytoplasmic fluorescence 
[13, 21, 24, 25]. Entry occurs through restricted membrane areas by an acid 
sphingomyelinase-dependent mechanism [25]. The population of cells that shows peptide 
entry via this mechanism can be clearly distinguished as cells with high intensity by flow 
cytometry. Direct cytoplasmic entry was reported to be higher for r9 compared to R9 in 
various cell types, including HeLa cells [15]. Here, we also observed a much larger 
proportion of HeLa cells with high total fluorescence after being treated with r9 versus R9 
at 20 M (Figure 4.2). On the other hand, for r9, flow cytometry histograms showed the 
presence of cells with lower fluorescence than was observed for R9, in agreement with the 
microscopy data (Figure 4.1). These differences indicate that r9 enters more efficiently by 
direct cytoplasmic entry and less efficiently via endocytosis. It should be noted, however, 
that a quantitative determination of peptide uptake by flow cytometry may be hampered by 
quenching of fluorescence of fluorophores bound to cellular structures or present in acidic 
vesicular compartments.  
 
 
Figure 4.2. Uptake of R9 and r9 measured by flow cytometry. HeLa cells were seeded in 24-wells plates and 
grown to ~ 75 % confluence. Cells were incubated with 10 (A) or 20 M (B) R9 or r9 for 20 min at 37°C, washed 
twice with heparin, trypsinized and resuspended in HBS. Peptide internalization in resuspended cells was then 
analyzed by flow cytometry. Insets represent median fluorescence intensity of 10,000 gated living cells. 
4.2.2 Quantification of uptake  
Confocal microscopy showed a more pronounced punctate staining for R9 in comparison to 
r9 in MC57 and HeLa cells at a peptide concentration of 5 M, indicative of a more 
efficient endocytic uptake. To quantitatively confirm these differences, a quantification 
method was developed based on fluorescence correlation spectroscopy (FCS) in cell 
lysates, in order to overcome difficulties potentially associated with fluorophore-based 
assays. Before lysis, cell-associated fluorescence was removed by incubation of cells with 
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heparin [26], which proved highly efficient in the removal of surface-bound fluorescence 
(Figure 4.1D). However, even after washing off all membrane-bound peptides, the 
fluorescence intensity could be influenced by a variety of factors that may differ between 
R9 and r9. For instance, instead of detecting a genuine difference in peptide uptake, it was 
also conceivable that differences in fluorescence intensity for R9- and r9-treated MC57 
cells may arise due to a higher brightness of the fluorophore when attached to R9. 
Moreover, quenching of fluorescence in potential peptide aggregates could affect peptide 
quantification. Furthermore, a fluorescein-labeled degradation product of R9 might be more 
strongly fluorescent than r9, for which no degradation is expected. Lastly, differential 
binding to poly-anions, such as oligonucleotides or protein aggregates, could lead to the 
removal of intact peptides during centrifugation steps which are frequently applied in 
quantification protocols.  
To address all of the above points, we exploited the capacity of FCS to provide 
information on the total fluorescence, the particle number, the fluorescence per molecule, 
and the presence of aggregates [27]. Nucleic acids were degraded with benzonuclease, 
followed by complete degradation of all proteinaceous components by proteinase K (Figure 
4.3).  
When we quantified the intracellular fluorescence of R9 and r9 with the above-
described protocol, the uptake of r9 was only 21 % of that of R9. Even when we corrected 
for detection efficiency (see legend of Figure 4.3), the uptake of r9 was still only 36 % 
compared to uptake of R9, supporting the observation that peptide uptake is indeed more 
efficient for R9. Notably, also the interaction with HS chains that will also be present in 
lysates did not significantly alter the fluorescence of R9 and r9 (Figure 4.4). 
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Figure 4.3. Quantification and analysis of fluorescence of internalized fluorophores from R9 and r9 by 
fluorescence correlation spectroscopy. (A-D) Autocorrelation functions acquired from MC57 cells incubated 
with R9 (A,B) or r9 (C,D). Measurements were obtained directly after lysis (A,C) or after a treatment of the lysate 
with benzonuclease and proteinase K (B,D). (E) Diffusional autocorrelation times D of R9 and r9 in MC57 cell 
lysates directly after lysis (black bars) or after being treated with benzonuclease and proteinase K (grey bars). The 
diffusion constant of R9 in lysates was unaltered by this treatment, suggesting that most of the fluorescence 
present in cell lysates represents degradation products also before proteinase K treatment. On the other hand, r9-
treated lysates showed shorter diffusion times ( D) upon enzyme treatment, i.e. a higher diffusion constant, which 
is attributed to a reduced association with digested cellular proteins and nucleic acids. Consistent with the 
expected degradation of R9, the diffusion of fluorophores in R9-treated samples was faster than that of r9 (43 vs 
76 s). After digestion, no aggregates were observed that could have compromised the acquisition of 
autocorrelation functions. Therefore, the fluorophore concentrations could be determined directly in cell lysates 
without any centrifugation steps that might have precipitated and thereby removed intact peptides. Notably, even 
after benzonuclease and proteinase K treatment, D values of intact r9 were longer compared to typical D values of 
r9 in buffer (40 to 50 s). This difference is most likely due to the increased viscosity of the lysate. The average 
number of fluorescent particles in the detection volume is inversely related to the amplitude of the autocorrelation 
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function. On this basis, besides the total fluorescence intensity, FCS provides information on molecule numbers 
that is not affected by potential differences in molecular brightness. Furthermore, the ratio of the total fluorescence 
divided by the number of molecules yields the fluorescence per molecule (FPM) (F,G). (F) FPM of R9 and r9 in 
lysates treated with benzonuclease and proteinase K. (G)  FPM of R9 and r9 in PBS incubated for 3 h at 37 °C 
with or without trypsin, as indicated. It was found that the fluorescence per molecule differed only marginally 
between r9 and intact or degraded R9, with similar effects of degradation in buffer (F) and in lysates (G). To be 
able to compare the uptake of R9 and r9, it was also needed to examine the detection efficiency. Since r9 cannot 
be degraded by proteinase K, it is still possible that the detection of fluorescently labeled r9 and arginine-coupled 
fluorophore, the ultimate degradation product of R9, does not occur with equal efficiency. To address this possible 
source of inaccuracy, a control experiment was carried out in which detection efficiency was analyzed for 10 or 50 
nM R9 or r9 added to lysates, which were then treated with benzonuclease and proteinase K. 50 and 10 nM were 
chosen because this resulted in a similar peptide concentration in the lysate as compared to cellular uptake 
experiments, ensuring its relevance. It was found that fluorophores attached to intact r9 were indeed less 
efficiently detected than fluorophores derived from protease-degraded R9 (42 +/- 6 % less efficiently; data not 
shown). In HBS, both peptides were detected with a comparable efficiency (r9 was detected 4 +/- 13 % less 
efficiently; data not shown). The data represent the mean +/- SEM. 
 
Figure 4.4. Effect of heparan sulfate on fluorescence of nona-arginine. 80 nM of R9 or r9 was incubated with 
no, 10 nM or 1 M HS and autocorrelation measurements were acquired by FCS. In panel A, the data show that 
concentrations of HS of up to 1 M do not affect the fluorescence significantly. Panel B shows the particle 
number, which reflects the relative peptide concentration, and panel C the fluorescence per molecule. In panel D, 
the diffusional autocorrelation times ( D) are represented, which indicate that diffusion of R9/r9 is slower in the 
presence of a high concentration of heparan sulfate (1 M). This indicates some interaction of the peptides with 
HS. However, the increase in D is too small to relate to large clusters. HS concentrations are indicated at the X-
axis. Black and grey bars indicate R9 and r9, respectively. 
 
Due to the complexity of the FCS-based method, we also used a simpler fluorimetry 
method to assess peptide internalization. With this method, we found that uptake of r9 was 
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46 +/- 2 % of that of R9 in MC57 cells, and comparable observations were made for HeLa 
cells (53 +/- 1 %), whereas no significant differences were observed in Jurkat cells (91 +/- 
8 %  of r9 compared to R9). 
Another factor possibly contributing to the observed differences in cellular uptake was 
the structural environment of the fluorophore. Since r9 corresponds to a retro-inverso R9, 
coupling of the fluorophore to the C-terminus of r9 should even more closely mimic R9. 
However, very similar cellular distributions of fluorescence were found for (i) N-terminally 
carboxyfluorescein-labeled and C-terminally amidated r9, and an (ii) N-terminally 
acetylated and C-terminally amidated r9, for which the carboxyfluorescein moiety was 
attached to the C-terminus [28] (Figure 4.5A), demonstrating that the position of the 
fluorophore does not explain the differences in distribution and uptake between r9 and R9. 
4.2.3 Peptide export  
 Another factor that may lead to a different distribution and amount of cell-associated 
fluorescence is the rate of export of either the CPP or its degradation products. To 
investigate whether R9 or its degradation products were retained more efficiently in HeLa 
or MC57 cells over the 1-h time course of the experiments, these cells were electroporated 
with a 5 M solution of either R9 or r9 (Figure 4.5B,C). Electroporation delivers a pulse of 
peptides directly into the cytosol. Therefore, this method is well suited to follow the release 
kinetics of molecules. Both, the images per se and the image-based quantification of the 
mean intracellular fluorescence illustrate that no relevant differences could be detected in 
the export of R9 and r9 after 30 min and 1 h, both in MC57 and in HeLa cells. This result 
indicates that a differential export is also not a likely reason for the observed differences.  
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Figure 4.5. Effect of fluorophore position and the rate of export on peptide uptake and/or retention in HeLa 
and MC57 cells. (A) Cellular uptake and distribution of R9, r9-Fluo and Fluo-r9 after a 45-min incubation in 
MC57 cells. Cells were seeded in 8-well microscopy chambers, grown to 75 % confluence and incubated with 5 
M of each peptide at 37°C. Cells were washed twice and confocal images were taken immediately. The scale bar 
represents 20 m. (B,C) Pulse-chase experiment of R9 and r9 in HeLa and MC57 cells. (B) Cells were 
electroporated with 5 M peptide, washed with medium and seeded in 8-well microscopy chambers. Confocal 
images were taken 30 min and 1 h after electroporation. Cells are round as they had to be detached from the 
surface before electroporation. The scale bar represents 10 m. (C) Quantification of mean intracellular 
fluorescence. The data represent the mean +/- SEM. For each condition, over 40 cells were analyzed. 
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4.2.4 Difference in uptake of other cationic L- and D-CPPs in HeLa and MC57 cells  
To investigate whether the differences in uptake were restricted to the poly-arginines R9 
and its all-D counterpart or were also valid for other types of cell-penetrating peptides, we 
compared the uptake of the L- and D-forms of the CPPs penetratin, and hLF, corresponding 
to amino acids 38 to 59 of human lactoferrin [20], in HeLa and MC57 cells (Figure 4.6A-
B). For both of these L-peptides and their D-counterparts, the D-peptides remained much 
more membrane-bound than the L-counterparts in MC57 cells, in agreement with the 
observations for the nona-arginine peptides. For hLF, membrane-bound fluorescence was 
observed for both stereoisomers, but endocytosis of D-hLF was clearly reduced, as 
quantitatively confirmed by measuring the intracellular fluorescence in cell lysates (see 
below and Figure 4.8).  
 
Figure 4.6. Differences in uptake are observed for various different CPPs, and are not explained by stability 
of D-peptides against cysteine proteases. For all experiments, cells were seeded in 8-well microscopy chambers, 
grown to 75 % confluence and incubated with 5 M of each peptide. Cells were washed twice, and confocal 
images were taken immediately. HeLa and MC57 cells were incubated for 45 min with L- or D-penetratin (A) or 
for 30 min with L- or D-hLF (B). (C,D) MC57 cells were pre-incubated with 40 M E64d before a 45-min CPP 
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incubation in the presence or absence of E64d with R9 or r9 (C), or with L- or D-penetratin (D). The scale bars 
represent 10 m. 
4.2.5 Effects of intracellular stability on peptide localization   
Previously, we reported that under conditions where endocytosis was the dominant route of 
uptake the cytoplasmic fluorescence, but not the vesicular fluorescence of L-penetratin in 
MC57 cells was reduced by the broad-range cysteine protease inhibitor E64d [29]. Cysteine 
proteases of the cathepsin family are a major part of proteolytic activity in the 
endolysosomal compartment. Therefore, the result indicated that fluorescein-bearing 
proteolytic fragments escape the endosome more efficiently than intact peptides. We thus 
reasoned that the differences in distribution of intracellular fluorescence of D- and L-
peptides observed by confocal microscopy might be related to the intracellular stability of 
the peptides. To investigate this possibility, MC57 cells were incubated with E64d and 
treated with either R9 or r9. Similar to our previous results, we observed that cytoplasmic 
fluorescence upon R9 and L-penetratin treatment was completely abolished by E64d 
(Figure 4.6C,D). However, vesicular fluorescence was unaffected. Moreover, no effect on 
the distribution of either CPP was apparent. These results indicate that the cytoplasmic 
fluorescence but not the differences in vesicular fluorescence are related to intracellular 
CPP stability. 
4.2.6 Stimulation of uptake of fluorescein-labeled r9 by unlabeled R9/r9 
We and others had demonstrated that CPPs can actively induce endocytosis [30, 31]. We 
therefore tested whether endocytosis of r9 could be increased by co-incubation with 
unlabeled R9. However, no increased internalization of r9 could be observed (Figure 4.7).  
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Figure 4.7. Effect of potential endocytosis triggers on uptake of L- and D-CPPs. (A) Uptake of fluo-R9 in 
MC57 cells in the presence or absence of unlabeled R9 or r9. MC57 cells were seeded in 8-well microscopy 
chambers and grown to confluence. Cells were incubated with 5 M fluo-r9 in the presence or absence of 5 M of 
unlabeled R9 or r9 for 45 min at 37°C. As a comparison, cells were also incubated with fluo-R9. After incubation, 
cells were washed and immediately analyzed by confocal microscopy. The scale bar represents 10 m. (B) Uptake 
of R9 in HeLa cells treated with the nitric oxide synthase inhibitor L-NAME. HeLa cells were seeded in 24-well 
plates and grown to confluence. Cells were pre-incubated with 200 M L-NAME or control medium for 30 min in 
the absence of serum and then for 30 min in RPMI containing 0 or 200 M L-NAME, 5 M R9 and 10 % fetal 
calf serum. Cell were washed, treated with trypsin, spun down, resuspended in HBS and analyzed by flow 
cytometry. Continuous lines indicate untreated control (R9) or no peptide (filled with grey). Dashed lines indicate 
R9 in the presence of 200 M L-NAME. Results from one representative experiment are shown. 
4.2.7 Role of HS chains in membrane binding and cellular uptake of L- versus D-CPPs  
Heparan sulfate chains have been shown to interact with arginine-rich cell-penetrating 
peptides [32, 33] and to play a role in the uptake of CPPs [34, 35]. We therefore 
hypothesized that binding of peptides to HS chains might contribute to the different uptake 
of L- and D-peptides. If this was the case, one consequence would be that Jurkat cells, for 
which no differences in uptake were observed, should expose fewer HS chains on their 
surface than MC57 and HeLa cells. Furthermore, removal of HS chains by heparinase 
should reduce the absolute difference in peptide uptake.  
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In order to test these predictions, first, the presence of HS chains on three cell types was 
investigated by immunofluorescence. Immunofluorescence staining of all three cell lines 
was conducted both separately (Figure 4.8A) and, in order to ensure maximum 
comparability of signal intensities, also in one sample (Figure 4.8B). In accordance with 
our prediction, there was a clear correlation between the presence of HS and the preference 
for internalization of R9 over r9. HS chains were present on MC57 cells and on HeLa cells, 
but were undetectable on Jurkat cells. 
To further investigate whether the membrane staining of the D-CPP observed for MC57 
and HeLa cells represented peptides binding to HS, MC57 cells were treated with 
heparinases to remove HS chains from the cell surface (Figure 4.8C). For r9, the heparinase 
pre-treatment of cells abolished the membrane-bound fluorescence. Only little punctate 
fluorescence inside the cells was still observed. For R9, heparinase treatment had very little 
effect on the distribution of fluorescence. Instead, there was a reduction in the intensity of 
the cytoplasmic fluorescence, demonstrating a reduction of uptake. In order to 
quantitatively investigate these differences cellular peptide uptake in all three cell lines was 
quantitated by fluorimetry after removal of membrane-bound peptides (Figure 4.8D-F). 
Consistent with the microscopy data, after heparinase treatment a clear trend was visible 
showing a greater absolute decrease of R9 than for r9 in HS-rich MC57 and HeLa cells, 
and for L-hLF compared to D-hLF in HeLa cells. A combined statistical analysis of the 
HS-rich HeLa and MC57 cells demonstrated that the absolute decrease of R9 after 
heparinase treatment was greater than for r9 (p < 0.01). When data for L- and D-hLF were 
also included in this analysis, the different effects of heparinase treatment on the uptake of 
L- and D-peptides were even more significant (p < 0.001), arguing that the absolute 
decrease of uptake of L-CPPs was significantly more affected by a heparinase treatment in 
HS-rich cells. In line with these findings, the effect of HS chain removal on r9 
internalization was non-significant.  
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Figure 4.8. Role of HS chains in CPP binding and uptake. (A) Detection of HS on HeLa, MC57 and Jurkat 
cells. MC57 cells and HeLa cells were seeded in 8-well microscopy chambers, and Jurkat cells were obtained 
from a culture flask at the start of the experiment. All three cell lines were probed for HS chains by indirect 
immunofluorescence of living cells. The scale bar represents 40 m. (B) Parallel detection of HS on HeLa, MC57 
and Jurkat cells. MC57 cells were distinguished by CFSE labeling and seeded together with HeLa cells in an 8-
well microscopy chamber. Jurkat cells were stained according to the same procedure in parallel and seeded in the 
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wells after the final washing steps. Jurkat cells could be detected based on their size and morphology. In the 
control, only the secondary antibody was applied. The scale bar represents 10 m. (C) Effect of HS chain removal 
on the uptake and distribution of R9 and r9 in MC57 cells. MC57 cells were pre-treated with heparinases for 1 h 
or left untreated. Cells were washed and incubated with 5 M of the indicated peptide for 45 min. HS chains were 
labeled by indirect immunofluorescence of living cells. The scale bar represents 20 m. (D-F) Quantification of 
the impact of HS chain removal on peptide uptake. HeLa, MC57 and Jurkat cells were pre-treated with 
heparinases (+) for 1 h to remove HS chains or left untreated (-), washed, and incubated for 45 min with 5 M of 
the indicated peptide. Subsequently, cells were washed with heparin to remove membrane-bound peptides, lysed 
and centrifuged. Fluorescence in the supernatant was measured using a microplate reader. The fluorescence of R9 
(D) and L-hLF (E) in untreated cells was set at 100 % to aid comparison with the treated peptides or analogs. In 
(F), the effect of a heparinase treatment on uptake of R9 and r9 (left bars), and other L-CPPs and D-CPPs (right 
bars, analysis includes L/D-penetratin and L/D-hLF) is depicted as the ratio of uptake before and after a 
heparinase treatment in cells expressing heparan sulfates. Error bars indicate the mean +/- SEM. * indicates p < 
0.05. 
4.2.8 Heparan sulfate binding 
Having shown that heparan sulfates contribute to the effectiveness of peptide entry, 
especially of L-peptides, it was still unclear at this point whether heparan sulfates serve as 
mere attachment factors, or as true receptors with an active role in the induction of 
internalization. The major reason for the inability to directly distinguish between these 
roles is that both mechanisms would contribute to the effectiveness of peptide entry. 
Similar practical problems are encountered when trying to distinguish between attachment 
factors and receptors in elucidating the entry mechanisms of viruses [36].  
To probe for differences in the interaction between heparan sulfates and L- and D-
CPPs, we first conducted SPR spectroscopy with immobilized heparan sulfate. With SPR, a 
slightly higher affinity of r9 for HS chains was observed compared to R9, whereas affinites 
for L- and D-penetratin were very similar (Figure 4.9A-D and table 4.2). With ITC, too, 
similar KD values were obtained for both peptide pairs, although these values differed 
somewhat from those obtained with SPR (Figure 4.9E-H and table 4.2). Notably, the 
stoichiometry, enthalpy (ΔH) and entropy (ΔS), but not the KD, were changed slightly for 
r9 compared to R9, indicative of a somewhat different mode of binding. In contrast, for L- 
and D-penetratin the contributions of enthalpy and entropy, as well as the stoichiometry 
and binding affinity, were all very similar. Therefore, it is very unlikely that the slight 
differences in HS-binding observed for R9 and r9 underlie the pronounced differences in 
behavior of these peptides at the plasma membrane in HeLa and MC57 cells.  
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Figure 4.9. Interaction between HS and L- and D- CPPs as determined by SPR and ITC. (A-D) SPR 
diagrams of D- and L-peptides binding to immobilized HS. Peptides and concentration ranges are indicated in the 
figures. (E-H) ITC of the interaction between HS and L- and D-CPPs. The raw ITC graphs show the reference 
power as a function of time over the course of a single representative experiment, where 1 l injections of 30 M 
HS were added to 200 l of 20 M R9 or r9 in the sample cell. The ITC graphs in the lower panels show the 
integrated heats per HS injection, expressed as heat per injected mole of HS, as a function of the molar ratio of HS 
and peptide in the cell. 
Table 4.2. Results of SPR and ITC binding studies between HS and L- and D-CPPs  
 
SPR ITC 
 
Peptide 
 
Kd ( M) 
 
Kd ( M) 
 
Stoichio-
metry   
 
ΔH  
(kcal/mole) 
 
ΔS (kcal/mole) 
degrees 
R9 0.30 ± 0.13 0.14 ± 0.04 8 ± 1 -99 ± 4 -0.32 ± 0.01 
r9 0.19 ± 0.06 0.16 ± 0.01 11 ± 1 -129 ± 7 -0.43 ± 0.03 
L-penetratin 0.53 ± 0.15 0.15 ± 0.02 10 ± 3 -78 ± 11 -0.25 ± 0.05 
D-penetratin 0.48 ± 0.02 0.16 ± 0.03 10 ± 3 -89 ± 9 -0.29 ± 0.03 
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4.2.9 Nitric oxide and uptake  
As a further potential molecular mechanism to explain the differences in the uptake of 
arginine-containing L- and D-peptides, we examined an involvement of nitric oxide 
formation. L-arginine released from the L-peptides through proteolysis may serve as a 
substrate for nitric oxide generation by nitric oxide synthase. Nitric oxide is a free radical 
that can lead to cellular stress and the activation of stress-induced p38, which could in turn 
stimulate endocytosis [37]. Cells were incubated with the nitric oxide synthase inhibitor L-
NAME. The differences in uptake efficiency that were observed for R9 and r9 were very 
minor (Figure 4.7B), indicating the absence of a pivotal role for nitric oxide generation in 
the differences in uptake of R9 and r9.  
4.2.10  Uptake of L/D- chimaeras of nona-arginine in MC57 cells 
Having strong indications that L- and D-CPPs differ with respect to triggering their uptake, 
we were interested to learn more about the structure-activity relationship of this trigger. 
Therefore, internalization of L/D-chimaeras of nona-arginine was assessed in MC57 cells 
(Figure 4.10). When only the C- and N-terminal L-amino acids were exchanged for D-
amino acids, endocytic internalization still occurred, but cytoplasmic fluorescence was 
abolished. In contrast, when multiple L-amino acids were mutated to D-amino acids, a 
persistent membrane-binding was observed, resembling the phenotype of r9. These data 
suggest that a consecutive stretch of L-amino acids is required to trigger efficient endocytic 
uptake.  
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Figure 4.10. Uptake of R9, r9, and of nona-arginine chimaeras composed of L- and D-amino acids in MC57 
cells. Cells were seeded in 8-well microscopy chambers, grown to 75 % confluence and incubated with 5 M of 
the indicated peptides for 45 min. Cells were washed twice and confocal images were taken immediately. The 
scale bar represents 10 m. 
 
4.3 Discussion 
According to the paradigm, chirality does not play a role in the uptake of CPPs. However, 
here we demonstrate a clear chirality-dependence in the uptake of the arginine-containing 
CPPs nona-arginine, hLF and penetratin. Differences in internalization were observed in 
MC57 and HeLa cells in a concentration range for which endocytosis dominates the uptake 
of arginine-containing CPPs [21]. No differences were observed in Jurkat cells, in 
agreement with previous observations [12].  
The preference for L-peptides was only observed in cells containing significant amounts 
of heparan sulfate on the plasma membrane. On these cells, D-CPPs of nona-arginine, 
penetratin and hLF remained strongly membrane-associated, whereas no such prominent 
association was observed in HeLa cells for the corresponding L-CPPs, except for L-hLF. 
Also, only in these HS-positive cell types was the internalization of L-CPPs higher 
compared to D-CPPs. The importance of the chirality of the amino acids was further 
underscored by the use of two nona-arginine chimaeras composed of D- and L-amino acids 
that showed different phenotypes of internalization, depending on the position and numbers 
of D-amino acids. For nona-arginine, HS was identified as an important interaction partner 
in MC57 cells, as its removal reduced the membrane-binding of r9. Additionally, HS chain 
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removal had a greater absolute effect on the internalization of all-L-CPPs in comparison to 
all-D-CPPs in MC57 and HeLa cells. 
Heparan sulfates have recently been proposed as receptors for arginine-rich peptides 
[34, 35]. This view is based on the observation that arginine-rich CPPs, upon their 
interaction with HS proteoglycans, induce actin rearrangements typical for 
macropinocytosis [34]. In our study, SPR and ITC binding assays indicated marginal 
differences in the binding of the various arginine-containing L- and D-CPPs to HS, 
supporting the notion that HS serve primarily as attachments factors instead of true 
receptors in MC57 and HeLa cells. As a consequence, the recognition event at the plasma 
membrane, which is responsible for the more efficient internalization of L-CPPs versus D-
CPPs, remains unknown at present. Since the internalization of L- and D-CPPs was much 
more similar after removal of HS chains, it is reasonable to speculate that the presence of 
HS chains strongly facilitates this unknown interaction. One prominent possibility is the 
presence of a protein receptor that carries HS chains, such as the recently proposed 
syndecan-4 [38]. An involvement of a protein factor associated with internalization of 
CPPs is supported by studies in CHO cells, where the selective removal of 
glycosaminoglycans only partially reduced internalization, whereas trypsin treatment 
almost completely abolished internalization via endocytosis [39]. A distinction between 
binding and internalization has also recently been observed for HS chain-directed single 
chain variable domain antibody fragments (scFv). Only one scFv of several tested was 
efficiently internalized, whereas others remained membrane-bound [40]. Remarkably, we 
were not able to stimulate uptake of labeled r9 by the addition of unlabeled R9, even 
though it had been previously shown that CPP can actively induce endocytosis [30, 31]. 
These data indicate that both isomers behave as distinct molecular entities at the plasma 
membrane. Interestingly, similar results were reported for the induction of nucleation zone-
dependent uptake [15]. 
Intracellular degradation [23, 29, 41] and re-export [18] have been shown to affect the 
cellular distribution and intracellular retention time of CPPs. Moreover, the sensitivity of 
the fluorescence of the fluorescein moiety to the chemical environment, e.g. pH or 
hydrophobicity, and to collision quenching with neighboring groups is well known. In 
addition, careful preparation of lysates is an important factor when comparing numbers of 
fluorophores from intact D- and (partially) degraded L-peptides. In our experiments, we 
could exclude all of these factors as a source of the observed differences. However, the 
cytoplasmic fluorescence observed after treatment of cells with L-peptides under conditions 
where endocytosis is the dominant route of uptake, very likely relates to their proteolytic 
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sensitivity, as R9 or L-penetratin-incubated cells were devoid of cytoplasmic fluorescence 
after pre-treatment with the endolysosomal protease inhibitor E64d (Figure 4.6). We had 
previously reported the same observation for L-penetratin [29]. Quite remarkably, the 
internalization pattern of an R9-analog with terminal D-amino acids reflected the same 
pattern observed with R9 after pre-treatment with E64d. We thus conclude that the terminal 
D-amino acids were sufficient to inhibit proteolysis in endocytic vesicles, while the central 
stretch of seven consecutive L-amino acids was sufficient to induce endocytosis effectively. 
Extracellular peptide degradation is also a very unlikely cause of differences in the 
internalization as shorter oligo-arginine fragments (< R9) are taken up with a considerably 
lower efficiency [12]. Regarding the heparin treatment we used, it may not have removed 
membrane-bound peptides completely, but this would only have led to an overestimation of 
the internalization of D-peptides.  
The reason for the higher proportion of HeLa cells showing internalization of r9 via 
direct translocation is not necessarily a consequence of a greater stability towards 
proteolytic activity. Instead, the reduction of internalization via endocytosis might 
accelerate accumulation of peptide at the plasma membrane, which might trigger direct 
translocation more rapidly. Consistent with this hypothesis, the concentration threshold at 
which the direct translocation occurs could be lowered by incubation of cells with 
endocytosis inhibitors [21]. 
Even though our results clearly refute the earlier paradigm of a chirality-independent 
uptake of CPPs, our results do not contradict earlier findings. Instead, prior experiments 
had been designed in such a way that they missed these differences. In accordance with 
previous findings, we did not detect a difference in the uptake of R9 and r9 in Jurkat cells 
[12]. When Tünnemann et al. compared the uptake of R9 and r9, they only focused on the 
number of cells that showed rapid translocation across the membrane [15].  
It should also be pointed out that differences were previously reported for molecular 
complexes containing L- and D-CPPs. Mason et al. found a reduced transfection efficiency 
for DNA-complexes containing the amphipathic peptide D-LAH4 compared to L-LAH3 
[42], and Abes et al. found a reduced biological activity of morpholino oligomer-peptide 
complexes with partial D-amino acid substitutions [43]. Remarkably, retro-inverso CPPs 
were much more toxic to cells, demonstrating that in spite of very similar side chain 
orientations, these peptides also induced very different biological responses [44]. Although 
these studies indicate a different behavior for peptides containing D-amino acids, none of 
these studies had explicitly addressed the impact of chirality on internalization efficiency. 
Chapter 4 – Cell-Type Dependent Preferences for Uptake of D- and L-CPPs 
96 
 
Taken together, our findings indicate that cell surface binding and the induction of 
internalization are distinct mechanisms with individual structure-activity relationships. For 
the CPPs nona-arginine, penetratin and the hLF peptide, our data indicate that binding to 
heparan sulfates is chirality-independent, whereas the efficiency of internalization is related 
to chirality. We envision that these findings will have important consequences for the use 
of L- or D- amino acids in drug delivery strategies in general. 
The cell line-dependence of our results also suggests a potential to employ the HS-
dependent discrimination of CPPs for tissue-selective targeting. The preferential uptake of 
arginine-containing L-CPPs by cells expressing HS may be exploited for a preferential 
targeting of these cells. Conversely, targeting to cells not expressing HS can be more easily 
accomplished with CPPs synthesized with D-amino acids.  
4.4 Significance 
Cell-penetrating peptides (CPPs) represent a class of short, usually cationic peptides that 
are able to efficiently induce cellular uptake of membrane-impermeable macromolecules. 
However, an important factor limiting the pharmacological potential of CPPs is their 
proteolytic instability, which can be overcome through incorporation of D-amino acids 
which renders the peptides protease resistant. Contrary to the current paradigm, our results 
show clear differences in the uptake efficiency of the L- and D-form of three arginine-
containing CPPs. These differences can be understood in terms of a two-step internalization 
process of CPPs at low concentrations: first, the peptides bind to heparan sulfates on the 
plasma membrane. Second, the peptides are internalized by endocytosis. Our data indicates 
that in the presence of HS chains only the second step occurs less efficiently for D-CPPs 
and can therefore be considered chirality-dependent. Data supporting this hypothesis 
include (i) the correlation of a more efficient internalization of L-CPPs with the expression 
of HS, and (ii) the pronounced membrane fluorescence of D-CPPs, but not L-CPPs, in HS-
expressing cells, which can be eliminated by a heparinase treatment. Moreover, HS 
removal affects mainly the internalization of L-CPPs in cell lines with high levels of HS. 
We could exclude alternative interpretations of the observed differences through a 
comprehensive set of control experiments. Even though our results disagree with the 
current paradigm of an equal efficiency of L- and D-CPPs, our results do not contradict any 
published findings, as these previous results addressed differences for only a limited set of 
conditions. For in vivo applications, the balance of in vivo proteolytic stability, cellular 
internalization efficiency and intracellular trafficking may ultimately be decisive. Results 
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obtained for chimaeric L/D-peptides revealed an interesting structure-activity relationship. 
It will be highly interesting to explore to which degree such peptides containing only few 
D-amino acids may combine the high stability of all-D-CPPs with the higher uptake of 
arginine-containing all-L-CPPs. 
4.5 Experimental procedures 
4.5.1 Materials 
All-L and all-D peptides were purchased from EMC microcollections (Tübingen, 
Germany). Chimaeric peptides (R9 (1,9) and R9(1,3,5,7,9)) were synthesized using 
standard Fmoc/OtBu-solid phase peptide synthesis protocols on a rink amide resin. Each 
amino acid was coupled using HOBt/HBTU in the presence of DIPEA as a base. Peptides 
were cleaved from the resin using TFA/TIS/H2O (92.5:5:2.5, v/v/v) and the crude peptides 
were purified on C18 reversed-phase high-performance liquid chromatography (HPLC) 
columns using water/acetonitrile gradients. N-terminal fluorophore labeling was performed 
using 5(6) -carboxyfluorescein as previously described [28]. Peptides were synthesized C-
terminally amidated and N-terminally fluorescein-labeled, unless stated otherwise. Purity 
was evaluated by analytical HPLC and identity confirmed by mass spectrometry. hLF 
peptides were oxidized by purging oxygen through the peptide solution for 5 min, followed 
by a 2-h incubation at 37°C. The oxidation leads to cyclization by disulfide bridge 
formation.  
The Zenon mouse IgG1 labelling kit was from Invitrogen (Karlsruhe, Germany), bovine 
serum albumin (BSA), octyl β-D-glucopyranoside, heparin and glucose were from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Heparan sulfate (average MW 15 kDa) was from 
Celsus (Cincinnati, USA). Heparinases I-III were purchased from IBEX (Montreal, 
Canada). The anti-HS VSV-tagged single chain Fv fragment HS4C3V was described 
previously [45] and the mouse anti-VSV (clone P5D4) antibody was from Boehringer 
Mannheim (Mannheim, Germany). E64d was from Bachem (Heidelberg, Germany). 
Standard chemicals were from Sigma-Aldrich and Merck (Darmstadt, Germany).  
4.5.2 Cell culture 
All cell lines were maintained in RPMI 1640 (PAN Biotech, Aidenbach, Germany) 
supplemented with 10 % heat-inactivated fetal calf serum (PAN Biotech) and passaged 
every 2 to 3 days. Cells were incubated at 37°C in a 5 % CO2, humidified incubator. 
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4.5.3 Confocal laser scanning microscopy and fluorescence-correlation spectroscopy 
(FCS) 
Confocal laser scanning microscopy and FCS were performed on a TCS SP5 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 
63 x N.A. 1.2 water immersion lens and a dual channel FCS unit. Fluorescein fluorescence 
was excited with the 488 nm line of an argon ion laser. Detection took place with a 500-550 
nm filter-block for FCS measurements and with a 500-550 nm detection range for confocal 
microscopy. Cells were maintained at 37°C on a temperature-controlled microscope stage.  
4.5.4 Peptide uptake 
MC57 and HeLa cells were seeded in 8-well microscopy chambers (Nunc, Wiesbaden, 
Germany) and grown to 75 % confluence. Jurkat cells were transferred from the tissue 
culture flask immediately before the experiment. Cells were incubated at 37˚C with 5 M 
of the peptides in RPMI 1640 supplemented with 10 % fetal calf serum. The duration of 
incubations is indicated for each experiment, separately. Cells were washed twice with 
medium after the incubation with peptides and living cells were analyzed immediately or 
after settling for about 15 min in the microscopy chambers (Jurkat cells) by confocal 
microscopy. Removal of HS chains from the cell surface was accomplished by a 1-h 
incubation at 37°C with RPMI 1640, supplemented with 1 % fetal calf serum and 33 
mIU/ml of heparinase I, 8 mIU/ml of heparinase II and 5 mIU/ml of heparinase III.  
4.5.5 Quantification of cellular uptake 
After incubation with the peptides, cells were washed with pre-warmed HEPES-buffered 
saline (HBS)/BSA/glucose (10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 
mM CaCl2, pH 7.4, containing 0.1 % (w/v) BSA and 5 mM glucose), treated twice for 5 
min at 37°C with 100 g/ml heparin in HBS/BSA/glucose and washed again with 
HBS/BSA/glucose. Cells were then lysed in 150 l lysis buffer (10 mM Bis-Tris propane, 
50 mM octyl β-D-glucopyranoside, 1 mM EDTA and 150 mM NaCl, pH 7.2) for 15 min on 
ice, the lysate was centrifuged for 10 min at 18,000 x g and the fluorescence in 120 l of 
the supernatant was measured using a Synergy 2 microplate reader (Biotek, Winooski, 
USA) by excitation at 488 ± 10 nm and detection at 528 ± 10 nm in a flat-bottom 96-well 
plate (Nunc). Values were corrected for total protein content on the basis of results from the 
Bio-Rad protein assay in microtiter plates with the dye reagent from Bio-Rad (München, 
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Germany). For quantification by FCS, 150 l of lysate were treated with 2 l of 
benzonuclease (2U; Novagen, Merck, Darmstadt, Germany) for 30 min at 37°C, followed 
by a 3-h incubation with 3.3 mg/ml proteinase K (diluted from a 20 mg/ml stock; Roche, 
Mannheim, Germany) at 37°C.  
4.5.6 Fluorescence correlation spectroscopy (FCS)  
Autocorrelation measurements of intact and degraded peptides in PBS and in lysates were 
performed at 37°C in a 384-well plate (175 m, low-base design, MMI, Eching, Germany). 
Proteolytic degradation of peptides in buffer was accomplished by a 3-h incubation at 37°C 
in PBS containing 400 g/ml trypsin and 40 g/ml EDTA (trypsin/EDTA solution 
purchased from PAN Biotech). Lysate preparation is described in the section 
„quantification of cellular uptake‟ in the main article. Autocorrelation functions were 
analyzed using the ISS VISTA software (ISS, inc., Illinois, USA). Fitting was performed 
according to a 3D-Gaussian model containing a triplet component. Diffusional 
autocorrelation times D which were used to assess degradation and the presence of 
aggregates were obtained from the fitting procedure. The particle number obtained from the 
fit was corrected for uncorrelated background (Koppel,1974) (eq. 1). 
 
G(0) = 1 + 1/Napp = 1 + (1-CPSb/CPSt)
2/Ncorr  (eq. 1) 
 
Where CPSt is the total signal (counts-per-second) and CPSb the background signal, Napp 
the apparent particle number obtained from the fit to the autocorrelation function and Ncorr 
the corrected particle number. The fluorescence per molecule (FPM) was then determined 
according to (eq. 2). 
 
FPM = (CPSt – CPSb)/Ncorr (eq. 2) 
4.5.7 Immunofluorescence 
Cells were washed with ice-cold HBS/BSA/glucose and incubated with 125 l of a 
periplasmic fraction containing the anti-HS single chain Fv fragment HS4C3V for 1 h on 
ice in 8-well microscopy chambers (MC57 and HeLa cells) or in the same volume in 
Eppendorf tubes (800,000 Jurkat cells). After incubation, cells were washed again with ice-
cold HBS/BSA/glucose and incubated for 1 h with an anti-VSV antibody (P5D4)/Zenon 
IgG1-Alexa Fluor 647 conjugate on ice. The antibody staining was analyzed by confocal 
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microscopy. When co-seeding MC57, HeLa and Jurkat cells, MC57 cells were 
distinguished from HeLa cells using the Celltrace CFSE proliferation kit (Molecular 
Probes, Invitrogen, Carlsbad, USA) according to the manufacturer‟s instructions.  
4.5.8 Pulse-chase experiment 
MC57 and HeLa cells were detached by trypsinization for 5 min and incubated with pre-
warmed RPMI 1640, supplemented with 10 % fetal calf serum. One million cells were 
mixed with 5 M of the indicated peptide and immediately electroporated using the Amaxa 
nucleofector kit R (Lonza, Basel, Switzerland), according to the manufacturer‟s 
instructions. After electroporation, cells were washed twice with medium and 125,000 cells 
per well were seeded in 8-well microscopy chambers. Confocal images were taken 30 min 
and 1 h after electroporation. Mean intracellular fluorescence was quantitated using the 
Image J software package (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/). 
4.5.9 Flow cytometry 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) at a density of 
40,000 cells/well two days prior to the experiment. For experiments probing for an 
involvement of NO synthase in uptake differences, cells were incubated for 30 min with or 
without 200 M N (G)-nitro-L-arginine methyl ester (L-NAME) in RPMI 1640 without 
serum followed by a 30-min incubation with 5 or 10 M R9 in the presence or absence of 
200 M L-NAME in serum-containing RPMI. Subsequently, cells were washed, detached 
by trypsinization for 5 min, spun down, re-suspended in 200 l HBS and cellular 
fluorescence was measured using a BD FACScan flow cytometer equipped with a 488 nm 
laser (BD Biosciences, Erembodegem, Belgium). The analysis was performed using 
Summit software (Fort Collins, USA). Results were based on 10,000 gated cells. 
4.5.10 Surface plasmon resonance (SPR)  
 SPR was performed on a Biacore 2000 (GE Healthcare, Diegem, Belgium). Streptavidin-
coupled chips (Sensor Chip SA, GE Healthcare, Uppsala Sweden) were first functionalized 
with biotinylated HS (working solution: 10 g/ml), leading to an immobilization level of 
approximately 100 and 200 RU. The peptides were injected at concentrations between 50 
and 1500 nM in HBS-P buffer (GE Healthcare). Peptide association and dissociation took 
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place for 12.5 and 10 min, respectively. All measurements were conducted at 25°C at a 
flow rate of 20 µl/min. To calculate KD values for the peptides, the binding curves of each 
peptide concentration were fitted using the 1:1 Langmuir binding model of the Biacore 
software. RUmax was fitted locally to take the differences in maximum binding level 
(RUmax) of the different peptide concentrations into account. At least two replicates were 
conducted for each peptide.  
4.5.11 Isothermal titration calorimetry (ITC) 
ITC experiments were performed with an ITC200 Microcal (MicroCal LLC, Wolverton Mill 
UK) at 5°C. Peptide and HS solutions were diluted in HBS to 30 M and 50 M, 
respectively. All solutions were degassed before use. The sample cell was filled with the 
peptide solution and 39 times 1 l of the HS solution was injected into the sample cell. To 
correct for dilution effects, the heat effects of the last five measurements of each run (in 
which no decrease of binding-specific heat effects was observed) were averaged and 
subtracted from the generated heat during experiments with HS and peptides. Data was 
analyzed using the ITC200 Microcal software. Fitting was accomplished using a one-site 
binding model.  
4.5.12 Statistical procedures  
Quantitative data represent mean +/- standard error of the mean. The threshold for 
significance was set at p < 0.05, based on a two-tailed paired Student‟s t-test. 
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Abstract 
Cell-penetrating peptides (CPPs) are a class of short peptides that induce the cellular uptake 
of a variety of cargo molecules. So far, relatively little attention has been paid to the 
relevance of the stereochemistry of individual amino acids on activity, despite recent 
findings that stereochemistry is important for arginine-rich peptides. The aim of this study 
was to address the role of the stereochemistry of individual amino acid replacements on 
biological properties of the amphipathic CPP transportan 10 (TP10). To this end, a set of 
eighteen TP10 analogs was prepared containing an L- or D-epimer of an NMR label at nine 
distinct positions in the TP10 sequence. Similar to arginine-rich peptides, major effects of 
the chirality of individual amino acids were found on cellular uptake, membrane binding 
and cytotoxicity. Surprisingly, there were no clear correlations between the secondary 
structure or the aggregation behavior in model systems and their behavior in a cellular 
environment. In addition, remarkable similarities in the dependency on heparan sulfate 
(HS) chains for membrane binding were observed, despite a lack of a measurable affinity 
of TP10 (analogs) for HS. In contrast, phosphatidylserine exposure was induced to a much 
greater degree by TP10 compared to R9. In suspension Jurkat cells, our results suggest that 
only some TP10 analogs have the capacity to directly translocate across the membrane at 
the concentration of 2 M. In conclusion, our results establish an important role of the 
stereochemistry of individual amino acid replacements of TP10 with regard to a variety of 
properties that are important for their use as CPPs.  
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5.1 Introduction 
Cell-penetrating peptides (CPPs) are a promising class of compounds that are being applied 
to shuttle membrane-impermeable cargo into the cell. To date, applications typically focus 
on biomedical research. Ultimately, the goal will be to apply these molecules for 
therapeutic purposes. After almost twenty years of research into CPPs, there is now a 
considerable understanding of the entry routes that CPPs may exploit to enter the cell [1, 
2]. There is widespread agreement that the route depends on multiple factors, including the 
type and concentration of the CPP, the cell type and the cargo, and that multiple pathways 
may be exploited simultaneously [1, 3, 4]. Many studies have been performed to relate 
uptake efficiency and route of uptake to the physicochemical characteristics of various 
subclasses of CPPs, typically in the presence of lipid vesicles or glycosaminoglycans [5-8]. 
Interestingly, until recently little attention had been paid to the stereochemistry of the 
peptides. This is partially due to the original concept of a stereochemistry-independent 
uptake mechanism for CPPs [9]. However, this initial concept has been refuted by us and 
others [10]. For the arginine-rich CPP nona-arginine (R9), for the amphipathic cationic 
CPP penetratin and for the cyclization-dependent CPP hLF, the uptake efficiency of all D-
peptides was lower than the uptake of all L-peptides in certain cell types. The molecular 
basis underlying these observations is currently not clear. However, we have obtained 
evidence that L- and D-peptides differ in their capacity to trigger endocytosis. In contrast, 
for uptake at higher concentrations via sphingomyelinase-dependent nucleation zones [11], 
also referred to as transduction [12], nona-arginine composed of D-arginines showed a 
slightly more efficient uptake compared to L-R9, which could be due to reduced proteolytic 
degradation or an increased accumulation at the plasma membrane [10, 12].  
Interestingly, for the CPP mastoparan, uptake and toxicity also depended on the 
stereochemistry [13]. This CPP is quite different from the aforementioned CPP in that it 
lacks arginines and is more membrane toxic than the arginine-containing CPP. The 
membrane toxicity is presumably related to the ability of mastoparan to induce pores into 
lipid membranes through which even polar molecules can pass [14-16]. Associated with 
this activity is the strong propensity of the C-terminal part of mastoparan to form an 
helix, even in solution [17, 18]. Therefore, the question arises to which degree the uptake 
efficiency of these membrane-active CPPs depends on stereochemistry and whether this 
can be related to secondary structure and aggregation behavior on the plasma membrane. 
In a related study using solid state NMR, we observed that epimerization of an NMR 
label at individual positions of TP10 influenced the secondary structure and the aggregation 
behavior of this peptide (manuscript in preparation; thesis of Susanne Fanghänel). To 
Chapter 5 – Importance of Epimerization in TP10 analogs 
110 
 
provide a better insight into a possible correlation of peptide conformation and uptake, we 
synthesized a set of fluorescein labeled analogs of these TP10 epimers. These analogs 
contained either the D- or L-variant of the 19F-NMR label CF3-bicyclopentylglycine (CF3-
BPG). Cellular uptake and intracellular distribution were investigated for both an adherent 
and a suspension model cell line. For the TP10 analogs, we find that activity as a CPP is 
strongly dependent on the chirality of single amino acid substitutions. Moreover, the 
behavior in cellular systems does not correlate with the behavior in artificial systems. In 
addition, the cellular activities of these subtly different peptides proved to be highly cell-
type dependent and unexpected with regard to the requirement of heparan sulfate chains. 
Together, the findings further stress the importance of stereochemistry as a determinant in 
CPP activity. In addition, the results emphasize the need to take into account the complex 
biological environment that CPPs encounter during the process of cellular entry in order to 
obtain useful knowledge for their use as drug delivery vehicles. 
5.2 Results 
5.2.1 Structural effects of fluorescein conjugation to TP10 analogs 
Solid-state 19F-NMR analyses revealed a major impact of the epimerization of individual 
amino acid positions on TP10 conformation and aggregation. Peptides with a D-epimer 
replacement in the C-terminal part had a disturbed helix formation when in contact with a 
lipid bilayer. This led to aggregation as -sheets via the intrinsically unstructured N-
terminal part in the presence of lipid vesicles. In order to explore to which degree this 
differential behavior affected uptake and would eventually permit a correlation of structural 
characteristics with cellular uptake, a collection of fluorescein-labeled analogs was 
synthesized. In the first step, we addressed whether for these peptides epimerization 
affected the conformation and/or aggregation behavior in a similar way as for the non-
fluorescent peptides. Although most peptides behaved similarly in the presence or absence 
of CF in oriented CD and 19F-NMR studies, some notable differences were observed (table 
5.1). The main difference was a reduced tendency to aggregate in the presence of the CF 
label, which is reflected by fewer CF-labeled TP10 analogs showing either -sheet 
formation and/or immobilization with oriented CD and solid state NMR, respectively. 
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Table 5.1. The secondary structure of CF-labeled TP10 analogs as measured by oriented 
CD and their immobilization as determined by 19F-NMR  
Epimerized 
position 
Oriented Circular Dichroisma Solid State NMRb 
L-CF3-Bpg D-CF3-Bpg L-CF3-Bpg D-CF3-Bpg 
Gly2 -helical -helical immobilized not immobilized 
Leu4 -helical -helical not immobilized not immobilized 
Leu5 -helical -helical not immobilized not immobilized 
Ile8 -helical -helical not immobilized not immobilized 
Leu10 -helicalc -helical not immobilized not immobilized 
Leu13 -helicalc -sheet not immobilized not immobilized 
Leu16 -helicalc -sheet not immobilized not immobilized
d 
Ile 20 -helical -helicalc not immobilized not immobilized 
Leu 21 -helical -helicalc not immobilized not immobilized 
a: after five days of incubation under a fully hydrated atmosphere (peptide/lipid ratio of 1:50) 
b: peptide/lipid ratio of 1:200 
c: was beta sheet without CF label 
d: was immobilized without CF label 
5.2.2 Uptake and membrane binding of TP10 analogs depends on the stereochemistry of 
the introduced 19F-NMR label 
The two TP10 analogs Gly2 L-CF3-Bpg and Leu4 L-CF3-Bpg showed a pronounced 
membrane staining that was stronger than the one observed for the wild-type peptide 
(manuscript in preparation). In contrast to this very similar cellular staining, these two CF-
labeled TP10 analogs exhibited different characteristics in solid-state 19F-NMR 
measurements. While the CF-labeled analog Gly2 L-CF3-Bpg was immobilized at a 
peptide/lipid ratio of 1:200, which is strongly indicative of aggregation, this was not the 
case for Leu4 L-CF3-Bpg. The observed membrane staining was analogous to what we 
had observed with arginine-rich peptides that are composed completely or mostly of D-
amino acids [10]. To assess a role of amino acid chirality in this binding pattern, we 
compared cell binding and uptake in HeLa cells of two TP10 analogs that showed a 
pronounced membrane binding when an L-CF3-BPG was introduced, with the TP10 
analogs that had a D-CF3-BPG substituted at the same position  (Figure 5.1). In addition, 
the pair of peptides with the L- or D-variant of the 19F-NMR label at position 16 was 
Chapter 5 – Importance of Epimerization in TP10 analogs 
112 
 
included, for which the D-variant showed a high tendency to form -sheets. Remarkably, 
changing the stereochemistry of the introduced NMR label had a major effect on the 
membrane staining. Membrane-bound fluorescence was markedly reduced or even absent 
for those peptides that had a D-CF3-BPG substitution in the sequence. In contrast, 
endocytosis was much less or not affected, as both TP10 Gly2 D-CF3, Leu4 D-CF3-Bpg 
and TP10 showed a similar punctate staining compared to the L-epimers. The peptide with 
a D-epimer substitution in position 16, TP10 Leu16 D-CF3, was an exception in that it did 
not show any cell binding and/or endocytosis at all.  
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Figure 5.1. Cellular association of TP10 and TP10 analogs with D- or L-CF3-BPG amino acid replacements 
in HeLa cells. HeLa cells were incubated with 5 M of the respective peptides for 30 min at 37°C, washed and 
imaged immediately by confocal microscopy. The scale bar corresponds to 20 m. 
5.2.3 Heparan sulfates and membrane binding 
For D-amino acid-containing arginine-rich peptides, we showed that the enzymatic removal 
of HS chains strongly reduced the membrane staining. Furthermore, isothermal titration 
calorimetry (ITC) measurements of the interaction of these peptides with heparan sulfates 
gave binding constants in the submicromolar range [10], suggesting that membrane staining 
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was due to binding to heparan sulfates at the cell surface. Since TP10 lacks arginine 
residues and has a strong propensity to form an amphipathic -helix [17, 18], we reasoned 
that enrichment at the plasma membrane would likely be independent of interactions with 
heparan sulfates.  
 To experimentally address this hypothesis, we cleaved off the HS chains from the cell 
surface with the enzyme heparinase III (Figure 5.2A). To make sure that heparinase did not 
modify the overall structure of the plasma membrane, the plasma membrane stain 
CellMask was included as a control after a heparinase treatment. The distribution and 
intensity for CellMask was not altered after the treatment. However, in contrast to our 
expectations, the heparinase treatment effectively reduced the intensity of the membrane 
staining of TP10 Gly2 L-CF3-Bpg. Also, TP10 Gly2 D-CF3-Bpg, for which no 
prominent membrane staining was observed, showed a reduction of punctate intracellular 
structures, supporting a role for HS chains for the productive internalization of this CPP. 
Since this result suggested a direct interaction between HS chains and TP10 analogs, we set 
out to measure the affinity of TP10 WT and the analog TP10 Gly2 L-CF3-Bpg for HS 
chains by ITC. Using similar conditions that gave submicromolar affinities for D/L-R9 and 
D/L-penetratin [10], we could not observe any binding enthalpy (Figure 5.2B). Since these 
results argued for an indirect binding to the HS layer, we furthermore considered the 
possibility that binding to the HS layer on the cell was enabled through some component in 
the fetal calf serum (FCS) that was included in all cellular experiments. To test this 
possibility, we performed the experiment in the presence or absence of FCS. A lower 
peptide concentration was used (2 M), because leaving out FCS in the experiment was 
expected to result in higher effective peptide concentrations [19]. Moreover, we 
investigated the ability of externally added HS chains to compete with plasma membrane 
binding. Very interestingly, externally added HS chains inhibited membrane binding of 
TP10 Gly2 L-CF3-Bpg.  No dependence on FCS components for membrane binding was 
detected.  
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Figure 5.2. Role of heparan sulfates in cell association. A) Effect of heparinase treatment on membrane staining 
of the TP10 analogs Gly2 L-CF3-Bpg and Gly2 D-CF3-Bpg. B) Isothermal titration calorimetry with HS 
titrated into a sample cell containing either TP10 or the TP10 analog Gly2 L-CF3-Bpg. C) Effect of omitting 
serum or competition with externally added HS chains on TP10 Gly2 L-CF3-Bpg membrane binding. 2 M of 
the indicated peptides were incubated for 30 min at 37°C in the presence (+) or absence (-) of fetal calf serum and 
in the presence of increasing amounts of HS. After the incubation, cells were washed twice and imaged 
immediately by confocal microscopy. The scale bar corresponds to 10 m (A) and 20 m (C). 
5.2.4 Induction of phosphatidylserine exposure by TP10 and R9 
In spite of the effect of heparan sulfate removal, which is difficult to interpret at present, 
the differences in HS binding argue for a different binding mechanism of these peptides to 
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the plasma membrane. To provide more insight into the way TP10 and its analogs affect the 
organization of the plasma membrane, we tested the ability of TP10 to induce 
phosphatidylserine (PS) exposure. Typically, PS is confined to the inner leaflet of the 
plasma membrane. Exposure of this phospholipid therefore indicates a disturbance of the 
lipid bilayer. In this case a concentration of 25 M was selected. For arginine-rich peptides 
at this concentration lipid remodeling through induction of sphingomyelinase activation 
occurs. However, the integrity of the plasma membrane barrier function remains preserved 
[11]. Already after four minutes a marked difference in PS exposure was observed, which 
co-occurred with massive internalization of peptides into the cytoplasm. R9 only induced 
punctate exposure of PS (Figure 5.3). Although most regions where nucleation zones 
occurred also showed PS staining, as was shown before [11], nucleation zones were not 
observed at all regions where PS was exposed. In contrast to the findings with R9, the 
incubation with TP10 resulted in PS exposure all over the cell, supporting the hypothesis 
that the activity of TP10 is much more directed towards the lipid bilayer as compared to 
R9.  
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Figure 5.3. Induction of PS exposure by R9 and TP10. HeLa cells were co-incubated with 25 M of the 
indicated peptides and AnnexinV-Alexa Fluor 647. Peptide internalization and PS exposure were followed from 
the first image acquired (t=0) up to 20 minutes. The scale bar corresponds to 20 m. 
5.2.5 Cytosolic uptake in suspension Jurkat cells 
Since all previous experiments in this study were performed in HeLa cells and differences 
in the uptake of CPPs have been observed for different cell types, uptake in the suspension 
Jurkat E6.1 cells was investigated as well. This cell line is particularly interesting for a 
comparison, because this cell line has been shown by us to expose little or no HS chains 
and because it shows comparable uptake for D- and L-arginine-rich peptides, unlike HeLa 
cells [10]. Given the apparent role of HS chains in enriching peptide at the membrane, one 
might wonder whether the TP10 analogs Gly2 L-CF3-Bpg and Leu4 L-CF3-Bpg would 
be less enriched at the membrane in these cells. In order to investigate this, the TP10 
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analogs Gly2 L-CF3-Bpg and Leu4 L-CF3-Bpg, and the corresponding D-epimer-
substituted analogs, were incubated with Jurkat cells (Figure 5.4). Indeed, no membrane 
binding was evident under these conditions. Instead, rather than showing a more 
pronounced membrane staining compared to the D-epimers, the L-epimers showed a more 
intense cytoplasmic fluorescence.  
Previously, we have established that cytoplasmic fluorescence of arginine-rich L-
peptides at a low peptide concentration (5 M) in adherent cell lines mostly reflects 
degraded peptide fragments. Upon incubation with the cysteine protease inhibitor E64d, the 
cytoplasmic fluorescence was abolished and fluorescence was confined to endocytic 
vesicles. Moreover, after E64d treatment, the diffusion speed of fluorescent particles was 
decreased, as measured in lysates from cells incubated with peptides. Together, these 
findings indicate that an E64d treatment results in a greater fraction of intact peptides that 
ineffectively escape from the endosome to the cytosol [7, 11]. Furthermore, in adherent cell 
lines D-amino acid CPPs are internalized via endocytosis as well, albeit to a lesser degree 
than L-peptides, but show no cytoplasmic fluorescence observable by confocal microscopy 
[10]. Because D-amino CPPs differ from L-amino acid CPPs in that they cannot give rise to 
degraded fragments, the absence of cytoplasmic fluorescence might relate to the inability of 
D-CPPs to be cleaved into peptide fragments that may escape to the cytosol. 
Initially, we assessed whether cytoplasmic fluorescence of R9 at 2 M was also 
eliminated by the protease inhibitor E64d in suspension Jurkat cells. The low concentration 
of 2 M was chosen because at this concentration R9 and r9 show clear differences in 
cytoplasmic fluorescence (Figure 5.4B), reminiscent of the E64d-sensitive differences that 
were observed in HeLa and MC57 cells at 5 M [10]. At 5 M in Jurkat cells, both R9 and 
r9 already show a pronounced cytoplasmic staining [10]. Most likely, Jurkat cells have a 
lower threshold for the rapid cytoplasmic uptake mechanism that is observed in MC57 and 
HeLa cells at concentrations starting from ~ 10 M. 
When we co-incubated the protease inhibitor E64d with the peptides at 2 M, the 
cytoplasmic fluorescence of R9 was practically abolished and the uptake phenotype of R9 
was converted to the uptake phenotype of r9 (Figure 5.4B). The reduction of cytoplasmic 
fluorescence after an E64d treatment is analogous to what was observed for R9 in MC57 
cells. However, both R9 and r9 were present inside the Jurkat cells with the same intensity. 
In this respect, these observations for Jurkat cells clearly differ from the observations made 
for MC57. In the latter, in the presence of E64d, r9 was much less efficiently endocytosed 
and remained much more membrane-bound [10]. Strikingly, at 2 M a weak plasma 
membrane staining also became evident in Jurkat cells, which was previously not observed 
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at higher concentrations [10]. Probably, this membrane staining is also present at higher 
concentration but was made visible due to the much greater laser intensity and/or digital 
amplification of the signal that was required to visualize the peptides at this low 
concentration. Since Jurkat cells have no or little heparan sulfates [10], this indicates that 
the peptides may either bind to other membrane sugars such as chondroitin sulfates [20] 
and/or negatively charged lipids or proteins of the plasma membrane. In contrast to the 
effect on R9, the protease inhibitor E64d did not affect the cytoplasmic fluorescence of the 
TP10 analogs at all, indicating that these peptides follow an alternative route towards the 
cytosol that does not involve passage via an E64d-sensitive compartment (Figure 5.4C).  
5.2.6 Membrane binding in Jurkat cells 
Since no membrane staining was observed for the TP10 analogs at 2 M, an uptake 
experiment was also performed at 10 M. Since at this concentration TP10 analogs may 
potentially damage the plasma membrane, the marker propidium iodide (PI) was included, 
which only enters cells that have a comprised membrane integrity (Figure 5.4D). Of all four 
peptides tested, only one peptide, TP10 Gly2 L-CF3-Bpg, was not overtly toxic at this 
peptide concentration, as reflected by the absence of an intracellular PI staining. Of note is 
that the PI staining was non-typical in that it did not clearly accumulate in the nuclei. Since 
the control without PI did not show any signal in the PI channel and the brightfield images 
showed very obvious toxic effects, this non-typical PI staining is most likely due to the 
phase of cell disintegration and/or the cell type in question. Remarkably, instead of a 
membrane-wide staining as observed in HeLa cells, the staining pattern for TP10 Gly2 L-
CF3-Bpg in Jurkat cells was restricted to parts of the membrane, indicating that this peptide 
has an increased affinity for specific membrane domains with an altered lipid 
microenvironment. Isolated instances of the staining of such membrane patches were also 
observed for the other peptides, albeit at a far lower frequency (data not shown). In 
addition, cytoplasmic fluorescence was detected at a similar level as at 2 M (Figure 5.4E). 
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Figure 5.4. A) Uptake of TP10 and analogs in Jurkat cells. Cells were incubated with 5 M of the respective 
peptide for 30 min at 37°C, washed twice by centrifugation, resuspended and allowed to settle in 8-well 
microscopy chambers. Analysis by confocal microscopy was performed as soon as cells had settled. B-C) Uptake 
of peptides in the presence or absence of the cysteine protease inhibitor E64d. Jurkat E6.1 cells were pre-incubated 
for 30 min with 100 M E64d or left untreated. Cells were washed, incubated in the presence or absence of 100 
M E64d for 30 min at 37°C and 2 M of the indicated peptides, washed and analyzed immediately by confocal 
microscopy. D-E) Jurkat cells were incubated for 30 min at 37°C with the indicated peptides at 10 M, washed 
and analyzed by confocal microscopy. In D, 5 g/ml propidium iodide (PI) was added after the incubation to 
distinguish intact cells from those with a compromised plasma membrane. The scale bars represent 10 m.   
5.3 Discussion 
Despite the field of CPPs moving ever closer to clinical applications, there is still relatively 
little known about the intermolecular interactions of CPPs in a cellular context. Given 
recent findings from our laboratory on all-D, all-L and D/L chimeric peptides, in particular 
the role of stereochemistry in CPP functionality requires further attention. Against this 
background, we investigated the molecular interactions between two model cell lines and 
various TP10 analogs containing the D- and L-variant of the NMR label CF3-Bpg. 
Comparisons were made with the prototypic arginine-rich CPP R9, which was used as a 
representative peptide from the subclass of arginine-rich CPPs [11, 12]. TP10 is generally 
considered as a much more membrane-active peptide because it causes membrane leakage 
at a much lower concentration compared to arginine-rich peptides [21, 22]. A main reason 
is its much higher tendency, compared to R9, to spontaneously insert into lipid membranes, 
where it undergoes conformational rearrangements [23]. 
Internalization efficiency, binding to the plasma membrane and cytotoxicity were 
strongly dependent on the stereochemistry of the amino acid that was introduced at distinct 
positions in the CPP sequence in a manner that was not evident from the conformation 
and/or aggregation behavior of the peptide. An exception was the lack of CPP activity of 
TP10 Leu16 D-CF3-Bpg, which is most likely due its very high tendency to aggregate via 
-sheets. 
Very prominently, TP10 Gly2 L-CF3-Bpg and Leu4 L-CF3-Bpg showed a 
pronounced membrane binding, which is reminiscent of our previous results for r9 and D-
penetratin [10]. Since the TP10 analogs do not contain any arginines, we were surprised to 
see that this membrane staining could be reduced either by a heparinase pre-treatment or by 
co-incubating the peptides with HS chains, even though ITC measurements showed no 
measurable affinity. In stark contrast, the arginine-rich CPPs R9 and penetratin showed 
submicromolar affinities for HS chains [10]. Nevertheless, the ITC values are in 
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accordance with previous studies, which showed that changing lysines to arginines on one 
side of a helical heparin-binding peptide improved heparin affinity from 640 nM to 3 nM 
[24]. The reason underlying the improved affinity is thought to be the 2.5 times higher 
enthalpic contribution of the binding of arginines to heparin in comparison to the binding of 
lysines [25]. The presence of fetal calf serum did not affect membrane binding of TP10 
Gly2 L-CF3-Bpg, ruling out the possibility that components in fetal calf serum mediate 
the binding between HS and TP10 Gly2 L-CF3-Bpg on cells. In HS-poor Jurkat, no 
membrane staining was evident for the TP10 analogs at low concentrations, providing 
further support for the idea that the presence of HS affects the membrane binding of TP10 
to the membrane. Although our results with a heparinase treatment were unexpected, 
previous studies have already shown that removal of HS chains by heparinase can lead to a 
reduced ability of TP10 to carry a PNA-cargo into the cytosol [26].  
Given the observation that TP10 does not directly bind to HS chains, the effects HS 
chains have on membrane binding and uptake might be influenced indirectly through 
changes in the properties of the plasma membrane, in particular the surface charge. One 
might argue that negatively charged membrane-bound HS chains might enrich ions or other 
molecules close to the membrane in a manner that might facilitate the interaction of the 
plasma membrane with TP10 analogs or, alternatively, affect the lipid composition of the 
external leaflet of the plasma membrane. According to this hypothesis, removal of HS 
chains would then indirectly decrease the ability of TP10 analogs to bind to the membrane. 
This ability could in principle also be abolished through the external addition of an access 
of HS chains, which would prevent the cell-surface HS chains from exerting this particular 
function required for TP10 analog binding and uptake. The details of such a potential 
mechanism are unclear at present. If the ability of HS to affect plasma membrane properties 
would indeed be required, then a similar external addition of HS chains would have no 
effect on TP10/TP10 analog uptake in Jurkat cells, which have low amounts or no HS 
chains on their surface. 
Regarding the membrane behavior of TP10 in comparison to arginine-rich peptides, 
previous studies have indicated that TP10 already causes membrane disturbances and/or 
effects on cell proliferation at much lower concentrations compared to arginine-rich 
peptides such as Tat or penetratin in both adherent and suspension cell lines [21, 22]. Our 
study further supports the differences in the membrane behavior of arginine-rich CPPs and 
TP10 through the comparison of R9 and TP10 with respect to their ability to induce PS 
exposure, a classical marker of membrane disturbance. Whereas R9 only caused local 
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exposure of PS, in accordance with previous observations [11], TP10 caused a rapid plasma 
membrane-wide presence of PS in a matter of minutes.  
Of further interest is that we exclusively observed intracellular staining, and thus no 
membrane staining, of the TP10 analog Gly2 L-CF3-Bpg at 2 M, whereas at 10 M the 
peptide stained membrane patches at the Jurkat cell membrane. Membrane patches were 
not as evident for the other three peptides tested in Jurkat cells. Interestingly, this specific 
TP10 analog also showed immobilization during the solid state NMR studies (table 5.1). 
This is a second example of a correlation between peptide behavior in an artificial system 
and in cells, next to the loss of CPP activity of Leu16 D-CF3-Bpg. To what extent the 
segregation of the peptide on the plasma membrane also occurs in other cell lines remains 
to be investigated. No such membrane patches were observed in HeLa cells. However, only 
concentrations of up to 5 M were tested in this cell line. The threshold for cytotoxicity 
also proved to be dependent on the enantiomer. In contrast to Gly2 L-CF3-Bpg the D-
epimer TP10 Gly2 D-CF3-Bpg showed massive membrane toxicity at 10 M in Jurkat 
cells (Figure 5.4D). 
Very remarkably, in Jurkat cells some, but not all, TP10 analogs also stained the cytosol 
at the low concentration of 2 M. Fluorescence staining of the cytosol was insensitive to 
E64d, which is indicative of intact peptide reaching the cytosol in an endocytosis-
independent fashion. The inhibitor E64d abolishes the cytoplasmic fluorescence of the 
proteolytically labile L-CPPs nona-arginine and penetratin in adherent MC57 cells [10]. For 
R9, the dependency on proteolytic breakdown for cytoplasmic fluorescence in Jurkat cells 
at 2 M was confirmed in this study (Figure 5.4B).  
In conclusion, for the TP10 analogs our results clearly show that various CPP properties 
depend on the stereochemistry of individual amino acids. Epimerization of a single amino 
acid has large effects on internalization efficiency, membrane binding and cytotoxicity. 
These characteristics had only a very limited correlation with the secondary structure and 
aggregation characteristics of these peptides as determined by solid-state NMR and 
oriented CD, demonstrating that such in vitro experiments still fail to recapitulate key 
molecular events associated with the interaction of these peptides with cells.  
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5.4 Experimental procedures  
5.4.1 Cell culture  
HeLa and Jurkat E6.1 cells were maintained in DMEM and RPMI 1640 (Gibco, Invitrogen, 
Eugene, U.S.A.), respectively, supplemented with 10 % fetal calf serum (FCS; PAN 
Biotech). All cells were incubated at 37°C in a 5 % CO2-containing, humidified incubator. 
Cells were passaged every 2 to 3 days. 
5.4.2 Solid-phase peptide synthesis (SPPS) 
All peptides were synthesized on an automated Syro II multiple peptide synthesizer 
(MultiSynTech, Witten, Germany) with standard Fmoc SPPS protocols and HOBt/HBTU 
as coupling reagents. The 19F-labeled amino acid CF3-Bpg was coupled for 2 h. Peptides 
were N-terminally labeled with CF before cleaving off the resin and side chain 
deprotection. For labeling, diisopropylcarbodiimide (DIC), HOBt and 5,6-CF were 
dissolved in dimethylformamide (DMF) in a molar ratio of 1:1:1, mixed with the peptide 
on the resin in a molar ratio of 5:1 and coupled for 12 h. After washing with DMF, 
dichlormethane (DCM), methanol (MeOH) and diethyl ether, piperidine (20% v/v in DMF) 
was added for 30 min. Afterwards the resin was washed with DMF, DCM and MeOH, 
dried under reduced pressure and the peptide cleaved off the resin and side chain 
deprotected using a mixture of trifluoroacetic acid (TFA) (93.5%), triisopropanyl (TIS) 
(4%) and H2O (2.5%), precipitated with diethyl ether and lyophilized. The crude peptides 
were purified by high-performance liquid chromatography (HPLC) on a preparative C18 
column (22x250 mm) (Vydac, Hesperia, CA, USA) using acetonitril water gradients 
supplemented with 5 mM HCl. The identity of all peptides was confirmed by mass 
spectrometry. The purity of the peptides was found to be over 95%. The concentration of 
fluorescein-labeled peptides was determined by measuring A492 in Tris-HCl buffer (pH 
8.8), assuming a molar extinction coefficient of 75,000 M-1 cm-1. 
5.4.3 Imaging of peptide uptake by confocal microscopy 
HeLa cells were seeded one (40,000 cells/well) to three (10,000 cells/well) days before the 
experiment in 8-well microscopy chambers (Nunc, Wiesbaden, Germany, or 8-well Ibidi 
chambers (Martinsried, Germany), and grown to 75 % confluence. Cells were incubated 
with the indicated concentrations of TP10 or TP10 analogs for 30 min at 37°C. Cells were 
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washed twice after incubation and living cells were analyzed immediately by confocal 
microscopy using a TCS SP5 confocal microscope (Leica Microsystems, Mannheim, 
Germany) equipped with an HCX PL APO 63 x N.A. 1.2 water immersion lens. Cells were 
maintained at 37°C on a temperature-controlled microscope stage. AnnexinV-Alexa Fluor 
647 was used at a dilution of 1:50 (Invitrogen). E64d (Bachem, Bubendorf, Switzerland) 
was used at a concentration of 100 M for pre- and co-incubations. For heparinase 
treatments, HeLa cells were pre-incubated with 750 IU of heparinase III (Ibex, Quebec, 
Canada) in DMEM containing 1 % FCS for 1 h at 37°C. 
5.4.4 ITC 
ITC experiments were performed with an ITC200 Microcal instrument (MicroCal LLC, 
Wolverton Mill UK) at 25°C, using comparable conditions as were used for arginine-rich 
peptides before [10]. Briefly, peptide and HS solutions were diluted in HBS to 60 M and 
75 M, respectively. All solutions were degassed before use. The sample cell was filled 
with the peptide solution and 39 times 1 l of the HS solution was injected into the sample 
cell. Data were analyzed using the ITC200 Microcal software.  
5.4.5 Oriented circular dichroism spectroscopy (OCD) 
OCD experiments were performed on a J-810 spectropolarimeter (Jasco, Tokyo, Japan) 
with an in-house set-up for the OCD-cell. Lipids were dissolved in chloroform and peptides 
in MeOH, appropriate amounts mixed and spread on a 12 mm diameter quartz glass plate. 
After drying under reduced pressure, the samples were hydrated over night at 40°C in 97 % 
relative humidity. The spectra were recorded in the range of 260 to 180 nm using a scan 
rate of 20 nm/min, 8-s response time, 1-nm bandwidth, at eight different rotations of the 
cell and referenced by subtracting the background signal that was recorded with a sample 
containing the same amount of lipids without peptides. 
5.4.6 Solid-state NMR spectroscopy 
All experiments were performed on a Bruker Avance 500 MHz NMR spectrometer (Bruker 
BioSpin, Rheinstetten, Germany) at 313 K. 31P-NMR was performed at a frequency of 
202.5 MHz using a Hahn echo sequence [27] with a 90° pulse of 5 μs, 30 μs echo time, a 
sweep width of 200 kHz, 4096 data points and proton decoupling using tppm [28]. Usually 
128 scans were recorded. 19F-NMR was performed at a frequency of 470.6 MHz using an 
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anti-ringing sequence with a 90° pulse of 3.25 μs, a sweep width of 500 kHz, 4096 data 
points and proton decoupling using tppm. For preparing the oriented samples, a 
DMPC/DMPG mixture in a molar ratio of 3:1 was dissolved in chloroform and peptide was 
dissolved in MeOH. Both solutions were thoroughly mixed and equally distributed on 18 
glass plates (15 mm x 7.5 mm x 0.08 mm) (Marienfeld Laboratory Glassware, Lauda-
Königshofen, Germany). The glass plates were stacked and hydrated at 48°C in 96% 
relative humidity for 24 h after drying under reduced pressure for at least 3 h. The hydrated 
samples were wrapped in parafilm and plastic foil before the NMR experiments. 
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Abstract 
Nowadays, the analysis of the uptake and intracellular distribution of cell-penetrating 
peptides mostly relies on fluorescence microscopy, using fluorescently labeled CPP 
analogs. However, fluorescence microscopy does not reveal to which degree fluorescence 
reflects the intact peptide or only breakdown products. We here introduce fluorescence 
correlation spectroscopy (FCS) as a powerful method to address peptide stability in cells 
and in cell lysates. Measurements in lysates of cells incubated with peptide yield 
information on degradation of the total cellular peptide content. In combination with 
protease inhibitors such measurements enable conclusions on trafficking pathways. 
Intracellular FCS measurements provide direct information on peptide degradation and 
association with cellular structures in intact cells. 
6.1 Introduction 
Conjugation to fluorophores has become the method of choice for analyzing the uptake of 
cell-penetrating peptides. Using confocal microscopy the uptake and subcellular 
distribution can be followed in real time [1-5]. Moreover, fluorescence enables a straight-
forward quantitative comparison of uptake efficiencies using flow cytometry. Nevertheless, 
most techniques that rely on fluorescence are not able to distinguish between intact, 
fluorescently labeled molecules and their degradation products, which can complicate the 
interpretation of results obtained with these techniques. In particular with respect to the 
subcellular localization it is not clear, to which degree the distribution of fluorescence 
reflects the characteristics of the intact peptide. Moreover, given that proteolytic stability, 
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both extracellular and intracellular, is of major importance for determining the uptake 
efficiency of a CPP, it is evident that there is an unmet need to follow the stability of CPPs 
during the course of experiments [6-9]. This requirement is furthermore illustrated by the 
fact that different CPPs and cargo constructs use distinct intracellular endocytotic pathways 
that differ strongly in proteolytic activity [1, 10-12].  
One technique that enables a direct detection of intact CPPs and CPP-cargo constructs 
and their digestion products without fluorescent labels is mass spectrometry [6, 13, 14]. 
Using stable isotopes as an internal standard this method can moreover provide information 
on absolute quantities. However, fully degraded peptides will not be amenable to detection 
by MS-based techniques. Another way of assessing delivery of intact molecules is through 
biological assays. The luciferase-based splice correction assay that detects the delivery of 
CPP-coupled oligonucleotides [15, 16] is a prominent example for these techniques. 
Nevertheless, in spite of the advancements that both types of techniques have brought to 
the detection of intact peptide reaching the cytosol, both types of methods fail to provide 
quantitative information on the sequestration and degradation of peptides in the 
endolysosomal compartment.  
Fluorescence correlation spectroscopy (FCS) is a technique that has the potential to 
complement these other techniques for providing information on peptide degradation in cell 
lysates and intact cells. FCS extracts information on the concentration and mobility of 
fluorescently labeled molecules from temporal fluctuations of the fluorescence intensity in 
a confocal detection volume the size of an E. coli [17]. In biological samples, mobility is a 
function of the size and molecular interactions of a molecule. When combined with 
imaging, such information can also be obtained for molecules in intact cells [18, 19]. This 
chapter provides protocols for FCS measurements of CPP integrity in cell lysates and in 
intact cells. For obtaining overall information on intracellular peptide break-down, a 
protocol for performing FCS experiments in lysates of human cervical carcinoma (HeLa) 
cells that were incubated with a CPP before lysis is described (see also Figure 6.1A-E). 
Lysosomal protease inhibitors are employed to assess the influence of various classes of 
lysosomal proteases in the intracellular breakdown of CPPs in endolysosomal 
compartments. The second protocol describes the measurement of the stability of CPPs 
composed of D- and L-amino acids in single living Jurkat E6.1 T cell leukemia cells. 
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Figure 6.1. Schematic overview illustrating sequential steps for the execution of an FCS experiment using 
cell lysates. 
6.2 Materials 
All cell lines are in principle amenable to analysis by fluorescence correlation 
spectroscopy. For measurements in cell lysates, interactions of peptides with cellular 
components such as DNA and cellular membranes can complicate especially the 
quantification of the fraction of intact peptides. Our own experience shows that these 
molecules are more prone to such interactions than proteolytic fragments. For intracellular 
FCS measurements, the feasibility and quality of the measurements is influenced to a 
significant degree by cellular characteristics such as size, morphology and mobility of cells.  
6.2.1 Preparation of lysates of HeLa cells treated with lysosomal protease inhibitors 
1. HeLa cells from the American-Type Culture Collection (ATCC, Manassas, USA); 
maintained in RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10 % 
fetal calf serum (Pan Biotech). 
2. 24-well culture plates (Sarstedt, Nümbrecht, Germany). 
3. Lysosomal protease inhibitors: Pepstatin A (Sigma-Aldrich, Steinheim, Germany), 
which can be dissolved at 3 mM in DMSO, and E64d (Bachem, Heidelberg, Germany) 
which can be dissolved in DMSO in concentrations up to 50 mM. Inhibitors can be stored 
at -20°C for months. 
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4. Lysis buffer: PBS containing 1 % (v/v) Triton-X-100 (Sigma-Aldrich). This solution is 
stable at room temperature (RT) for months. For each experiment, add a fresh protease 
inhibitor cocktail from a frozen or dry stock (Roche Diagnostics, Mannheim, Germany). 
5. Fluorescein-labeled nona-arginine (R9) (EMC microcollection, Tübingen, Germany). All 
peptides are dissolved in a minimal amount of DMSO (peptide concentration ~ 10 mM). 
Concentration is determined by measuring A492 in Tris-HCl buffer (pH 8.8) assuming a 
molar extinction coefficient of 75,000 M-1 cm-1. Peptides dissolved in DMSO can be stored 
for extended periods at 4°C. 
6. Heparin (Sigma-Aldrich): Dissolve at 2 mg/ml in H2O and freeze aliquots at -20°C. 
Aliquots are stable for months. Do not re-use thawed aliquots. 
6.2.2 FCS measurements in HeLa cell lysates 
1. Trypsin/EDTA solution. PBS containing 400 g/ml trypsin and 40 g/ml EDTA. 
Trypsin/EDTA mix was purchased from PAN Biotech. 
2. 384-well plate (175 m, low-base design, MMI, Eching, Germany) 
3. Tris buffer: 100 mM Tris-HCl, pH 8.8. 
4. Bovine serum albumin (BSA; Sigma-Aldrich): 5 % (w/v) BSA stocks can be prepared by 
adding BSA to water, which will dissolve by itself without mixing. When dissolved, aliquot 
and freeze at -20°C, where it will be stable for months. Aliquots can be thawed and 
refrozen several times. 
5. TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped 
with an HCX PL APO 63 x N.A. 1.2 water immersion lens and an FCS detection unit fitted 
with a 500-550 nm filter cube (Leica Microsystems, Mannheim, Germany). The 
carboxyfluorescein moieties were excited by the 488 nm line of an argon ion laser.  
6. ISS VISTA software (ISS, inc. Illinois, USA). 
6.2.3 Preparation of live cells treated with nona-arginine composed of D- and L-amino 
acids 
1. Jurkat E6.1 T cell leukemia cells (ATCC) maintained in RPMI 1640 supplemented with 
10 % fetal calf serum (both Pan Biotech). 
2. Fluorescein-labeled nona-arginine composed of L- (R9) or D- (R9) amino acids (EMC 
microcollections).  
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6.2.4 Intracellular FCS measurements in living Jurkat cells 
1-4. As for 6.2.2. 
5. The microscope was fully encapsulated in an air-heated incubator with humidity control, 
in order to maintain cell viability during the measurement procedure.  
6. Globals for Spectroscopy software (Laboratory for Fluorescence Dynamics, Irvine, CA, 
USA). 
6.3 Methods 
6.3.1 Preparation of lysates of HeLa cells treated with lysosomal protease inhibitors 
1. Seed HeLa cells at a density of 80,000 cells/well in a 24-well plate in 800 
% fetal calf serum. 
2. 24 h later, wash cells and pre-incubate for 30 min with 10 M pepstatin A to inhibit 
aspartic proteases [20] or with 40 M E64d to inhibit cysteine proteases [21]. Include two 
untreated controls1 and a control for the vehicle of pepstatin A (0.33 % DMSO).  
3. Remove medium containing lysosomal protease inhibitors or control vehicle. Incubate 
for 60 min at 37°C with 5 M R9 in the presence of the inhibitors or control vehicle at the 
same concentration as during the pre-incubation. 
4. Wash cells twice with RPMI supplemented with 10 % fetal calf serum and incubate them 
twice for 5 min at 37°C with 100 g/ml heparin in RPMI containing 10 % fetal calf serum 
to remove surface-bound peptides 2. 
5. Add 500 l of freshly prepared lysis buffer3 to the cells and incubate samples for 60 min 
on ice for complete lysis. 
6. Agitate the lysate by pipetting and centrifuge the lysate for 20 min at 20,000 g at 4°C to 
remove any remaining membrane debris4. Freeze lysates at -20°C until further use5. 
                                                          
1 To lysates of untreated controls, intact and degraded R9 will be added. These measurements will serve as 
references for the analysis of the degree of degradation. The background signal of untreated controls will be 
applied for correcting particle numbers estimated by the analysis software. 
2 In our hands, a heparin treatment at the indicated concentration performs as well as trypsin to remove surface-
bound nona-arginine, but is a milder treatment for the cells. 
3 The application of a minimal amount of lysis buffer reduces the likelihood of any interferences of the lysis buffer 
in the FCS measurements due to changes in refractive index. 
4 It is expected that some remaining debris-bound peptides will be removed by centrifugation. The amount will 
depend on the interactions of the peptide with lysate components. Free fluorophores that result from the 
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6.3.2 FCS measurements in HeLa cell lysates 
1. For obtaining a reference of digested peptide, digest R9 with PBS containing trypsin 
(400 g/ml) and EDTA (40 g/ml) 16 h at 37°C. 
2. Coat the wells of a 384-well plate with a 0.1 % BSA solution in PBS for 30 min at RT to 
reduce adsorption of peptides to the walls of the wells. Afterwards wash twice with PBS. 
3. Dilute cell lysates 5x in Tris buffer (pH 8.8)6 and keep lysates on ice until the 
measurement. 
4. Include a well containing 10 nM fluorescein in PBS as a standard and a well containing 
pure PBS7. Also include wells for trypsin-degraded R9 and intact R9 in a similar cell 
lysate/buffer composition as the samples treated with lysosomal protease inhibitors. 
5. Determine the laser power that maximizes the signal-to-ratio of the signal8. Use the FCS 
wizard of the Leica SP5 software to control the laser power and the ISS vista software 
package for the acquisition of the FCS data.  
6. Determine the structure parameter and the triplet time using fluorescein9.  
7. Perform autocorrelation measurements of intact and trypsin-degraded R9 added to 20% 
cell lysate/80% TRIS-buffer10. 
                                                                                                                                                   
degradation of labeled peptides are less prone to removal by centrifugation due to less association with lysate 
components. 
5 Of course, FCS experiments can also be conducted without the freezing step. However, for practical reasons, it is 
often desirable to freeze the lysates on the day that the cellular experiment was conducted. We recommend to store 
lysates no longer than a few days at -20°C to avoid unwanted storage effects. 
6 A buffer with a pH of 8.8 is used because in this pH range, the brightness of the fluorescein moiety attached to 
the peptides is optimal, which yields a better signal-to-noise ratio in the FCS measurements. In a similar manner, 
buffering conditions for other fluorophores should be optimized for obtaining optimum fluorescence brightness as 
well. 
7 As FCS measurements provide optimum signal-to-noise ratios for concentrations of fluorophores between 1-100 
nM, samples should be diluted accordingly. The inclusion of a PBS control for background fluorescence enables 
the adjustment of the laser intensity to the optimal signal-to-noise ratio [22].  
8 Above a certain laser power, the specific fluorescence signal will not increase anymore because of saturation of 
the fluorophores. Instead, only the background signal will further increase. The optimum laser power yields an 
optimum ratio of specific signal over background. Especially for more photosensitive dyes such as fluorescein, 
bleaching of fluorophores at higher laser powers may impose a further constraint. 
9 A too large structure parameter is either an indication of a misaligned pinhole or incorrect adjustment of the 
correction ring for the thickness of the coverslip, or of the presence of several molecular species with similar 
diffusion autocorrelation times. A structure parameter between 4 and 8 should be obtained. 
10 In 384-well plates, a volume 50 l is standard in our laboratory, although volumes as low 20 l are also 
sufficient. 
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8. Add the cell lysates to BSA-coated wells of the 384-well plate and perform 
autocorrelation measurements of 5 x 10 s per sample. 
6.3.3 Analysis of lysate FCS measurements using the ISS software package 
1. Choose a 3D Gaussian model assuming a triplet term and one diffusive component and 
fix the structure parameter and the triplet term to the values determined for the fluorescein 
standard.  
2. Determine the diffusion autocorrelation time of trypsin-degraded R9, using a 3D 
Gaussian model assuming one diffusing species. For samples containing different fractions 
of degraded peptide, which will be fitted with a two-component model, the diffusion 
autocorrelation time of the fast component will be fixed to this value (representing fully 
degraded R9). Remaining variables are allowed to vary. 
3. Fit the intact R9 using a two-species model. Fix the fast component at the diffusion time 
of the fully degraded R9. Intact R9, in the presence of lysate, bears two components: (a) a 
slow component, reflecting peptide interacting with high-molecular weight molecules from 
the lysate, and (b) a fast component, reflecting peptide molecules that do not interact with 
molecules from the lysate. Therefore, fitting intact R9 with a two component fit where the 
fast component is fixed at the diffusion time of the degraded peptide will also result in a 
small percentage of fast component (13 % in the present experiment). The fraction intact 
R9 in the lysates from HeLa cells treated with lysosomal protease inhibitors can be 
calculated by a normalization of the fraction slow component, taking into account the 
fraction of fast component that is observed for the completely intact R9, according to the 
following formula: 
fraction intact R9sample in lysate = fraction slow component sample in lysate/(1- fraction fast 
component intact R9 in lysate  ) (1) 
4. Proceed with the fitting procedure for all other measurements using a 3D Gaussian 
model assuming two diffusing species and a fixed fast component, representing degraded 
R9 as well as intact R9 not interacting with lysate components. Calculate relative quantities 
of intact R9 according to formula 1. 
6.3.4 Interpretation of result 
Examples of raw autocorrelation curves from an experiment using lysosomal protease 
inhibitors can be found in Figure 6.2A,B. An overlay of representative curves from 
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different treatments illustrates that the autocorrelation curves are unaffected by a treatment 
with DMSO or pepstatin A, but a clear shift to the right, representing a slower diffusion, is 
observed for the lysate obtained from HeLa cells treated with E64d (Figure 6.2C). The shift 
to the right indicates the presence of more intact R9.The slower diffusion time is not just a 
reflection of the higher molecular weight, but indicates the association with other cellular 
components present in the lysate, which is not observed for degraded R9. This is illustrated 
by the differences in diffusion time between degraded and intact R9 in buffer and in the 
buffer lysate-mixture. In buffer, degraded R9 shows a diffusion time of about 30 s, 
compared to about 47 s for intact R9 (the actual values will differ between days and 
between set-ups). The differences are much larger in the lysate-buffer mix, where degraded 
R9 has an average diffusion time of 74 s compared to 900 s for intact R9. Relative 
quantities of intact R9 after the incubation in the presence or absence of lysosomal protease 
inhibitors were calculated. In cells incubated with E64d, 60 % of R9 had remained intact, 
whereas all other conditions led to a percentage of intact R9 lower than 20 % (Figure 
6.2D). This result therefore demonstrates that in HeLa cells, R9 is mainly degraded by 
cysteine proteases and that this degradation can be inhibited by the cysteine protease 
inhibitor E64d. Besides information on the average diffusion time through the confocal 
volume, FCS measurements also provide information on the concentration, represented as 
the average background-corrected fluorescent molecule number in the confocal volume at 
any given time, which can be calculated as follows: 
 
Gtot(0) = 1 + 1/Napp = 1 + (1-CPSb/CPSt)
2/Ncorr [22] 
 
A comparison of the lysate peptide concentrations from the samples above showed that in 
the samples treated with E64d, the concentration, as reflected by the average molecule 
number N, was substantially lower (N= 0.29 vs. 1.17-1.38) than for the other three samples. 
Since we previously established that E64d does not affect uptake as witnessed by confocal 
microscopy in live cells (data not shown), we assume that this observation reflects an 
increased removal of debris-bound peptide during the centrifugation step included to obtain 
a homogeneous solution. This furthermore underscores the differences in intracellular 
association of R9 in cells treated with E64d compared to other treatments or no treatment.11  
                                                          
11This interpretation assumes equal initial cell numbers and an equal lysis efficiency. An additional control where 
absolute protein concentrations are determined could be included as further proof. 
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Figure 6.2. Fluorescence correlation spectroscopy for the analysis of the stability of R9 in HeLa cells treated 
with lysosomal protease inhibitors. (A,B) Autocorrelation functions of lysates from HeLa cells incubated with 5 
M R9 for 1 h at 37°C without inhibitor (A) or with 40 M E64d (B). Lysates were prepared after the incubation 
in the presence of protease inhibitors. (C) Comparison of representative fits for autocorrelation curves obtained 
from HeLa cell lysates obtained as described above. Included are the control treated with peptide only, cells 
treated with DMSO as a vehicle control, 10 M pepstatin A and 40 M E64d. All lines indicate fits that were 
obtained using a 3D Gaussian model assuming a triplet state and the presence of a slow-diffusing and a fast-
diffusing molecular species. (D) Quantification of intact R9 in HeLa cells treated with lysosomal protease 
inhibitors. Relative quantities of intact R9 were determined using a two-species 3D Gaussian triplet model with 
intact and degraded R9 as references. 
6.3.5 Preparation of live cells treated with nona-arginine composed of D- and L-amino 
acids 
1. Spin down 300,000 Jurkat E6.1 leukemia cells and resuspend in 200 l RPMI + 10 % 
fetal calf serum containing 500 nM R9 or r9.  
2. Incubate for 30 min at 37°C. Wash with RPMI supplemented with 10 % fetal calf serum, 
spin down for 5 min and resuspend in fresh medium. Seed cells in 8-well microscopy 
chamber (Nunc, Wiesbaden, Germany) and allow them to settle. 
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6.3.6 Intracellular FCS measurements in living Jurkat cells 
1. Determine and fix the structure parameter and the triplet time using fluorescein as 
described above. 
2. 1 h after the wash step, single cells are identified by confocal microscopy12 and the 
confocal detection volume is positioned in the nucleus. 
3. Autocorrelation measurements are acquired in each cell for 5 x 10 s using the ISS vista 
software. Repeat the procedure in at least 3 or 4 cells and in the background of the same 
incubation chamber. 
6.3.7 Analysis of intracellular FCS measurements using Globals for spectroscopy 
software 
1. Define a 3D Gaussian diffusion model assuming a triplet term and two diffusive 
components with offset. 
2. Determine the triplet time ( T), the lateral radius of the detection volume ( xy) and the 
structure parameter (ratio of z / xy) by fitting the autocorrelation function acquired for the 
fluorescein standard. Fix these values in the fit for the peptide samples. Allow other 
variables to vary. 
3. Perform global curve fitting. Results for living Jurkat cells are shown in Figure 6.3.  
6.3.8 Interpretation of result 
Unlike measurements in cell lysates, intracellular FCS measurements do not give 
consecutive measurements (10 s each) that can be easily combined, because the calculated 
autocorrelation functions can differ quite substantially (Figure 6.3). In contrast, curves 
should be inspected individually. Cells were incubated with 500 nM peptide. This 
concentration is considerably lower than concentrations typically used for following the 
uptake of peptides by confocal imaging. As a consequence, no fluorescence could be seen 
inside the cells. The positioning of the confocal detection volume was therefore based on 
transmission images (Figure 6.3A,D). 
In all cases, measurements showed a rapid bleaching at the beginning of the acquisition 
of autocorrelation functions, indicating the presence of a substantial amount of immobile 
peptides in the cell. Because no diffusion occurs for this population of peptides, no reliable 
estimates of the quantity can be made. In addition, we observed that during some 10-s 
                                                          
12 Make sure to identify the cells with a low laser power in order to minimize photobleaching. 
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measurement intervals of Jurkat cells treated with R9, species with a high mobility were 
dominant (Figure 6.3E, left curve), reminiscent of free fluorescein. The average molecule 
number N corresponded to a concentration of free fluorophores of less than 50 nM. During 
other measurement intervals, a slower diffusive component was more dominant, reflecting 
intact R9 interacting with cellular components (Figure 6.3E, right curve). The slower 
diffusing component was also observed for r9 (Figure 6.3C), in addition to measurement 
intervals where no signal above the background was present (Figure 6.3B).  In contrast, no 
rapidly diffusing molecular species was observed in cells treated with r9, confirming the 
assumption that the rapidly diffusing species indicates the presence of breakdown products 
of R9. Moreover, bleaching was more dominant for r9, furthermore indicating a larger 
immobile fraction of r9. 
 
Figure 6.3. Intracellular FCS of R9 and r9 in Jurkat cells. Jurkat cells were treated with 500 nM R9 or r9 for 
30 min, spun down and washed, and seeded in 8-well microscopy chambers. After 1 h, the detection volume for 
FCS measurements was placed into the nuclei of living cells identified by transmission microscopy, as indicated in 
panel A (for r9) and D (for R9). The cross-hair cursor indicates the position of the detection volume in the optical 
plane. The scale bar indicates 5 m. Representative measurements for r9 (B and C) and R9 (E) are indicated. In 
panel F, the relative frequencies of autocorrelation functions with a dominating fast or slow component (R9) or 
slow component and background signal (r9) are indicated. The result in F reflects the average ratio of 
measurements from 3 (R9) and 4 (r9) different cells. The left autocorrelation function in E shows an example in 
which the fast component was dominant, whereas the dominance of the slow component can be seen in C and the 
right curve in E. B shows an uncorrelated background signal from the nucleus of r9-treated cells. 
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7.1 Introduction 
Protein therapy aims to use in vitro produced proteins to intracellularly replace or 
complement faulty ones [1, 2], making it a promising strategy to fight protein deficiency 
diseases [3, 4]. Unfortunately, the hurdles a protein must take to reach its therapeutic effect 
have hampered clinical applications. Many proteins suffer from poor in vivo stability, and 
cellular uptake and directed intracellular trafficking are hard to achieve [5]. Due to these 
issues, the success of protein therapy is limited to a small set of lysosomal diseases  [3, 4], 
for which delivery efficiency is still low, costs are high, and long-term efficiency has not 
yet been established. 
 A way to overcome some of these limitations is to couple therapeutic proteins to cell 
penetrating peptides (CPPs) which promote the cellular uptake of their linked cargoes [6, 
7]. It has become clear, however, that most CPP-mediated uptake of proteins occurs via 
endocytosis. Poor release from the endosome and proteolytic breakdown have been 
identified as major factors limiting the biological activity of delivered molecules [3, 4]. 
Protection may be achieved by encapsulation of unmodified proteins inside delivery 
vehicles such as liposomes that display CPPs [8, 9]. Once inside the cell, the enzyme is 
released. However, inside the cytoplasm, the lifetime of an enzyme may be limited by 
denaturation or degradation. 
 Cells often use compartmentalization to organize, isolate, or protect enzymes, which 
provides optimal conditions for specific cellular reactions. In compartments, e.g. 
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organelles, reactants are exchanged by diffusion, channels, or transporter molecules. 
Therefore, it stands to reason that the introduction of new protein functionality to a cell 
may be best achieved by delivering the biomacromolecule encapsulated in a porous shell 
[10], mimicking an organelle. To be suited for protein therapy, this artificial compartment 
should be stable in the bloodstream and capable of cellular uptake. Furthermore, it should 
offer protection against proteases but be permeable to the substrates and products of its 
cargo. 
 Here, we describe the preparation and cellular uptake of enzyme-loaded polymersome 
capsules, and we report on the intracellular routing and activity of these nano-objects in 
mammalian cells. Cellular internalization of the capsules is mediated by the CPP tat linked 
to their surfaces [11]. 
7.2 Results and discussion 
Polymersomes are self-assembled vesicles made from block copolymers and may be 
regarded as stable alternatives to liposomes [2, 12]. They have dimensions in the nanometer 
range, a size considered to be suitable for in vivo applications [13]. Their properties can be 
engineered by changing their constituent polymers. As illustrated in , we present here a 
polymersome with a semi-porous membrane based on polystyrene40-block-poly[L-
isocyanoalanine(2-thiophen-3-yl-ethyl)amide]50 (PS-PIAT, 1) [14]. Enzyme-filled PS-PIAT 
polymersomes have been reported as efficient nanoreactors [15-17], capable of protecting 
their contents from proteolytic degradation [18]. To promote the cellular uptake of such a 
nanoreactor, an azide-containing version of tat was covalently linked to a polystyrene-
block-poly(ethylene glycol)-oxanorbornadiene (PS-PEG-crDA, 2) using a Cu-free tandem 
cycloaddition-retro-Diels-Alder (crDA) „click‟ reaction [19]. Coassembly of 10 wt.-% PS-
PEG-tat (3) with PS-PIAT thus constructed a tat-presenting nano-capsule, hereinafter 
referred to as a tat-polymersome (Figure 7.1). 
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Figure 7.1. a) Structures and cartoon representations of the used polymers; b) In our strategy, 10 wt.-% of 3 was 
mixed with 1 to produce porous tat-functionalized polymersomes loaded with protein. 
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 Figure 7.2 shows transmission electron microscopy (TEM) images of polymersomes 
prepared in hepes-buffered saline (HBS) containing either green fluorescent protein (GFP, 
a) or horseradish peroxidase (HRP, 1b, c). Neither the handling, the aggregation behavior, 
nor the spherical morphology of the polymersomes was influenced by the admixture of 3, 
which is in line with previous results for PS-PEG-enzyme conjugates [20]. The tat-
polymersomes had an average diameter of 114 +/- 28 nm, with no obvious size variation 
between the polymersomes with different protein contents. This demonstrates that the tat-
polymersomes provide a modular platform for protein and enzyme encapsulation. 
 
Figure 7.2. Transmission electron micrographs of PS–PIAT polymersomes prepared in HBS. a) GFP-
loaded, with 10 wt.-% 3; b) HRP-loaded; c) HRP-loaded, with 10 wt.-% 3. Scale bars: 1 μm. 
 To investigate whether tat would induce efficient cellular uptake, unmodified 
polymersomes and tat-polymersomes, both loaded with GFP, were incubated with a variety 
of cell lines (HeLa, Jurkat and HEK 293). To this point, directed cellular uptake of 
polymersomes was restricted to cells with high phagocytic activity, i. e. the intrinsic ability 
to engulf large particles [21-23]. As shown in Figure 7.3, tat-polymersomes were taken up 
by all three cell types. No internalization of unmodified polymersomes was detected. 
Residual fluorescence could be attributed to extracellular polymersomes that had not been 
washed away. Having established their efficient internalization, we set out to investigate 
the route of uptake. 
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Figure 7.3. Confocal micrographs of different cell types incubated with GFP-loaded polymersomes with or 
without tat. Scale bars: 10 μm 
 Arginine-rich peptides like tat are a class of CPPs for which endocytosis is known to be 
important, and macropinocytosis is the endocytic pathway that has been most regularly 
associated with their cellular uptake [24, 25]. Also, given the average size of the present 
polymersomes (114 nm), macropinocytosis can be expected to be the most prominent 
mechanism for their uptake, as size-restrictions are typically ascribed to other pathways 
[26]. 
 To address the involvement of macropinocytosis in uptake, HeLa cells were incubated 
with GFP-loaded polymersomes and fluorescently labeled dextran, a polysaccharide that is 
a marker for macropinocytosis. Incubation was limited to 25 minutes to prevent endosomal 
mixing and ensure that colocalization did indeed result from endocytosis along a shared 
uptake route. Cells co-incubated with both GFP-loaded tat-polymersomes and Texas Red-
labeled dextran (70 kDa) showed a prominent Texas Red fluorescence. The GFP signal that 
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was detected was low, but colocalized with the dextran signal (Figure 7.4). Next to the 
colocalization, uptake through a common route was supported by two further observations. 
First, with tat-free polymersomes, Texas Red fluorescence was greatly reduced, indicating 
that tat-polymersomes induced the uptake of dextran (Figure 7.4c). Second, dextran 
inhibited the uptake of polymersomes, as can be concluded by comparison of GFP 
fluorescence in Figure 7.4a,b. 
 
Figure 7.4. Confocal micrographs of HeLa cells incubated. a) GFP-loaded tat-polymersomes and Texas Red-
labeled dextran (70kDa); b) GFP-loaded tat-polymersomes; c) GFP-loaded polymersomes and Texas Red-labeled 
dextran (70kDa). Scale bar: 20 μm. 
 Next, we investigated the fate of tat-polymersomes after their uptake into cells. A 
frequently observed trafficking route for cell-penetrating peptides leads to late endosomes 
and lysosomes [27]. These compartments have an acidic pH and can be labeled by 
Chapter 7 – Cellular Integration of a Nanoreactor  
150 
 
Lysotracker Red. After incubation of HeLa cells with tat-polymersomes for four hours, a 
considerable fraction of the GFP signal colocalized with acidic vesicles (Figure 7.5). An 
almost equally large population of GFP-containing punctuate structures retained a neutral 
pH, indicated by the lack of Lysotracker staining. It is unclear whether this indicates that 
polymersomes were retained in non-acidic vesicles, as reported for tat-cargo constructs 
[28], or whether the absence of colocalization indicates cytosolic delivery. Both options 
would be advantageous for the use of polymersomes in protein therapy, as they avoid 
acidification. 
 
Figure 7.5. Confocal micrographs of HeLa cells incubated with GFP-loaded tat-polymersomes and 
Lysotracker Red. Scale bar: 20 m. 
 The efficient uptake of tat-polymersomes through pinocytosis and their merely partial 
colocalization with acidic vesicles are promising starting points for the introduction of 
enzyme-loaded nanoreactors into cells. We previously reported a variety of nanoreactors 
containing different enzymes, one of which was horseradish peroxidase (HRP) [18, 29]. A 
substrate that is neutral under physiological conditions both prior to and after oxidation by 
HRP is 3,3‟,5,5‟-tetramethylbenzidine (TMB, 4) [30]. It can diffuse through most lipid-
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based membranes, making TMB in the culture medium intracellularly available. The 
oxidation product of TMB is easily detected by measuring its absorbance (λ = 370 nm). 
 To assess the ability of polymersome nanoreactors to function inside cells, we 
incubated HeLa cells with HRP-loaded tat-polymersomes for four hours to allow their 
internalization. The cells were then washed and incubated with TMB (120 μg/ml) and H2O2 
(250 µM). Visual inspection of the samples revealed the intracellular activity of HRP by 
the appearance of a blue color. Microscopy showed that the stain emanated from the cells, 
leading to the formation of precipitates (Figure 7.6). The rate at which TMB was converted 
was linearly dependent on the administered dosage of polymersomes (Figure 7.9). 
 
 
Figure 7.6. Representative transmission micrographs of HeLa cells containing HRP-loaded tat-
polymersomes after 30 min. of TMB conversion. The scale bars approximate 30 μm; 4 is TMB. 
 This demonstrated that the assay provided the possibility to quantitatively assess 
cellular HRP activity. Therefore, we next investigated how long intracellular activity of 
HRP-loaded tat-polymersomes persisted over time. Four hours after internalization, 75% of 
the original activity was still present. After 16 hours, 42% of the original activity was 
preserved (Figure 7.7a). These results show that the polymersome-based approach 
maintained activity to a much higher degree than what was reported for free HRP trafficked 
to lysosomes, which achieved a lysosomal half-life of ~1 hour [31]. The half-life of HRP 
encapsulated in PS-PIAT polymersomes in buffer is 15 days [18]. To identify why the HRP 
activity decreased over time, we tested the effects of chloroquine and nordihydroguaiaretic 
acid (NDGA) on our system. Both compounds can induce the release of endosomal 
contents into the cytoplasm [27, 32]. If the observed decrease was due to degradation of the 
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enzyme molecules in an acidic environment or endosomal recycling and cellular release, 
then these compounds should increase HRP activity. However, none of them exhibited a 
pronounced effect (Figure 7.7b). The reason for the decrease in HRP activity is therefore 
unknown at present. 
 In summary, we have designed a polymersome nanoreactor that is capable of entering 
cells, where it can induce intracellular catalysis. To this point, the cellular delivery of 
polymersomes was restricted to cells with an intrinsically high phagocytic activity. The 
catalytic activity conferred to the cells was maintained at levels that were significantly 
higher than those reported for soluble enzymes. The results therefore represent a significant 
step towards a functional artificial organelle. 
 
Figure 7.7. Activity of intracellular HRP-loaded tat-polymersomes over time (“control” denotes HRP-loaded 
polymersomes without 3). a) TMB conversion at various points of time after cell uptake; b) The effect of 
chloroquine and NDGA; cells were pulsed with chloroquine or NDGA during the final hour of incubation. 
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7.3 Materials and methods 
7.3.1 Synthetic procedures 
Polystyrene40-block-poly[L-isocyanoalanine(2-thiophen-3-yl-ethyl)amide]50 (PS-PIAT, 1) 
was a gift of Hans-Peter M. de Hoog and prepared as previously described [33]. Azido-tat 
was a kind donation by Morten Borre Hansen and synthesized using standard solid phase 
peptide synthesis protocols (sequence: N3-YGRKKRRQRRRGC(acm)-NH2). The azide 
moiety was introduced through diazo transfer to the N-terminus while the peptide was still 
on the resin. Other chemicals, methods and instrumentation were previously reported [17]. 
GFP was expressed as previously reported [34]. 
7.3.2 3-Trifluoromethyl-7-oxa-bicyclo[2.2.1]hepta-2,5-diene-2-carboxylic acid ethyl 
ester (S1) 
Ethyl 2-fluorobut-2-ynoate (0.9101 gr, 5.47 mmol) was added to a Schlenk tube and fitted 
with a stopper, evacuated and backfilled with N2. 3-Methylfuran (1.2 equiv., 514 μL, 6.57 
mmol) was added to the reaction vessel, which was then heated to 40°C and left to stir for 4 
days. The resulting mixture was purified by column chromatography (ether/pentane, 1:4 
v/v, Rf-values: 0.56 (S1), 0.14 (methylfuran)). After evaporation of the solvent and drying 
in vacuo, S1 was obtained as a yellow oil, all of which was used to subsequently prepare 
S2. 1H NMR (400 MHz, CDCl3): δ = 1.32 (m, 3H), 2.00 (d, 3H), 4.29 (m, 2H), 5.31 (d, 
1H), 5.57 (d, 1H), 6.58 (d, 1H); HRMS (EI+) m/z calcd for C10H10F3O3 [M+H]+ 
234.0506, found 234.050. 
7.3.3 3-Trifluoromethyl-7-oxa-bicyclo[2.2. ]hepta-2,5-diene-2-carboxylic acid (S2) 
All product resulting from the synthesis of S1 was dissolved in THF (30 mL) and kept at 
0°C. Aqueous NaOH (13 mL, 1 M) was dripped to the solution over a period of 30 min, 
after which the reaction mixture was allowed to warm to room temperature and stirred for 
another 2 hrs. It was then washed with EtOAc (3X) and dried (MgSO4). The resulting 
mixture was co-evaporated with CH2Cl2 twice and dried in vacuo, yielding S2 as an off-
white wax (0.4575 g, 38% over two steps) 1H NMR (400 MHz, CDCl3): δ = 2.00 (d, 3H), 
5.34 (d, 1H), 5.59 (d, 1H), 6.59 (d, 1H); HRMS (EI+) m/z calcd for C8H6F3O3 [M+H]+ 
206.0191, found 206.019. 
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7.3.4 α-ω-Poly(ethylene glycol)65-diazide (S3) 
Dihydroxy-PEG65 (10.2 g, 3.4 mmol) was dissolved in CH2Cl2 (30 mL) and Et3N (10 
equiv., 4.74 mL, 34 mmol) was added under stirring. After one min., mesonyl chloride 
(MeSO2Cl, 10 eq, 2.62 mL, 34 mmol) was dripped to the solution and it was left to stir for 
16 hrs. The reaction was quenched by addition of CH2Cl2 (40 mL), after which it was 
washed with brine (6X) and evaporated to dryness. The product was dissolved in DMF (60 
mL) and sodium azide (NaN3, 6 equiv., 1.35 g, 20.4 mmol) was added. This mixture was 
left to stir for 16 hrs at room temperature, concentrated in vacuo, dissolved in CH2Cl2 and 
washed with brine (3X). Afterwards, the product was isolated by precipitation in hexane 
and dried in vacuo to obtain S3 as a white powder (5.0 g, 49%) GPC: Mn: 2.9 kg mol-1, 
Mw: 3.0 kg mol-1, Mw/Mn: 1.04; 1H NMR (400 MHz, CDCl3): δ = 3.31 (t, 4H), 3.4-3.9 
(b, ~260H); FTIR-ATR: 3550, 2859, 2098 (v N3), 1636 cm-1. 
7.3.5 α-ω-Poly(ethylene glycol)65-diamine (S4) 
S3 (5.372 g, 1.79 mmol) was dissolved in THF (40 mL), to which PPh3 (10 equiv., 4.70 g, 
17.9 mmol) was added. After 16 hrs, the reaction was quenched with ultrapure water and 
the solvent was evaporated in vacuo. The residue was suspended in ultrapure water and 
filtered through a hyfloplug. After repeated suspension and filtration, lyophilisation yielded 
S4 (2.808 g (52.3%) with 2% PPh3O) as a white powder. 1H NMR (400 MHz, CDCl3): δ = 
2.86 (t, 4H), 3.50 (t, 4H) 3.4-3.9 (b, ~256H); FTIR-ATR: 3550, 2859, 2127, 1636, 1470, 
1440 cm-1. 
7.3.6 α-ω-Poly(ethylene glycol)65-dioxanorbornadiene (S5) 
S4 (0.68 g, 0.23 mmol) and S2 (1.1 equiv., 0.11 g, 0.5 mmol) were dissolved in CH2Cl2 (5 
mL). DMAP (2.2 equiv., 0.125 g, 1 mmol) was added, and the mixture was cooled to 0°C. 
EDC (1.1 equiv., 0.1 g, 0.5 mmol) was added to the solution, which was left to stir for 1h. 
It was then allowed to return to room temperature and stirred for an additional 16 hrs. The 
mixture was washed with aqueous HCl (1M, 2X) and with brine (2X). The combined HCl 
layers were washed with CH2Cl2, after which the combined organic layers were 
concentrated in vacuo. The residue was dissolved in CH2Cl2 and washed with an aqueous 
NaHCO3 solution (5%, 1X) to remove traces of acid. The product was then lyophilized 
from ultrapure water to obtain S5 as a white solid (0.504 g, 65%). 1H NMR (400 MHz, 
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CDCl3): δ = 1.98 and 2.16 (s, 3H), 2.88 and 2.95 (d, 2H), 3.4-3.9 (b, ~256H), 5.35 (d, 1H), 
5.52 (d, 1H). 
7.3.7 α-Bromo-ω-methyl-polystyrene38 (S6) 
CuBr (141.7 mg, 1 mmol) was added to a Schlenk tube, which was evacuated and 
backfilled with argon three times. A solution of distilled styrene (80 equiv., 8994 μl, 80 
mmol), anisole (4 equiv., 426.6 μl, 4 mmol), PMDETA (1 equiv., 205.1 μl,1 mmol) and α-
methylbenzyl bromide (initiator, 1 equiv., 135.4 μl,1 mmol) was added to the Schlenk tube 
and stirred. The mixture was allowed to react at 90°C until the conversion was 50% 
(monitored by NMR and GPC analysis). The reaction was quenched by rapid cooling and 
the product was precipitated in methanol. The resulting solid was dissolved in toluene and 
precipitated in methanol twice and subsequently dried in vacuo. S6 was obtained as a white 
powder (4.262 g, 97%). 1H NMR (400 MHz, CDCl3): δ = 1.04 (b, 3H), 1.2-2.3 (b, ~114H), 
4.45 (b, 1H), 6.3-7.3 (b, ~190H); FTIR-ATR: 3026, 2919, 2845, 2358, 2243, 1942, 1872, 
1802, 1600 cm-1; GPC: Mn: 3510, Mw: 3803, PDI: 1.05. 
7.3.8 α-Azido-ω-methyl-PS38 (S7) 
S6 (2.118 g, 0.54 mmol) was dissolved in DMF (40 mL) and heated to 80°C. NaN3 (10 
equiv., 375.1 mg, 5.4 mmol) was added to the solution, which was left to react overnight. 
The solvent was evaporated and the residue was redissolved in CH2Cl2 and filtered using a 
paper filter. The volume of the mixture was reduced in vacuo and the product was 
precipitated in methanol. The resulting N3- PS39-Me (7) was obtained as a white powder 
(1.93 g, 91%). 1H NMR (400 MHz, CDCl3): δ = 1.04 (b, 3H), 1.2-2.3 (b, ~114H), 3.95 (b, 
1H), 6.3-7.3 (b, ~190H); FTIR-ATR: 3028, 2915, 2363, 2103 (ν N3), 1714, 1597, 1489, 
1464, 1066, 1018, 754, 698 cm-1; GPC: Mn: 3934, Mw: 4278, PDI: 1.08. 
7.3.9 Me-polystyrene50-block-poly(ethylene glycol)65-oxanorbornadiene (2) 
PS S7 (268 mg, 0.0536 mmol) and PEG S5 (1.6 equiv., 293 mg, 0.085 mmol) were 
dissolved in distilled THF (10 mL) and stirred for 10 days at 40ºC. After evaporation of the 
solvent the crude reaction mixture was separated by silica column chromatography (eluents 
CH2Cl2 and MeOH, from 1:0 to 4:1 v/v). Repeated precipitation in ultrapure water yielded 
2 as a white powder (22.6 mg, 5.1%). 1H NMR (400 MHz, CDCl3): δ = 1.2-2.3 (b, 
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~114H), 3.4-3.9 (b, ~256H), 5.12 and 5.34 (s, 2H, oxanorbornadiene bridging protons), 6.3-
7.3 (b, ~190H); GPC: Mn: 5203, Mw: 5720, PDI: 1.09. 
7.3.10 Me-polystyrene50-block-poly(ethylene glycol)65-block-tat (3) 
Azido-tat (1.12 equiv., 4.95 mg, 3.18 μmol) and 2 (22.6 mg, 2.83 μmol) were dissolved in 
DMF (2 mL) and stirred for 30 days at 40ºC. The crude reaction mixture was concentrated 
in vacuo and purified by size exclusion chromatography (Biobeads column in DMF). After 
concentration in vacuo and lyophilisation from dioxane, 3 was obtained as a white solid 
(18.8 mg, 69.5%). 1H NMR (400 MHz, CDCl3): δ = 1.2-2.3 (b, ~114H), 3.4-3.9 (b, 
~256H), 6.3-7.3 (b, ~190H) (numerous small peaks for tat are visible. The bridging protons 
of oxanorbornadiene from 2 had disappeared, indicating full conversion); GPC: Mn: 6807, 
Mw: 7174, PDI: 1.04. Staining on TLC plates with chlorine-TDM was positive for amines. 
7.3.11 tBuO-polystyrene50-block-poly(ethylene glycol)65-block-tat using Cu(II)-catalysis 
(S8) 
Azido-tat (5.18 mg, 3.33 μmol), PS50-PEG65-acetylene (1.6 equiv., 41.6 mg, 5.2 μmol, for 
synthesis, see ref [4]), CuBr (6 equiv., 6.76 mg, 0.047 mmol) and PMDETA (6 equiv., 
10.13 μL, 0.047 mmol) were dissolved in THF/H2O (2:1 v/v, 3 mL) and stirred for 4 days. 
After 2 days, sodium ascorbate was added (6 equiv., 4 mg, 0.02 mmol). After 3 days the 
reaction mixture was evaporated and the crude product was purified by silica column 
chromatography CH2Cl2/MeOH, 3:1 v/v). Lyophilisation yielded a mixture of S8 (33%) 
and unreacted PS-PEG as an off-white solid (22.5 mg, 72%). 1H NMR (400 MHz, CDCl3): 
δ = 1.2-2.3 (b, ~150H), 3.4-3.9 (b, ~260H), 6.3-7.3 (b, ~250H) (numerous small peaks for 
tat are visible); FTIR-ATR: 3442, 3018, 2915, 2867, 1942, 1869, 1774, 1722, 1644, 1597, 
1489, 1445, 1346, 1290, 1247,1100, 1026, 940, 845, 750, 698, 538 cm-1; GPC: Mn: 9432, 
Mw: 9616, PDI: 1.02; Staining on TLC plates with chlorine-TDM was positive for amines. 
7.3.12 Analysis of Cu-levels in PS-PEG-tat 
Inductively coupled plasma - mass spectrometry (ICP-MS) analysis was used to assay Cu-
levels in PS-PEG-tat block copolymers. PS-PEG-tat was prepared through either the Cu-
catalyzed azidealkyne cycloaddition (CuAAC, synthesis vide supra) or the tandem 
cycloaddition-retro-Diels-Alder reaction between an azide and an oxanorbornadiene (crDA, 
compound 3). The indicated amount of polymer was destructed in concentrated nitric acid 
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(0.5 mL) at 80°C for 3 hours. The samples were cooled to room temperature and silver 
acetate (AgOAc) was added as an internal standard (2 mg mL-1 in ultrapure water, 1.25 
mL). The total volume of each sample was then brought to 5.0 mL using ultrapure water 
prior to measurement. Resulting ppm values for Cu were standardized on values for the 
internal standard Ag to enable expression of Cu per milligram. The ratio between CuAAC 
and crDA Cu-levels was (71.84/9.08·10-2) = 791.20. 
7.3.13 HEPES-Buffered Saline Solution 
HEPES-buffered saline (HBS) used in this report was prepared from a 10X-stock solution. 
Diluted 1X buffer contained 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 
10 mM), NaCl (135 mM), KCl (5 mM), CaCl2 (1.8 mM), MgCl2 (1 mM), pH = 7.4. 
7.3.14 General Procedure for Polymersome Formation 
A solution of PS40-PIAT50 (admixed with 10 wt.-% of 3, when applicable) in THF (0.5 
mL, 1.0 g·L-1) was manually injected into HBS (2.5 mL) using a pipette. For HRP-filled 
polymersomes, prior to THF addition, 200μL of HBS was replaced by 200μL of HRP 
solution (2.5 g·L-1, (Sigma, type XII) in ultrapure water). For GFP-filled polymersomes, 
96μL of HBS was replaced by 96μL of GFP solution (3.75 g·L-1 in HBS). After 
equilibration for 30 minutes the suspension was transferred to a Spectra/Por (Breda, The 
Netherlands) Biotech Cellulose Ester Dialysis Membrane tube (MWCO: 300kDa). The 
dispersion was dialyzed against HBS for 36 hours, with regular changes of the dialysis bath 
to fresh HBS. The resulting vesicles were analyzed with TEM and stored in a glass vial. To 
attenuate incidental concentration differences between tat- and non-tat batches of GFP 
polymersomes used in the same fluorescence-based experiments, their concentrations were 
standardized based on adsorption at 490 nm of their GFP cargo through dilution with HBS. 
7.3.15 Cell Culture 
HeLa and Jurkat E6.1 cells were maintained in RPMI 1640 and HEK 293 cells in DMEM 
(Both PAN Biotech, Aidenbach, Germany), each supplemented with 10% fetal calf serum 
(FCS; PAN Biotech). All cell lines were incubated at 37°C in a 5% CO2-containing, 
humidified incubator. 
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7.3.16 Confocal Laser Scanning Microscopy 
Confocal laser scanning microscopy was performed on a TCS SP5 confocal microscope 
(Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 x N.A. 1.2 
water immersion lens. Live cells were maintained at 37°C on a temperature-controlled 
microscope stage. GFP, lysotracker and Texas Red were excited using a 488 nm argon ion 
laser, a HeNe 561 nm laser and a HeNe 594 nm laser, respectively. Emission was detected 
between 500 and 550 nm for GFP, between 575 and 670 nm for lysotracker and between 
610 and 700 nm for Texas Red. 
7.3.17 Cellular Uptake and Colocalization Studies 
HeLa cells or HEK cells were seeded at a density of 30,000 cells per well one day before 
the experiment in 8-well microscopy chambers (Nunc, Wiesbaden, Germany). Jurkat cells 
were counted at the day of the experiment and 300,000 cells were incubated with 
polymersomes in each well. For uptake studies, GFP and tat-GFP polymersomes were 
added to a final concentration of 50 μg/mL (polymer / medium). Cells were incubated with 
polymersomes in fresh medium containing 10% FCS at 37°C for four hours. For 
colocalization experiments using lysotracker red (Invitrogen, Eugene, USA), the 
polymersome concentration was 16.7 μg/mL (polymer / medium) and during the last 60 
min 100 nM lysotracker was added. Cells were washed twice with fresh medium and 
imaged immediately using confocal microscopy. For colocalization studies with dextran, 
polymersomes at a concentration of 16.7 μg/mL were incubated with 0.2 mg/mL Texas 
Red-labeled dextran (MW = 10,000; Invitrogen) for 25 min, after which they were washed 
and imaged immediately as described above. 
7.3.18 Quantification of Polymersome Uptake by Flow Cytometry 
Adherent HeLa or HEK 293 cells were seeded in 24-well plates (Sarstedt, Nümbrecht, 
Germany) at a density of 80,000 cells per well one day before the experiment. At the day of 
the experiment, 600,000 Jurkat E6.1 suspension cells were used per condition. For uptake 
studies, polymersomes were diluted in RPMI supplemented with 10% FCS to the 
concentrations 16.7 and 50 μg/mL (polymer / medium). Cells were incubated with the 
polymersomes for 4 h at 37°C, washed twice with HBS, trypsinated for 5 min at 37°C to 
dissociate cells (HeLa and HEK 293 cells) or to enhance removal of membrane-bound 
polymersomes (Jurkat E6.1 cells) and washed again by centrifugation using fresh medium 
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containing FCS. For the dextran inhibition assay, HeLa cells were treated with 
polymersomes at the concentrations of 16.7 or 50 μg/mL (polymer / medium) for 25 min at 
37°C in the presence or absence of 0.2 or 0.4 mg/mL Texas red-labeled dextran (MW = 
10,000). For all conditions, cellular fluorescence of 10,000 cells, gated on the basis of 
forward and sideward scatter, was measured using a BD FACScan flow cytometer 
equipped with a 488 nm laser (BD Biosciences, Erembodegem, Belgium). Data were 
analyzed using Summit software (Fort Collins, USA). Represented data, shown in Figure 
7.8, have been corrected for background fluorescence and were normalized on the basis of 
the uptake of tat-modified polymersomes at the highest measured concentration for each 
experiment and/or cell line. 
 
Figure 7.8. Flow cytometric quantification of the cellular uptake of tat-polymersomes. a) The uptake of tat-
polymersomes by different cell lines at different concentrations after 4h incubation at 37°C. b) The effect of 
increasing concentrations of dextran on the uptake of tat-polymersomes after 25 min incubation at 37°C. 
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7.3.19 Horseradish Peroxidase (HRP) Assay 
HeLa cells were seeded at a density of 6,000 cells per well one day before the experiment 
in 96-well plates (Sarstedt, Nümbrecht, Germany) and grown to 75% confluence. 
Incubation with the indicated concentrations of HRP-polymersome [100% reflects 167 
μg/mL (polymer / medium)] took place in HBS containing 5 mM glucose and 0.1% bovine 
serum albumin (BSA, all Sigma-Aldrich, Zwijndrecht, the Netherlands) (HBS+). If 
indicated, cells were pulsed with 75 μM chloroquine (Sigma-Aldrich) or 25 μM or 100 μM 
nordihydroguaiaretic acid (NDGA; Sigma-Aldrich) during the final hour of the incubation. 
After the four hour incubation, cells were washed and grown in RPMI + 10% FCS with 1% 
of a standard penicillin-streptomycin preparation (Gibco) for the indicated periods. To 
assay the intracellular HRP activity, cells were washed and incubated with 60 μg/mL of the 
membrane-permeable HRP substrate 3,3‟,5,5‟-tetramethylbenzidine (TMB; Sigma-Aldrich) 
in the presence of 250 μM H2O2 (Malinckrodt Baker, Deventer, the Netherlands) for 30 min 
at 37°C. The conversion of the product was measured each two minutes via the absorption 
at 370 nm (A370). Represented values have been corrected for the A370 of cells that did 
not receive the substrate. All conditions have been tested at least in duplicate during single 
experiments.  
7.3.20 Dose Dependence of HRP Activity on Polymersome Concentration 
The rate at which TMB was converted was linearly dependent on the administered dosage 
of polymersomes. Dilution with HBS of the original 167 μg / mL (polymer / medium) 
dispersion to 50% or 25% of its original polymersome content resulted in a corresponding 
decrease in HRP activity (Figure 7.9). 
 
Figure 7.9. Dose-dependence of the rate of TMB conversion by polymersome-loaded cells on the 
concentration of the tat-polymersome dispersion that was used to load the cells. [100% polymersomes reflects 
167 μg/mL (polymer / medium)] Conversion was measured after 30 minutes and standardized to 100% for 100% 
polymersomes; “Free HRP” denotes cells treated with HRP that was not encapsulated in tat-polymersomes. 
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8.1 Introduction 
Cell-penetrating peptides (CPPs) have attracted much interest in recent years as they have 
the ability to induce cellular uptake of almost any kind of cargo to which they have been 
attached [1-8]. CPPs are typically 8-30 residues long; in nearly all cases conjugation to the 
cargo of choice is based on covalent attachment, or association via uncontrolled charge-
based interactions [9-12]. Covalent attachment can be achieved chemically or, if the cargo 
is a protein, via genetic fusion. Chemical coupling often involves conditions which may 
compromise sensitive cargos like proteins. In addition, coupling reactions are often rather 
unselective, which may lead to linking of (multiple) CPP(s) to essential functional amino 
acid residues in proteins. Moreover, it may also lead to impairment of the cargo [13, 14]. 
Genetic fusion, albeit selective, may result in low expression levels [15] and is a strategy 
that is inherently labor-intensive in case a variety of CPPs is to be examined. 
Non-covalent association systems, of which the streptavidin-biotin system is the 
paradigmatic example, have been of enormous benefit for the biomolecular sciences [16]. 
These non-covalent association systems have also been implemented in delivery systems to 
develop a methodology that separates the synthesis of cargo and CPP, after which a 
supramolecular interaction brings both elements together in a non-covalent delivery vehicle 
[17-20]. However, the few non-covalent delivery systems available to date have their 
shortcomings: streptavidin [17, 19] is of considerable size and also requires the covalent 
modification of one interactor with biotin. Another system which has been employed is the 
interaction of oligohistidine tags with oligovalent nitrilotriacetic acid (NTA) tags, 
facilitated by metal ions [21-24]. In this system, some selectivity can be achieved by 
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adjusting the oligovalency of NTA and histidine [25]. However, the presence of metal-ions 
may lead to binding and inactivation of protein cargos, besides the issue of their inherent 
cytotoxicity [18, 20, 26, 27]. 
In this respect, coiled-coil forming peptides form an interesting alternative, as strong 
and specific binding can be achieved by two short, complementary interaction partners [28, 
29]. The leucine zipper motif, found in many transcription factors, belongs to this class of 
peptides [30-32]. These peptides consist of a heptad repeat, abcdefg, in which residues a 
and d are hydrophobic, packing together with a‟ and d‟ from the second peptide in a knobs-
into-holes manner [33]. Residues e and g are often charged residues responsible for key i to 
i‟+5 electrostatic interactions ensuring heterodimerization and providing directionality of 
the peptide pair (parallel vs. anti-parallel) [34, 35]. Very recently, such leucine zippers were 
used to link a small fluorescent molecule to a polymer non-covalently and transport the 
entire complex into cells [36]. However, like the streptavidin-biotin system, this approach 
also suffers from being fairly sizable. 
Here we present a novel, low-molecular weight, non-covalent and modular transduction 
system based on the strong and specific binding of two complementary leucine zippers 
(Figure 8.1) [29]. Our delivery system consists of three modules: a CPP (module 1), which 
can be conjugated via copper-catalyzed azide/alkyne „click chemistry‟ to a leucine zipper 
peptide (module 2). Subsequently, this CPP-leucine zipper peptide can bind specifically to 
its complementary leucine zipper fused to a proteinaceous cargo (module 3). 
The advantages of this modular design over covalent systems and genetic fusion-protein 
approaches are multiple: (i) The modular assembly allows easy variation of the CPP 
(module 1). This feature could be of great interest to the field of targeted delivery using 
homing peptides to target specific organs/tumours as different organs are targeted by 
different peptides [37, 38]. (ii) The CPP can be synthesized independently of the cargo and 
independently of the leucine zipper. This fragment synthesis strategy confers a synthetic 
freedom enabling the otherwise laborious and complicated synthesis of longer CPPs and 
leucine zippers. (iii) It is possible to use non-natural amino acids such as D-amino acids. 
(iv) Functionalities e.g. labels can be introduced on the leucine zipper (module 2) without 
affecting the cargo. 
To evaluate the effectiveness of this association system in a cell biological context we 
conjugated an enhanced green fluorescent protein non-covalently to a TAT peptide, a CPP 
derived from an HIV transcription factor [39, 40]. 
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Figure 8.1. Overview of the modular assembly process of the leucine zipper-based non-covalent association 
and transduction system. First a CPP (module 1) is „clicked‟ to a leucine zipper peptide (module 2), which binds 
specifically to its complementary leucine zipper peptide linked to a proteinaceous cargo; here GFP-LZ (module 3). 
R = Ac or S0387.  
8.2 Results and Discussion 
The azide-functionalized TAT peptide azido-YGRKK-RRQRRR-GC(Acm)§ (module 1) 
was prepared by solid phase peptide synthesis (SPPS) and a subsequent on-resin 
diazotization of the N-terminus [41]. The azide-functionalized TAT peptide was cleaved 
from the resin using trifluoroacetic acid and purified by reversed-phase HPLC. The mass 
and purity of the purified product were verified by ESI mass spectrometry and analytical 
reversed-phase HPLC, respectively. The clickable leucine zipper (module 2) was prepared 
by coupling of propargylamine to an aldehyde resin via reductive amination, followed by 
standard SPPS using the resulting secondary amine as a starting point [42]. In this way the 
alkyne functionality was introduced at the C-terminus of the leucine zipper peptide 
(KIAALKE)3. This allowed labeling of the N-terminus with carboxyl-S0387 (a 
commercially available Cy5 analog) by means of a HATU-mediated peptide coupling. 
Subsequently, the S0387-labeled, alkyne-functionalized (KIAALKE)3 peptide was cleaved 
from the resin and analyzed as described above for module 1. Finally, S0387-labeled 
alkyne-functionalized (KIAALKE)3 was „clicked‟ to azido-TAT using CuSO4/sodium 
ascorbate as a copper(I) source and lutidine as copper ligand. The resulting S0387-
(KIAALKE)3-triazolo-TAT (S0387-LZ-TAT) conjugate was purified by reversed-phase 
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HPLC and the mass and purity were verified by MALDI mass spectrometry and analytical 
HPLC, respectively. Unlabeled (KIAALKE)3-TAT (LZ-TAT) was prepared in a similar 
way, except that this peptide was acetylated N-terminally instead of labeled with S0387. 
The GFP-leucine zipper, GFP-(EIAALEK)3, (GFP-LZ, our model cargo) was cloned into a 
DNA plasmid as a fusion protein, expressed in and purified from E. coli by means of His-
tag affinity chromatography [43]. The purity and mass were verified by SDS-PAGE 
electrophoresis and HR-ESI, respectively. 
We first verified that the two leucine zippers were able to heterodimerize after linkage 
to TAT and GFP, respectively, by measuring their binding constant by means of isothermal 
titration calorimetry (ITC, Figure 8.2). The ITC data yielded a KD of 181 nM (KD=KA
-1), 
which is similar to the dissociation constant of unfunctionalized leucine zippers (data not 
shown and ref. [44]). This demonstrates that the affinity of the leucine zippers for each 
other is not affected by GFP or TAT. The calculated stoichiometry of 1.14 supports a one-
to-one heterodimerization. 
 
Figure 8.2. Isothermal titration calorimetry of LZ-TAT and GFP-LZ. (A) Raw heats acquired by titrating of 
LZ-TAT into a solution of GFP-LZ. (B) The integrals of the heat peaks were fitted to a one-site binding model, 
providing the association constant KA and the stoichiometry N. Experiments were performed in 10 mM phosphate 
buffer pH 7.0. 
The interaction between the leucine zippers was studied further by conducting dual-
color fluorescence cross-correlation spectroscopy (FCCS) for GFP-LZ and S0387-LZ-
TAT. FCCS extracts information on molecular interactions of differently labeled molecules 
from temporal fluctuations of fluorescence intensity in overlapping confocal detection 
volumes [45]. Since FCCS is a method especially suitable for detecting association at low 
nanomolar concentrations, GFP-LZ and S0387-LZ-TAT were first allowed to associate at 
12.5 μM for 5 min at 4°C, after which they were diluted to 62.5 nM. A strong cross-
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correlation was acquired for the two leucine zippers, whereas no cross-correlation was 
detected if one of the two leucine zippers was replaced by the corresponding free 
fluorophore (Figure 8.3A-D). 
To quantify the fraction of associated particles, first, a double-labeled oligonucleotide 
was used as a positive reference showing maximal cross-correlation (Figure 8.3E). For 
S0387-LZ-TAT, almost complete association with GFP-LZ was observed, whereas over 
half of GFP-LZ species were associated with S0387-LZ-TAT species. Although these 
results seem to indicate a slightly altered stoichiometry, we could attribute the different 
values to differential affinities for the walls of the 384-wells plate used in the FCCS 
experiment, as a 3.3-fold excess of GFP-particles over S0387-labeled particles was 
detected in the solution, calculated on the basis of the estimated particle number in the 
confocal volume (1.8 for GFP and 1.1 for S0387) and the size of the confocal detection 
volume (0.3 fl for the GFP-channel and 0.6 fl for the S0387-channel) [46]. The FCCS 
measurements demonstrated that the non-covalent leucine zipper complexes were stable at 
concentrations below the KD-value, which is indicative of a slow dissociation-rate.  
 
 
Figure 8.3. Interaction of leucine zippers as detected by FCCS. A) Association of GFP–LZ and S0387–LZ–
TAT; B) a Rhodamine Green (RhG) and Cy5 double-labeled oligonucleotide (ON) served as positive control; C) 
GFP–LZ in the presence of S0387 or D) GFP in the presence of S0387–LZ–TAT. (C) and (D) were used as 
negative controls. E) The percentage of bound fraction of S0387 fluorophores (ch2) and GFP (ch1) was calculated 
by normalizing their cross-correlation amplitudes to those of Cy5 and RhG from the double-labeled ON, which 
were defined as 100% association. Errors bars represent the standard deviation of ten measurements of 10 s. 
Having established the potential of the leucine zipper-tag as a non-covalent transduction 
system in a non-cellular context, we next investigated its transduction competence in living 
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cells. Hence, HeLa cells were incubated with GFP-LZ:LZ-TAT complexes and uptake was 
investigated by confocal laser scanning microscopy. As expected, intracellular transduction 
of GFP-LZ was profoundly stimulated when complexed with LZ-TAT; GFP was clearly 
visible in vesicular structures inside the cells (Figure 8.4A). Uptake was only observed for 
the complexes formed from GFP-LZ and TAT-LZ. 
CellMask Deep Red was applied to stain the plasma membrane (after incubation with 
the leucine zippers) to verify that the punctate green structures were indeed localized inside 
cells and not fluorescent aggregates on the plasma membrane. GFP-LZ and CellMask Deep 
Red did not co-localize, thus establishing that the punctate green structures are 
predominantly localized intracellularly (Figure 8.4A). Washing with heparin to remove 
leucine zippers potentially bound to the cell surface did not change the appearance of the 
confocal images demonstrating that the GFP-LZ and LZ-TAT are indeed taken up by the 
cells (data not shown). Importantly, no intracellular delivery of GFP was observed when 
free GFP (no leucine zipper) was incubated with LZ-TAT, ruling out the possibility that 
cellular uptake could be a result of an unspecific interaction between LZ-TAT and GFP 
itself. To exclude the possibility that GFP-LZ internalization was enhanced through 
unspecific induction of macropinocytosis by TAT [13], GFP-LZ was also co-incubated 
with unlabeled free TAT (no leucine zipper) (Figure 8.4B). Indeed, no internalization of 
GFP-LZ was observed, confirming that a specific interaction between TAT-LZ and GFP-
LZ is indeed the primary driving force for internalization. 
 
 
Figure 8.4. Confocal microscopy showing efficient transduction of GFP–LZ by LZ–TAT into HeLa cells. A) 
Leucine zippers (2.5 M) were incubated with HeLa cells for 60 min at 37°C. The plasma membrane was stained 
with Cell-Mask Deep Red. B) HeLa cells were incubated with S0387-labeled LZ–TAT, GFP–LZ, TAT or GFP 
(1.25 M each) for 60 min at 37°C. Yellow structures indicate colocalization, scale bars=10 m. 
After demonstrating that LZ-TAT is able to deliver GFP-LZ intracellularly through a 
specific non-covalent interaction, the next issue to be addressed was whether the leucine 
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zippers remain associated inside cells. In an attempt to answer this question, S0387-LZ-
TAT was co-incubated with GFP-LZ (Figure 8.4B). The overlay of the confocal images 
from this experiment showed numerous yellow punctate dots indicating subcellular co-
localization of the zippers. However, next to yellow dots, red and green dots were observed 
as well, indicating that the ratio of GFP-LZ and S0387-LZ-TAT differs widely between 
intracellular vesicles. Although elucidating the exact intracellular fate requires a more 
exhaustive study, which is beyond the scope of this communication, this observation 
suggests that the leucine zippers do not remain fully associated inside cells. One possibility 
is that the low endosomal pH promotes dissociation of leucine zippers [44].  
In conclusion, by taking advantage of the specific binding of two complementary 
leucine zippers, we have developed a modular, non-covalent delivery system for leucine 
zipper-functionalized cargos. When a cell-penetrating peptide (CPP), TAT, was attached to 
one leucine zipper and mixed with its complementary leucine zipper bearing a GFP-cargo, 
the resulting non-covalent complex was transported into cells. Importantly, cells only took 
up the GFP-cargo when the complementary leucine zipper-TAT was added. Since the 
delivery system is modular, the leucine zipper-TAT can easily be altered either by varying 
the CPP or by adding functionalities to the leucine zipper such as labels. In this proof-of-
concept study we have shown that GFP can be introduced into cells via a non-covalent and 
modular transduction system. This may pave the way for transduction of other 
(therapeutically active) proteins. 
8.3 Materials and Methods 
8.3.1 Experimental 
Aldehyde resin was purchased from Novabiochem and Fmoc-L-amino acids were from 
Bachem or Novabiochem. S0387 was purchased from Few Chemicals (Bitterfeld-Wolfen, 
Germany). All other chemicals were purchased from Baker, Fluka or Sigma Aldrich and 
used as received. Mass spectra were recorded on a Bruker Biflex MALDI-TOF (high 
resolution 0-4000 and low resolution >4000, Bruker Daltronik, Bremen, Germany), a low 
resolution Thermo Finnigan LCQ ESI-ion trap (Thermo Fischer, Breda, The Netherlands) 
or a high resolution ESI-TOF JEOL AccuTOF (JEOL, Nieuw-Vennep, The Netherlands).  
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8.3.2 General peptide synthesis and purification 
Peptides were synthesized on a Labortec640 (Labortec, Bubendorf, Schwitzerland) 
employing a standard Fmoc solid-phase peptide synthesis (SPPS) protocol. Semi-
preparative RP-HPLC purification of peptides was performed using a C18 and a 
MeCN/water gradient containing 0.1% trifluoroacetic acid. The fractions were analyzed by 
ESI-ion trap mass spectrometry and analytical RP-HPLC using a C18 column. 
8.3.3  Infrared spectroscopy 
Infrared spectroscopy was performed on a Thermo Wattson IR300 spectrometer, fitted with 
a Harrick ATR unit (Thermo Fischer, Breda, The Netherlands). Dry samples were 
compressed on the ATR crystal with a pressure of 0.5 kg. Infrared spectra were recorded 
for 32 scans at 4 cm-1 resolution and a sample gain of 1, and background-subtracted. 
8.3.4 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) was carried out on an ITC200 (MicroCal, 
Northhampton, MA, USA). Peptides and proteins were dissolved in 10 mM phosphate 
buffer pH 7.0. The titration experiment was carried out at 5°C and stirring at 500 rpm as a 
series of 39 injections of 1.0 μL with a duration of 2.0 s and a spacing of 240 s. The 
integrals of the measured heat peaks were fitted to a one-site binding model using Origin 
7.0 with a MicroCal ITC plug-in and the binding stoichiometry (N), association constant 
(K), molar enthalpy (ΔH) and entropy (ΔS) of binding were extracted.  
8.3.5 Confocal laser scanning microscopy and fluorescence cross-correlation 
spectroscopy (FCCS) 
Confocal laser scanning microscopy and FCCS were performed on a TCS SP5 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 
63 x N.A. 1.2 water immersion lens and a fluorescence-correlation spectroscopy (FCS) 
unit. For confocal microscopy, cells were kept at 37°C on a temperature-controlled 
microscope stage. GFP was excited with a 488 nm argon ion laser. Emission of GFP was 
collected using a 500-550 nm detection range for confocal microscopy and with a 500-550 
nm band-pass filter for FCCS measurements. S0387 and CellMask Deep Red were excited 
with a 633 nm HeNe laser. Emission for confocal microscopy was collected between 650 
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and 720 nm for S0387 and between 650 and 750 nm for CellMask Deep Red. For FCCS, 
emission of S0387 was collected with a 647-703 nm filterblock. 
Autocorrelation and cross-correlation measurements for FCCS were performed in a 
384-well plate (175 m, lowbase design, MMI, Eching, Germany). Autocorrelation and 
cross-correlation functions were calculated with an ISS VISTA software package (ISS, 
Illinois, USA). Fitting was performed according to a 3D-Gaussian model containing a 
triplet component for GFP and S0387. The particle number obtained from the fit was 
corrected for uncorrelated background [47]: 
 
Gtot(0) = 1 + 1/Napp = 1 + (1-CPSb/CPSt)2/Ncorr 
 
A similar model without a triplet component was used for cross-correlation analysis. To 
correct for bleed-through effects of GFP into the S0387 channel, the true, corrected relative 
cross-correlation amplitude Ĝ0;x/G0,g (green channel) was calculated by the method 
described by Bacia et al. [48]: 
 
Relative cross-correlation amplitude (green) = Ĝ0;x/G0,g = ((G0;x/ G0,g) - kGr(CPSg/CPSr))/(1 - 
kGr(CPSg/CPSr)) 
 
Where G0;x is the uncorrected cross-correlation amplitude at the diffusional 
autocorrelation time (τ)=0 and G0,g the autocorrelation amplitude of GFP at τ=0. kGr 
corresponds to the bleed-through ratio of GFP from the green into the red channel, 
determined by taking the ratio of the counts per second (CPS) values in the red (S0387) and 
green (GFP) channel (CPSr/CPSg). The relative cross-correlation amplitude for the red 
channel was determined by dividing the corrected cross-correlation amplitude Ĝ0;x by the 
autocorrelation amplitude G0,r in the red channel: 
 
Relative cross-correlation amplitude (red) = Ĝ0;x/G0,g 
 
Since the dimensions of confocal detection volumes are wavelength-dependent, the 
relative cross-correlation values never reach 1.0. Therefore, a double-labeled 
oligonucleotide, containing rhodamine green (RhG) and Cy5 as fluorophores, similar to an 
oligonucleotide published previously  [49], was included as positive control. To calculate 
the number of particles in a complex, values obtained with the double-labeled 
oligonucleotide were used as a reference and defined as 100% association. 
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8.3.6 Cellular uptake experiments 
Leucine zipper complexes were prepared in two steps. First, the leucine zippers (25 μM 
each) were mixed and incubated in phosphate buffer (10 mM, pH 7.0) at 4°C for at least 5 
min. Subsequently, complexes were diluted in HBS (10 mM HEPES, 135 mM NaCl, 5 mM 
KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4) containing 5 mM glucose to the indicated 
concentrations. Controls with GFP and TAT were prepared in the same way, i.e. by first 
mixing solutions of these molecules with S0387-LZ-TAT or GFP-LZ respectively, 
followed by a dilution into HBS with glucose. Likewise, when incubation was carried out 
with GFP-LZ only, GFP-LZ was also first diluted to 25 μM and then further diluted into 
glucose-containing HBS to the indicated concentration. All cellular experiments were 
conducted with HeLa cells, which were seeded two days before the experiment in 8-well 
microscopy chambers (Nunc, Wiesbaden, Germany) at a density of 20,000 cells/well. At 
the time of the experiment, cells had grown to 75% confluence. To determine whether 
cellular uptake of GFP-LZ was mediated by LZ-TAT, cells were first incubated with 
leucine zipper complexes (2.5 μM) or controls for 60 min at 37°C, washed with serum-
containing medium, and incubated for 5 min with the plasma membrane stain CellMask 
Deep Red (5 μg/ml). Then, cells were washed three times with serum-containing medium 
and imaged immediately by confocal laser scanning microscopy. This experiment was also 
performed with two additional heparin washes included (2x5 min with heparin, 500 μg/ml 
in HBS supplemented with glucose) to remove cell surface-bound leucine zippers (data not 
shown). To determine colocalisation of leucine zipper-tagged molecules, HeLa cells were 
incubated with GFP-LZ and S0387- LZ-TAT (both 1.25 μM) for 60 min, washed three 
times with serum-containing medium and visualized by confocal laser scanning 
microscopy. 
8.3.7 Expression and purification of GFP-(EIAALEK)3 (GFP-LZ) 
Expression of leucine zipper-tagged GFP: E. coli BLR (DE3) cells containing a pET-15b 
plasmid carrying GFP-(EIAALEK)3 as a fusion gene with an N-terminal Histag [50] were 
used for protein expression. Expression was induced by addition of IPTG (0.5 mL, 1M) and 
protein was expressed for 5 h at 30°C.  
Protein purification: The protein expression culture was pelleted at 4,000 rpm and 4°C for 
15 min using a Sorvall RC-5 centrifuge (Thermo Fischer, Breda, The Netherlands). The 
supernatant was discarded and the pellet stored at -20°C. After thawing, the pellet was re-
suspended in lysis buffer (25 mL, 50 mM NaHPO4, 10 mM imidazole and 300 mM NaCl, 
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pH 8.0) on ice. To this suspension lysozyme (225 μL, 100 mg/mL in water) and PMSF 
(225 μL, 17 mg/mL in MeOH) were added. After gentle shaking at 4°C for 30 min the 
suspension was sonicated (2x3 min at output 6 and 40% duty cycle) using a Branson 
Sonifier 250 (Marius Instruments Nieuwegein, The Netherlands). The resulting cell lysate 
was spun at 1,000 rpm and 4°C for 30 min using a Sorvall RC-5 centrifuge (Thermo 
Fischer, Breda, The Netherlands). The pellet was discarded and the supernatant incubated 
with Ni-NTA agarose beads (washed twice with lysis buffer) at 4°C for 1 h. This 
suspension was added to a filter tube and the beads were allowed to settle on the filter. The 
flow-through was collected and re-incubated with Ni-NTA beads. The column was washed 
with 20 column volumes of washing buffer (10 mL, 50 mM phosphate, 20 mM imidazole, 
300 mM NaCl, pH 8.0) and then 6 column volumes of elution buffer (3 mL, 50 mM 
phosphate, 250 mM imidazole, 300 mM NaCl, pH 8.0) to elute the GFP-LZ. Green 
fractions were combined and dialyzed against buffer (4x 500 μL 10 mM phosphate pH 7.0) 
using 10 kDa MWCO centrifugal filters (Millipore, Cork, Ireland). The mass was verified 
by ESI-TOF [M+H]+ m/z: 33371.8 (calcd. 33371.6) and the purity was checked by SDS-
PAGE (10% acrylamide). 
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9 Summary and future directions 
Despite a sharp increase in the understanding of diseases at the molecular level over the last 
decade and the concomitant validation of numerous therapeutically relevant drug targets, 
yearly drug approvals have not increased in number. In fact, most drug development efforts 
are currently still aimed at only a small percentage of disease-associated proteins that are 
considered suitable for drugging. One of the main reasons is that a substantial part of these 
target proteins needs to be targeted at sites that are involved in protein-protein interactions. 
For the foreseeable future, obtaining sufficient selectivity for pharmaceutical applications 
towards these targets with small molecules is going to remain a bottleneck. Therefore, the 
scientific and pharmaceutical community is shifting gears towards the development of 
biological molecules as alternatives to small molecules, as these so-called undruggable 
proteins can be targeted highly selectively with a variety of biological molecules. Although 
biologicals already represent a growing fraction of newly approved medicines, expected to 
reach 15-50% of the novel medicines in 2015, the application of biologicals for therapeutic 
purposes is currently limited to extracellular applications [1]. Nevertheless, increasing 
efforts are being undertaken to develop biomacromolecules that can be delivered into cells, 
where they can address the largely unexplored intracellular target space.  
This thesis deals with a promising approach for delivery of biomacromolecules into 
cells: the application of cell-penetrating peptides (CPPs), which have a well-established 
capacity to induce the cellular uptake of a large variety of cargo molecules. More 
specifically, the main aim of this thesis was to gain a better mechanistic insight into the 
activity of CPPs, with the underlying goal of advancing the use of CPPs towards 
therapeutic applications. Towards this end, the first chapter gives a general introduction 
about the current state of affairs in drug development and also introduces the molecule 
class of CPPs with its main characteristics and its interactions with cellular components. 
9.1 Side effects of drug carriers 
Target selectivity and side effect profiles are of crucial importance for any drug. 
Traditionally, these topics are directly related to the properties of the drug. However, with 
the rise of molecular entities dedicated to drug delivery, it is of critical importance to 
realize that not just the macromolecule to be delivered needs to have a high selectivity and 
an acceptable side-effect profile, but that the delivery vehicle itself may also generate side 
effects. Though initially considered as Trojan horses, the question of vehicle-related side 
effects is receiving more and more attention also for CPPs, as reports about specific side 
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effects induced by CPPs, either in vitro or in vivo, have steadily accumulated over the last 
decade. Therefore, in the second chapter, an overview of the biological responses that are 
elicited by cationic drug carriers is given, in particular those elicited by CPPs. Ultimately, 
the identification of the mechanism of induction of these side effects may lead to the 
rational engineering of delivery vehicles that do not have these side effects. Additionally, a 
better understanding of the principles that govern cellular internalization may lead to hybrid 
peptides that both possess the ability to internalize into cells and exert a therapeutically 
relevant activity.  
9.2 Understanding the activity of cell-penetrating peptides 
Chapter three to five deal with distinct mechanisms by which these peptides enter cells. 
Chapter three provides a detailed mechanistic insight into a peptide entry mechanism that 
was described several years earlier, but for which little progress had been made on the 
understanding of the molecular basis of the mechanism [2]. The hypothesis that formed the 
basis of this chapter was that direct cytoplasmic uptake at high (>10 M) peptide 
concentrations involved activation of the lipid remodeling enzyme acid sphingomyelinase. 
The hypothesis was based on observations that this protein could be a shared target of 
multiple drugs that were found to inhibit this uptake mechanism. A series of carefully 
designed experiments were conducted that provided experimental support for this 
hypothesis. In chapter four, data are reported showing that uptake of cationic CPPs is 
dependent on chirality in certain cell-types, which questions a long-standing paradigm on 
the receptor-independence of the uptake of these peptides. The results shown in this chapter 
strongly suggest that the endocytic uptake of cationic CPPs is a two-step process. Initially, 
peptides bind to heparan sulfates on the cell surface, a step independent of chirality, as 
could be confirmed in vitro by isothermal titration calorimetry. The second step, which is 
chirality dependent, is triggering the endocytic uptake of the peptides. It was also shown 
that this chirality-dependent trigger was not present in all cells, but correlated with the 
presence of heparan sulfates on the cell surface. For the nucleation zone-dependent uptake 
mechanism there was no clear role for amino acid chirality, as the somewhat higher uptake 
of D-R9 via this mechanism can be explained by the higher proteolytic stability of D-R9 as 
compared to L-R9. Alternatively, the difference might also be due to the fact that 
endocytosis preferentially depletes L-peptides from the cell surface.  
Chapter five deals with an amphipathic CPP that is not dependent on arginines for 
activity, the chimeric transportan analog TP10. The CPP is composed N-terminally of 
residues derived from the neuropeptide galanin and C-terminally of residues derived from 
Summary and future directions 
184 
 
the wasp venom peptide mastoparan. The two parts are linked via a lysine residue. The 
effect of epimerization of NMR labels at individual positions of the sequence on properties 
such as cytotoxicity, internalization efficiency and membrane binding was investigated. As 
with the arginine-containing peptides, strong effects of amino acid chirality on all of these 
properties were found. Unexpectedly, no clear correlation between their secondary 
structure and/or aggregation behavior in model systems and their properties in a cellular 
environment was found. When comparing the results with previous results obtained with 
the arginine-containing peptides R9 and penetratin (chapter four), it was found that, 
despite the absence of arginines in TP10, there were remarkable similarities in the 
dependence on heparan sulfate chains for membrane binding. In contrast, the induction of 
phosphatidylserine exposure of TP10 was much greater compared to R9. In suspension 
Jurkat cells, some, but not all, TP10 analogs were able to efficiently reach the cytosol 
through a pathway that could not be affected by a broad-range cysteine protease inhibitor. 
No such protease inhibitor-insensitive translocation at low concentrations was observed for 
the arginine-rich CPP R9, providing evidence that TP10 directly translocates across the 
plasma membrane. 
To reach the cytosol after endocytic internalization, peptides still need to translocate 
across the endosomal membrane. Although internalization into endosomes can be achieved 
with high efficiency for most biomacromolecules, endosomal sequestration still remains a 
major impediment for the further development of these molecules towards clinically useful 
drugs. When sequestered in endosomes, cargo and vehicles will be exposed to an acidic and 
hydrolytic environment, which will severely damage the cargo. Assessing the integrity of 
cargo and/or delivery vehicle over time inside cells is therefore an important analytical 
aspect in the optimization of delivery constructs. To address this issue, a fluorescence 
correlation spectroscopy-based method to measure the intracellular stability of CPPs is 
described in the sixth chapter. Next to following degradation over time, the method is also 
suitable to investigate the specific enzymes that are involved in degradation, whenever 
specific inhibitors for these enzymes are available. 
9.3 From biology to application   
As alluded to before, CPPs have the capacity to carry a wide range of cargo into cells. The 
seventh chapter reports on the exploitation of the capacity of the HIV-1 derived CPP Tat 
to shuttle polymersomes inside cells. Polymersomes are spherical particles that self-
assemble from amphiphilic block copolymers. The polymersomes that were applied 
consisted of polystyrene-polyisocyanopeptide (PS-PIAT), had an average diameter of 114 
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+/- 28 nm and were loaded with proteins. Conjugation of the Tat peptide to these 
polymersomes with a copper-free click reaction endowed the polymersomes with the 
capacity to efficiently enter various cell types. Intracellular trafficking studies indicated that 
polymersomes were internalized via macropinocytosis and that they were partially directed 
towards acidic compartments. However, even in these conditions, the polymeric bilayer 
protected the enzymatic activity, as illustrated by the longer maintenance of the activity of 
the model enzyme horse-radish peroxidase compared to results from a previous study using 
free horse-radish peroxidase trafficked to the lysosome. In chapter eight, a modular 
approach for the CPP-mediated delivery of proteins is reported. Also in this study, the 
model CPP Tat was applied, whereas green fluorescent protein was used as a model cargo. 
The modular approach consisted of two complementary leucine zippers, of which one was 
fused to the cargo protein and one to the CPP. The modularity of the approach is also 
underscored by the fact that CPPs are coupled to the leucine zipper via a copper-free click 
reaction, which enables the easy and rapid exchange of the CPP that is being employed. 
9.4 Future directions 
The near future in the field of CPPs and CPP mimics is certainly going to be highly 
exciting, as the first CPP-based medicines are moving closer to regulatory approval and 
more and more novel candidates of medicines employing CPP-based functionalities are 
entering clinical trials (see chapter two). It has now become clear that CPP or their 
evolved counterparts are not merely either „good‟ or „bad‟ delivery vehicles, but that the 
context in which they are applied is critical for the chance of success. Moreover, the 
insights into the general process of cell entry that have been generated over the last decade 
through the use of CPPs are tremendous. Emanating from this knowledge, several 
interesting trends can now be observed in the application of CPP and CPP mimics as drug 
delivery vehicles or in related fields stimulated by CPP research. Specifically, five 
promising areas of research can be distinguished. The first is the combination of the 
pharmacophore and the capacity to internalize in one domain. The most frequently used 
way to achieve this combination in a peptide is to apply quantitative structure-activity 
relationship-based algorithms for the identification of cell-permeant proteomimetic 
peptides [3]. The second trend is the use of the guanidinium group, of which the ability to 
drive internalization became evident through the field of CPPs, to decorate a variety of 
transporters, including peptoids, small molecules, carbohydrates or polymers [4-7]. Studies 
showing that these guanidinium-rich transporters also exploit heparan sulfates for their 
entry [8] and compete with poly-arginine peptides for internalization [9] support the 
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hypothesis that the internalization mechanism of CPPs has been successfully transferred to 
synthetic CPP mimics. The third trend is towards overcoming the relative lack of 
specificity of CPPs through targeting disease-specific interactions or characteristics. The 
approach is reminiscent of the use of small molecules, which also generally have a system-
wide distribution and only achieve specificity through targeting molecules and/or molecular 
pathways implicated in disease. An example of this approach is the Tat-mediated delivery 
of siRNA against proteins involved in oncogenic pathways [10]. In this case, specificity 
was not obtained through selective delivery, but through targeting proteins that are 
overexpressed or constitutively active exclusively in tumors. A second example is the use 
of antisense oligonucleotides aimed at splice correction in Duchenne muscular dystrophy 
using Pip5 transduction peptides, leading to the production of a functional dystrophin 
protein [11]. In the last case, however, specificity was further enhanced through local 
intramuscular injections in a recent successful clinical I trial [12]. A fourth research area of 
active interest is the generation of stimuli-responsive CPPs. Here, the CPP functionality is 
exposed upon encountering a certain trigger. A prominent example of this approach is the 
use of a tissue- or tumor-specific protease activity to cleave a linker connecting a CPP and 
an anion stretch that forms an activity-inhibiting ionic interaction with the cationic CPP 
before cleavage [13]. A promising new direction in this field is the in vivo selection for the 
cleavage site using phage display, which obviates the need for any a priori knowledge on 
the nature of the tumor protease activity [13]. The last notable direction in which the CPP 
field is moving is towards tissue-specific CPPs. Various selection strategies have been 
developed or are now in development that aim to identify tissue-specific CPPs, with the 
promise to improve the selectivity and therefore potentially reduce side effects when 
conjugated with bioactive moieties [14-16].  
9.5 Conclusion 
In conclusion, much of what has been learned from CPPs, from the improved 
understanding of the pathways of cellular entry to the molecular determinants that are 
required for efficient cell entry, is driving progress and fostering innovation in drug 
delivery research far beyond the specific field of CPPs. Therefore, it is safe to say that the 
research into the biology of CPPs has already made important contributions to the fields of 
biology and medicine in general and drug delivery in particular, irrespective of whether the 
future will see many next-generation medicines entering the clinic in which the CPP as 
such is still recognizable. Against this background, I also hope that through generating key 
novel insights into the biology of CPPs, the relevance of this thesis is not just restricted to 
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the scientific field of CPPs, but that it represents a valuable contribution to the whole field 
of drug delivery.  
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Nederlandse samenvatting 
Door het ontcijferen van het menselijke genoom is men veel meer over de biologie van 
ziektes te weten gekomen. Echter, tot nu toe heeft die kennis helaas nog niet geleid tot veel 
nieuwe medicijnen. Een voorname reden is dat het bijzonder moeilijk is om de manier 
waarop eiwitten met elkaar communiceren te blokkeren met „klassieke‟ medicijnen zoals 
die tegenwoordig veelal door de farmaceutische industrie gemaakt worden. Gelukkig zijn 
er veel nieuwe ideeën voor andere soorten medicijnen, meestal gebaseerd op biologische 
moleculen zoals eiwitten of DNA. Hoewel men de laatste jaren aanzienlijke vooruitgang 
heeft geboekt met de ontwikkeling van deze „next-generation‟ medicijnen, blijft het nog 
altijd moeilijk om de medicijnen op de juiste plek in het lichaam te krijgen. Met name bij 
het in de cel krijgen van grote moleculen van therapeutische waarde blijken veel factoren 
een rol te spelen. 
 Dit proefschrift gaat over een veelbelovende methode om de toekomstige biologische 
medicijnen in de cellen te krijgen: de toepassing van cel-penetrerende peptiden, die vanaf 
dit punt CPP‟s zullen worden genoemd. CPP‟s zijn zeer kleine eiwitten waarvan 
onderzoekers ongeveer 20 jaar geleden hebben aangetoond dat ze in staat zijn om veel 
grotere moleculen, waaronder grote eiwitten, de cel binnen te brengen. Het belangrijkste 
doel van dit proefschrift is om een beter inzicht te genereren in hoe deze kleine eiwitten het 
transport van grote moleculen in de cel bewerkstelligen, met het onderliggende doel om 
CPP‟s als bouwstenen in toekomstige medicijnen te gaan gebruiken. In het eerste 
hoofdstuk wordt een algemene inleiding gegeven over de huidige stand van zaken in 
medicijnontwikkeling. Daarnaast worden in het eerste hoofdstuk ook CPP‟s geïntroduceerd 
en worden hun belangrijkste eigenschappen uiteengezet. 
 Omdat bijwerkingen van essentieel belang zijn voor ieder medicijn, is het ook 
belangrijk om te weten of CPP‟s mogelijke bijwerkingen hebben. Gedurende de laatste tien 
jaar zijn er inderdaad een aantal studies gepubliceerd waarin duidelijk werd dat CPP‟s niet 
enkel potentiële medicijnen de cel binnen brengen door te functioneren als een zogeheten 
Trojaans paard, maar dat ze tevens belangrijke interacties aangaan met cellen die de basis 
kunnen vormen van bijwerkingen. Kennis over de aspecten van de CPP die 
verantwoordelijk zijn voor de bijwerkingen kan helpen bij de ontwikkeling van nieuwe 
varianten van CPP‟s die deze bijwerkingen niet hebben. Met deze overwegingen als basis is 
het tweede hoofdstuk geschreven. In dit hoofdstuk wordt een overzicht gegeven geven van 
de biologische effecten die CPP‟s en andere medicijntransporters kunnen hebben op cellen 
en in het lichaam.  
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 Het derde tot en met het vijfde hoofdstuk behandelen mechanismes die de CPP‟s 
gebruiken om cellen binnen te komen. Het derde hoofdstuk beschrijft een mechanisme dat 
reeds enkele jaren eerder beschreven werd, maar waarover een onvoldoende begrip bestond 
wat betreft het onderliggende moleculaire werkingsmechanisme. De hypothese die ten 
grondslag lag aan deze studie was dat CPP‟s, mits aanwezig in hoge concentratie, het 
enzym zure sphingomyelinase kunnen activeren voor een opnamemechanisme dat 
werkzaam is bij hoge CPP concentraties. Dit actieve enzym catalyseert vervolgens de 
omzetting van het lipide sphingomyeline naar ceramide en fosforylcholine, waarbij 
ceramide een cruciale rol speelt bij het werkingsmechanisme dat leidt tot opname.  
De aanleiding van het vierde hoofdstuk was de vergelijking van CPP‟s die opgebouwd 
zijn uit L-aminozuren met CPP‟s die opgebouwd zijn uit D-aminozuren. CPP‟s opgebouwd 
uit L-aminozuren kunnen worden afgebroken door enzymen in het lichaam, terwijl CPP‟s 
gemaakt met D-aminozuren volledig stabiel zijn. De conventionele gedachte was dat beide 
CPP‟s met gelijke efficiëntie de cel binnen gaan. Echter, de experimentele bevindingen 
laten zien dat dit niet het geval is. In de meeste cellen die getest zijn, zijn CPP‟s gemaakt 
van L-aminozuren duidelijk actiever. In het bijzonder zijn er duidelijke aanwijzingen dat 
opname van CPP‟s een proces is dat uit twee stappen bestaat. De eerste stap is dat ze 
binden aan suikers die vastzitten aan de membraan van de cel. De tweede stap is dat ze de 
cel binnen gaan. Bevindingen die worden beschreven in het vierde hoofdstuk laten zien 
dat enkel de tweede stap afhangt van het type aminozuur; de binding aan de suikers die 
vastzitten aan het membraan is vrijwel identiek. 
In hoofdstuk vijf wordt een ander type CPP onderzocht dan wat gebruikt is in de 
voorgaande studies. Het betreft een chimeer CPP dat opgebouwd is uit een deel van het 
neuropeptide galanin en het wespengif mastoparan. Deze CPP gaat meer directe interacties 
aan met de celmembraan en is al bij lagere concentraties toxisch in vergelijking met andere 
typen CPP‟s. Diverse varianten van deze CPP zijn onderzocht die slechts op één punt van 
elkaar afwijken. Hierdoor was het mogelijk was om subtiele veranderingen in het peptide te 
koppelen aan het biologische gedrag. Deze studie laat zien dat kleine modificaties sterke 
effecten kunnen hebben op diverse CPP eigenschappen zoals opname-efficiëntie, binding 
aan de celmembraan en toxiciteit. 
Wanneer CPP‟s de cel binnen gaan, zijn ze nog niet altijd op de plek van bestemming. 
Normaal gesproken worden ze via endosomen, hetgeen afgesloten compartimenten zijn, de 
cel binnen gebracht. De vloeistof waarin deze compartimenten zich bevinden, het cytosol, 
of de kern, waarin zich het DNA bevindt, is vaak de eindbestemming van de CPP-
gebaseerde medicijnen. Om veelbelovende therapieën te kunnen optimaliseren is het 
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belangrijk om te weten in hoeverre CPP‟s of vergelijkbare constructen nog intact zijn nadat 
ze door de cel zijn opgenomen. Om dit te kunnen onderzoeken wordt in het zesde 
hoofdstuk een methode beschreven om te analyseren in hoeverre de CPP‟s die de cellen 
zijn binnengegaan nog intact zijn. Daarnaast worden ook methodes beschreven om te 
onderzoeken welke enzymen betrokken zijn bij de afbraak van de CPP‟s binnen de cel. 
 Hoofdstuk zeven is het eerste hoofdstuk van dit proefschrift dat een directe applicatie 
bevat van CPP‟s. In dit hoofdstuk wordt gebruik gemaakt van de capaciteit van CPP‟s om 
grote structuren de cel binnen te brengen. Een CPP afkomstig van het HIV virus, genaamd 
Tat, werd gebruikt om een artificieel organel, een soort plastic bol gevuld met enzymen, de 
cel binnen te brengen. Dit artificiële organel, ook wel polymersoom genoemd, heeft een 
gemiddelde diameter van 114 +/- 28 nm en was na koppeling met de CPP in staat om 
diverse celtypes binnen te komen. Doordat de eiwitten omringd waren door een plastic 
wand werden ze beschermd tegen schade die door cellulaire eiwitten aangebracht zou 
kunnen worden. Een tweede toepassing van CPP‟s in dit proefschrift wordt beschreven in 
hoofdstuk acht, hetgeen een modulair systeem betreft dat gebruikt kan worden om op 
eenvoudige wijze verschillende eiwitten naar cellen binnen te brengen. Het systeem maakt 
tevens gebruik van de HIV-afkomstige CPP Tat en was gekoppeld aan een leucine zipper. 
Een complementaire leucine zipper was gekoppeld met het fluorescente eiwit green 
fluorescent protein (GFP), dat als model eiwit fungeerde. Aangezien de twee 
complementaire leucine zippers sterk aan elkaar binden, wordt de transport functie van de 
CPP gebruikt om het eiwit de cel binnen te krijgen. Er is geen sprake van een directe 
koppeling tussen de CPP en het te transporteren eiwit. Daarom is het relatief gemakkelijk 
om het type eiwit dat moet worden afgeleverd uit te wisselen. 
  De nabije toekomst in het CPP veld zal een spannende periode worden, nu de eerste 
CPP-gebaseerde medicijnenkandidaten dichter bij goedkeuring komen om als medicijn 
gebruikt te worden. Het is nu ook duidelijk dat CPP‟s niet zonder meer „goed‟ of „slecht‟ 
zijn, maar dat hun waarde sterk afhangt van de specifieke applicatie. Ook is het duidelijk 
dat CPP‟s, onafhankelijk van hun eventuele toekomstige toepassing in de kliniek, al 
belangrijke inzichten hebben gegenereerd die van grote waarde zijn in het onderzoeksveld 
van het gericht afleveren van medicijnen. In het licht van deze overwegingen hoop ik dat de 
inzichten in de biologie van CPP‟s die in dit proefschrift beschreven worden niet slechts 
een waardevolle contributie zijn voor het CPP onderzoeksveld, maar tevens van waarde 
zullen zijn voor het veld van gerichte medicijnafgifte als geheel. 
Curriculum Vitae 
192 
 
Curriculum Vitae 
Wouter Verdurmen werd op 8 maart 1983 geboren te Hulst. In 2001 haalde hij zijn VWO-
diploma aan het Reynaertcollege in Hulst. Een jaar later begon hij aan de studie 
Bedrijfscommunicatie in Nijmegen, waarvan hij in 2003 zijn propedeuse haalde. In 
datzelfde jaar switchte hij naar Biomedische Wetenschappen en in 2006 deed hij zijn 
bachelorstage bij dr. Fons van der Loo op het gebied van gentherapie bij reumatoïde 
artritis. In het eerste jaar van zijn Master Biomedische wetenschappen onderzocht hij 
tijdens een onderzoeksstage in de groep van professor Wim de Grip de activatie van G-
eiwitten. Tijdens het tweede jaar ging hij naar de Universiteit van Oxford voor een stage in 
de groep van Tony Watts over de G-eiwit gekoppelde receptor de neurotensin receptor type 
1. Na in 2008 zijn master cum laude behaald te hebben is hij direct begonnen met zijn 
promotie onder begeleiding van professor Roland Brock op het gebied van cell-penetrating 
peptides. De resultaten van zijn promotieproject staan in dit proefschrift beschreven. Aan 
het einde van zijn promotie heeft hij een Rubicon beurs van NWO gekregen waarmee hij 
vanaf 1 september 2012 een tweejarig onderzoek doet als postdoc aan de universiteit van 
Zürich onder begeleiding van professor Andreas Plückthun. In het kader van het 
onderzoeksproject zal getracht worden om eiwitten als medicijn te ontwikkelen voor 
toepassingen in cellen. 
  
List of publications 
193 
 
List of publications 
Ruttekolk IR, Witsenburg JJ, Glauner, H, Bovee-Geurts PH, Ferro ES, Verdurmen WP, 
Brock R. The intracellular pharmacokinetics of terminally capped peptides. Mol Pharm. 
(2012). 9:1077-1086 
 
Verdurmen WP, Bovee-Geurts P, Wadhwani P, Ulrich A, Hällbrink M, van Kuppevelt T, 
Brock. R. Preferential uptake of arginine-rich L- versus D-amino acid cell-penetrating 
peptides in a cell type-dependent manner. Chem Biol. (2011) 18:1000-1010. 
 
Verdurmen WP, Brock R. Biological responses towards cationic peptides and drug carriers. 
Trends Pharmacol Sci. (2011) 32: 116-124 
 
Hansen MB, Verdurmen WP, Leunissen, EH, Minten I, van Hest JC, Brock R, Löwik DW. 
A modular and non-covalent transduction system for leucine zipper-tagged proteins. 
Chembiochem. (2011) 12: 2294-2297 
 
Ruttekolk IR+, Verdurmen WP+, Chung YD, Brock R. Measurements of the Intracellular 
Stability of CPPs. Methods Mol Biol. (2011) 683: 69-80.  
+ these authors contributed equally 
 
Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Chau Dam T, Verdurmen WP, Brock R, 
Probst J, Schlake T. Protein expression from exogenous mRNA: Uptake by receptor-
mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. (2011) 8: 627-
636 
 
Ruttekolk IR, Chakrabarti A, Richter M, Duchardt F, Glauner H, Verdurmen WP, 
Rademann J, Brock R. Coupling to polymeric scaffolds stabilizes biofunctional peptides for 
intracellular applications. Mol Pharmacol. (2011) 79: 692-700 
 
Verdurmen WP, Thanos M, Ruttekolk IR, Gulbins E, Brock R. Cationic Cell-Penetrating 
Peptides Induce Ceramide Formation via Acid Sphingomyelinase: Implications for Uptake. 
J Control Release (2010) 147:171-179 
 
List of publications 
194 
 
Verdurmen WP+, van Dongen SF+, Peters RJ, Nolte RJ, Brock R, van Hest JC. Cellular 
Integration of an Enzyme-Loaded Polymersome. Angew Chem Int Ed Engl. (2010) 49: 
7213-7216. 
+ these authors contributed equally 
 
Duchardt F, Ruttekolk IR, Verdurmen WP, Lortat-Jacob H, Bürck J, Hüfnagel, H, Fischer 
R, van den Heuvel, M, Löwik, DW, Vuister GW, Ulrich A, de Waard M, Brock R. A cell-
penetrating peptide derived from human lactoferrin with conformation-dependent uptake 
efficiency. J Biol Chem. (2009) 284: 36099-36108 
  
Dankwoord 
195 
 
Dankwoord 
Ondanks de hardnekkige perceptie bij sommigen, promoveren doe je niet alleen. Dit is in 
het bijzonder van toepassing op mijn promotie, want ik heb gedurende de afgelopen jaren 
het geluk gehad om met zéér veel mensen samen te werken, zowel kleinschalig als 
grootschalig. In mijn geval had ik dubbel geluk, want het waren stuk voor stuk erg fijne 
samenwerkingsverbanden! De volgende mensen wil ik in het bijzonder bedanken: 
 
De keuze met wie ik moet beginnen om te bedanken is voor mij eenvoudig, dat is mijn 
promotor. Roland, bedankt voor het snel en adequaat beantwoorden van al mijn vragen, 
voor alle tijd die je in mijn ontwikkeling hebt gestoken, voor de kennis die ik van je heb 
opgedaan en voor het altijd positief en optimistisch blijven. Wat mij betreft heb je je taak 
als promotor duidelijk overstegen. 
 
Daarnaast wil ik ook zeker mijn voorganger op het gebied van cell-penetrating peptides 
in onze groep, Ivo, bedanken. Gedurende de eerste periode van mijn promotie ben jij 
degene geweest die me op weg heeft geholpen in het lab. Binnen deze korte periode heb ik 
ontzettend veel van je geleerd, in het bijzonder confocale microscopie en fluorescentie 
correlatie spectroscopie.  
 
Ook van de rest van de groep heb ik veel opgestoken. In het bijzonder zou ik daarvoor 
Jenny en Petra willen bedanken. Van jullie heb ik meer geleerd dan jullie je waarschijnlijk 
realiseren. Niettemin omdat ik ook al van jullie kennis gebruik mocht maken tijdens mijn 
masterstage enkele jaren eerder! En Merel en Theo, bijzonder bedankt voor het helpen bij 
het voorbereiden van het proefschrift.  
 
Waar ik onze hele groep voor wil bedanken, is het feit dat er altijd een leuke sfeer in 
onze groep heerste. Er zijn heel wat mensen gekomen en gegaan tijdens de vier jaren die ik 
hier heb rondgelopen, maar de goede sfeer is gelukkig altijd gebleven. Dus daar wil ik 
jullie stuk voor stuk voor bedanken: Alokta, Giel, Ivo, Jenny, Joris, Judith, Marco, Merel, 
Michael, Petra, Rike, Sip, Theo, Wim en Yi-Da. Ook mijn studenten Jos, Lauke, Robyn en 
Sabine wil ik erg bedanken voor hun nuttige werk.  
 
` Dat onderzoek leuk is, werd mij (onder andere) duidelijk uit de samenwerking met jou, 
Stijn. Er was maar één enthousiast telefoontje van mij nodig over mysterieuze blauwe 
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naalden die uit cellen kwamen en je stond al bij het NCMLS op de stoep om deze blauwe 
naalden samen te bewonderen én vast te leggen met de digitale camera. Jij wist me te 
vertellen dat het kristalnaalden waren. De leuke herinneringen aan dit experiment hebben 
me mede overtuigd om het op de cover te plaatsen. Het plezier wat ik had in de 
samenwerking op het gebied van de polymersomes heb ik gelukkig kunnen voortzetten met 
Ruud, en geldt in even zo grote mate voor het project met Morten en Dennis met de leucine 
zippers. Dus jullie ook bedankt voor de fijne samenwerking! In het bijzonder wil ik ook Jan 
noemen. Jou wil ik niet alleen bedanken voor de fijne samenwerking, maar natuurlijk ook 
voor de tijd en energie die je hebt gestoken in het meedenken over en mogelijk maken van 
de volgende stap in mijn carrière. 
 
In addition, I would like to express my thanks for the nice collaboration on the R9-
chimearas and the TP10 analogs with Parvesh and Anne. Currently, close to the end of my 
project, the project is even taking a very interesting twist, so I‟m sure our collaboration on 
this topic will continue for at least a little while from the time of this writing. 
 
Weer terug naar het Nederlands, wil ik verdergaan met het bedanken van diegenen die 
mij niet direct op de werkvloer hebben geholpen, maar zeker wel indirect met het opladen 
van de batterij. En dat kan op verschillende manieren: door het voeren van geanimeerde 
discussies, uiteraard onder het genot van een drankje, in café Jos; door het bijwonen van 
gezellige etentjes en feestjes, zowel binnens- als buitenshuis; door het kijken van de (alle) 
films uit de IMDB top 250, door het ophalen van oude herinneringen; en door samen stoom 
af te blazen tijdens het hardlopen, in het zwembad, op de fiets of in de bergen. Dus iedereen 
die één of meerdere van deze activiteiten met mij gedaan heeft: bedankt! 
 
Ook wil ik diegenen bedanken die zonder twijfel de grootste bijdrage hebben geleverd 
aan het mij brengen waar ik nu ben: mijn ouders, Dennis, Erwin en Noël. Ik wil jullie 
bedanken voor de onvoorwaardelijke steun, mijn keuzevrijheid, en voor het geven van het 
goede voorbeeld. 
  
Net zo makkelijk als de keuze met wie het dankwoord te beginnen is ook de keuze met 
wie het dankwoord te eindigen. Hoe kan het ook anders, dat ben jij, Sascha. Bedankt voor 
het zijn van de de reden dat ik na iedere werkdag, hoe leuk ik het ook vind om te werken, 
zelfs met nog meer plezier naar huis ga.  
 
